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_e aim of this work was the establishment of quantitative structure-activity relationships for
series of systematically altered benzenesulfonamide ligands of human Carbonic Anhydrase II
by macromolecular X-ray crystallography and kinetic isothermal titration calorimetry. Two
series of alkyl and alkyloxy substituted compounds were to be investigated to investigate the
inuence of diòerent alkyl chain geometries on the thermodynamics and kinetics of binding
and furthermore compare the kinetic results of the alkyl series with kinetic data from surface
plasmon resonance experiments from a previous study for the same compounds. Furthermore,
the inuence of varying uorination patterns on the one hand and the inuence of structurally
similar para-substituents with diòerent eòects on ligand acidities on the other hand were to
be exmained with respect to their inuence on the thermodynamics and kinetics of ligand
binding. Given the relative novelty of the concept of kinetic isothermal titration calorimetry, a
measurement protocol that provides for the robust determination of both thermodynamic and
kinetic parameters from one experiment, a novel titration protocol for microcalorimetricmea-
surements that aims at simultaneously providing these at minimal input of protein and ligand
material and high experimental eõciency was to be established and validated. Furthermore, an
already known, highly potent inhibitor of human Carbonic Anhydrase II was to be examined
to investigate the thermodynamic and kinetic driving forces for its high potency. Additionally,
separated enantiomers of a hetereocyclic Carbonic Anhydrase inhibitor were investigated both
crystallographically and by means of microcalorimetry in order to assess, whether the crys-
tallographically usually not observed enantiomer shows inhibitory against human Carbonic
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Objective
Anhydrase II and whether the compound racemizes under experimental conditions. A further
study was aimed at the concentration-dependend occupancy of a Carbonic Anhydrase inhibitor
in a second binding site, that could be potentially useful for the in silico predictions. A previously
started proof-of-concept fragment-screening campaign was to be continued. Moreover, one
aim of this thesis was to obtain neutron diòraction data for human Carbonic Anhydrase II in
complex with the artiûcial sweetener saccharin in order to elucidate the protonation state of
saccharin in the bound form.
2
Summary
_e data presented here show that diòerent geometries of para-alkyl substituents of a benzene-
sulfonamide scaòold can have a signiûcant inuence on the thermodynamic and kinetic binding
parameters and suggest, that the ûne-tuning of the ligand geometry to match the geometry of
the active site leads to a reduced dissociation rate of the protein-ligand complex and thus to a
prolonged binding in the active site. In addition, it was found that the kinetic data extracted by
isothermal titration calorimetry correlate with data from experiments with surface plasmon
resonance for a subset of compounds, despite a diòerence of one order ofmagnitude that could
not be explained so far. Furthermore, the investigation of uorinated benzenesulfonamide
ligands revealed complex structural-thermodynamic and structural-kinetic relationships, which
could not be fully elucidated herein, but suggest that uorination of a meta-position of the
aromatic part of the benzenesulfonamide backbone favors high association as well as small
dissociation rates. In addition, it has been shown that a higher degree of uorination does not
necessarily have an advantage for the thermodynamic or kinetic binding proûle or aõnity itself.
Furthermore, structurally similar ligands with only one para-substituent but diòerent acidities
indicate that the association rate of complex formation beneûts from increased acidity. A new
measurement protocol for microcalorimetricmeasurements was analyzed for its precision and
compared with other possiblemeasurement protocols and showed that it is best suited for the
reliable simultaneous determination of thermodynamic and kinetic data by microcalorimetry.
_emicrocalorimetric investigation of an already known and supposedly very potent Carbonic
Anhydrase inhibitor showed an unexpected two-step binding behavior,which, however, excludes
3
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a 2 : 1 binding of inhibitor and protein. Time-dependent experiments suggest that the binding
process between protein and ligand leads to a thermodynamically and kinetically preferred
complex. _e investigation of a chiral heterocyclic Carbonic Anhydrase inhibitor could not
conclusively clarify, whether the crystallographically apparently non-binding enantiomer also
shows inhibitory activity. However,microcalorimetric investigations allow the conclusion that
racemization occurs under experimental conditions,whichmakes the clariûcation of the original
question considerablymore diõcult. Soaking of Carbonic Anhydrase crystals in solutions of
diòerent concentrations of a ligand showed, that the occupancy of a second binding site was too
weak to allow modeling of the ligand, which made it impossible to investigate the concentration
dependence of the occupancy in this binding site. Concentration diòerences, however, resulted
in diòerent occupancies of the active site. A crystallographicmodel based on neutron diòraction
data of human Carbonic Anhydrase II in complex with saccharin was not obtained. However,
an attempt was made to assess the protonation state of saccharin in the active site of the enzyme
by experimental phasing using high-resolution X-ray diòraction data. _e continuation of a
fragment screening showed the binding of further small molecules in Carbonic Anhydrase
crystals. An analysis with the Pan-Dataset Density Analysis program suggests, that electron
density maps are strongly dependent on the time of soaking of the crystals.
4
Zusammenfassung
Die hierin vorgestellten Daten zeigen, dass verschiedene Geometrien eines para-
Alkylsubstituenten eines Benzolsulfonamidgerüsts einen deutlichen Einuss auf die
thermodynamischen und kinetischen Bindungsparameter haben können und deuten darauf
hin, dass die Feinabstimmung der Komplementarität der Molekülgeometrie des Liganden
auf die des aktiven Zentrums des Proteins zu einer verlangsamten Dissoziationskinetik des
Protein-Ligand Komplexes und somit zu einer längeren Blockade des aktiven Zentrums führen
kann. Zusätzlich wurde festgestellt, dass diemit isothermer Titrationskalorimetrie extrahierten
kinetischen Daten mit Daten aus Experimenten mit Oberächenplasmonenresonanz für eine
Teilmenge von Verbindungen korrelieren, trotz eines bisher nicht zu erklärenden Unterschieds
von einer Größenordnung. Darüber hinaus zeigte die Untersuchung von uorierten Benzolsul-
fonamidliganden komplexe strukturthermodynamische und strukturkinetische Beziehungen,
die hierin nicht vollständig aufgeklärt werden konnten, aber darauf hindeuten, dass die selektive
Fluorierung einer meta-Position des aromatischen Rings hohe Assoziations- als auch niedrige
Dissoziationsraten begünstigt. Außerdem konnte gezeigt werden, dass hochgradiger uorierte
Analoga nicht notwendigerweise einen Vorteil für das thermodynamische oder kinetische
Bindungsproûl oder die Aõnität selbst haben. Darüber hinaus deuten strukturell ähnliche
Liganden mit nur einem para-Substituenten, aber unterschiedlichen Aciditäten darauf hin,
dass eine erhöhte Acidität des Liganden erhöhte Assoziationsraten begünstigt. Ein neues
Messprotokoll für mikrokalorimetrischeMessungen wurde auf seine Präzision hin analysiert
undmit anderen möglichen Messprotokollen verglichen und zeigte, dass es sich am besten für
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die zuverlässige gleichzeitige Ermittlung von thermodynamischen und kinetischenDatenmittels
Mikrokalorimetrie eignet. Diemikrokalorimetrische Untersuchung eines bereits bekannten
und vermeintlich sehr potenten Carboanhydraseinhibitors zeigte ein unerwartetes zweistuûges
Bindungsverhalten, das eine reine 2 : 1 Bindung von Inhibitor und Protein jedoch ausschließt.
Zeitabhängige Experimente lassen den Schluss zu, dass der Bindungsvorgang zwischen Protein
und Ligand zu einem thermodynamisch und einem kinetisch bevorzugten Komplex führt.
Die Untersuchung eines chiralen heterocyclischen Carboanhydraseinhibitors konnte nicht
abschließend klären, ob auch das kristallograûsch scheinbar nicht bindende Enantiomer auch
inhibitorischeWirkung zeigt. Mikrokalorimetrische Untersuchungen weisen jedoch darauf
hin, dass unter den experimentellen Bedingungen Racemisierung Auritt, was die Klärung
der ursprünglichen Frage deutlich erschwert. Das Tränken von Carboanhydrasekristallen in
Lösungen unterschiedlicher Konzentrationen eines Liganden zeigte, dass die Besetzung einer
zweiten Bindestelle zu schwach war, um kristallographisch modelliert zu werden, was die
angestrebte Untersuchung der Konzentrationsabhängigkeit der Besetzung unmöglich machte.
Konzentrationsunterschiede sorgten jedoch für unterschiedliche Besetzungen des aktiven
Zentrums. Ein kristallograûsches Modell, das auf Neutronenbeugungsdaten der humanen
Carboanhydrase II im Komplex mit Saccharin basiert, wurde nicht erhalten. Es wurde jedoch
versucht, den Protonierungszustand von Saccharin an der aktiven Stelle des Enzyms mit Hilfe
von hochaufgelösten Röntgenbeugungsdaten durch experimentelle Phasierung zu beurteilen.
Die Fortsetzung eines Fragment-Screenings zeigte die Bindung weiterer Kleinmoleküle in
Carboanhydrasekristallen. Eine Analysemit dem Pan-Dataset Density Analysis Programm lässt
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1.1 Rational Drug Design
Rational Drug Design aims at the improvement of binding aõnity of a small-molecule with a
given scaòold for a protein that is of interest for the treatment of a certain disease, based on
the understanding of the assembly and disassembly of protein-ligand complexes.1 In the early
days of drug development, serendipity was the determining factor for success, as shown by
the example of acetylsalicylic acid. It had been synthesized for the ûrst time in 1879, but its
mechanism of actionwas not elucidated until 1971.2,3 Since then, the development of novel drugs
has increasingly emancipated itself from serendipity-based discoveries and high-throughput
screenings ofmillions of compounds toward the knowledge-based approach of structure-based
drug design (SBDD).1,4 A fundamental requirement for SBDD is the knowledge about the three-
dimensional shape and physicochemical properties of a given receptor, ideally with information
about the binding of organicmolecules that act as probe heads and can serve as potential starting
points for the design of a lead-likemolecular scaòold.1,5 Macromolecular X-ray crystallography
(MX) is themethod of choice to obtain these information, which can also be complemented
by neutron diòraction data to obtain information about protonation states or sites of a pro-
tein that are amenable to proton exchange.6 Cryogenic electron microscopy (cryo-EM) and
microcrystal electron diòraction (MicroED) become increasingly important, the former one
especially for large protein complexes that are diõcult to crystallize, the latter as a powerful tool
for the determination of both macromolecular structures as well as the compositions of small-
9
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molecule crystals.7–9 Furthermore, X-ray free-electron lasers (XFELs) enable the time-resolved
observation of biomolecular recognition processes.10 Also, nuclear magnetic resonance (NMR)
spectroscopy is a powerful tool to follow a binding event in solution, whereas the previously
mentionedmethods investigatemolecules in the crystalline state.11,12 Structural data from the
abovemethods are then combined with biophysical data about the binding between target and
ligandmolecules in so called quantitative structure-activity relationships (QSARs) to assess the
potential ofmolecular scaòolds as new lead structures and furthermore elucidate the fashion
in which aõnity of a ligand for a target is conveyed.13,14 Fox et al. diòerentiate at least nine
individual processes, e.g. desolvation and conformational changes, that are necessary for the
overall process of biomolecular recognition.15 _ese processes can occur aer one another or
partly simultaneously and thereby render the task of separating their individual contributions to
the overall binding process experimentally quite complex, if not impossible.15 If QSAR studies
are to derive universally valid and applicable coherences, it becomes exceedingly important to
keep the inuence of these processes constant to empirically observe as few superimposed eòects
as possible, ideally only one.15,16 _is is usually achieved by employing a suitablemodel system
for the respective question.15 Quite intuitively, themore systematically a QSAR study is planned,
i.e. the smaller the chemical modiûcations of a lead scaòold are within the series of investigated
congenericmolecules, the higher is the chance of increasing the number of processes whose
inuence on themeasured parameters will remain constant across all derivatives in amolecular
series.15 Iterative, highly systematic chemical changes can then not only disclose general trends
that might also be applicable to other protein-ligand systems but may also pinpoint optimal
performance as well as pitfalls in the molecular series and thereby enable deduction of the
responsible characteristic as described for example by Krimmer et al. and Cramer et al. in the
investigation of water networks surrounding protein-ligand complexes.17–19 Furthermore, data
for highly systematicmolecular series may also be used to parameterize computer programs
which are then capable of predicting the properties of protein-ligand systems that are diõcult to
10
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observe experimentally.20 However, this approach comes at the expense of a comparably slow
exploration of conceivable chemical space and is therebymore time and resource consuming
compared to studies that are less systematically designed. _is might be a probable reason for
the relative scarcity of such systematic studies.21 But despite a certain probability that trends
derived from such studies will partly adhere to the studied systems themselves without wider
applicability, there is also the chance that a higher number of such highly systematic studies will
enablemutual comparisons, which will eventually lead to fundamentally applicable principles
for the design of novel drug molecules.21
1.2 Thermodynamics and Kinetics in Drug Design
At the heart of every QSAR study is the question for the strength, i.e. the aõnity, with which
diòerent molecules bind to a receptor. Aõnity can be derived from the chemical equilibrium as
shown in reaction (1) for a simple one to one binding reaction between protein (P) and ligand





Mathematically, the equilibrium is described by the equilibrium association constant (Ka), the
equilibrium dissociation constant (Kd), the association rate constant (k1) and the dissociation
rate constant (k–1). Aõnity, usually expressed as Ka, is the fundamental quantity in drug design,
as it provides information about the strength of the interaction between protein and ligand
without the necessity of further knowledge about the contributing factors that determine it.22,23
However, Kd is usually the preferred quantity to compare the aptitude of diòerent ligands to
bind to a protein. From the law ofmass action (2) corresponding to reaction (1) it is deducible
that, for a one to one interaction, Kd bears the unit of concentration and corresponds to that
equilibrium concentration of free ligand, at which half of the initial amount of free protein is
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converted into the protein-ligand complex. _is renders Kd amore intuitive and thus convenient








Aõnity per se only gives information about the strength of binding of a ligand as a whole to a
protein. It does not, however, provide evidence about the fashion in which aõnity is conveyed,
i.e. in which manner chemical changes on a lead scaòold inuence the thermodynamic and
kinetic parameters that govern the bound state and can shed light on the details of themolecular
processes involved.16 _us, it is important to partition aõnity into its contributors ot obtain
further insights.21
1.2.1 Thermodynamic Partioning
A spontaneous chemical binding reaction between protein and ligand is characterized by a
negative (i.e. favorable) value of diòerence in Gibbs free energy (∆G), which can be obtained
via equation (3) including the universal gas constant (R) and temperature (T).22 ∆G in turn
comprises enthalpic (diòerence in enthalpy (∆H)) and entropic (diòerence in entropy (∆S))
contributions as shown by the Gibbs-Helmholtz equation (4).22
∆G = R ⋅ T ⋅ lnKd (3)
∆G = ∆H − T ⋅ ∆S (4)
Under the prerequisite of systematically designedQSAR studies, ∆H can be used as ameasure for
the change in the numbers and/or strengths of non-covalent interactions formed between protein
and ligand during assembly of the complex.24 Furthermore, it can be used to assess the quality
of the geometric orientation of functional groups with respect to their contribution to ∆G.24
12
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With increasing improvements in the applicability ofmicrocalorimetry for the investigation of
biomolecular recognition events, the assumption was put forward that strong enthalpic binders
make for better drug candidates compared to binders with weaker enthalpic contributions. _e
terms ‘enthalpically driven binder’ and ‘entropically driven binder’ were coined, referring to
that quantity of a ligand’s thermodynamic binding signature that predominantly contributes
to aõnity.25 In addition to the possibility of directly engineering individual protein-ligand
contacts, the knowledge about enthalpic and entropic contributions can be used to rationalize
crystallographic observations like highly disordered or exible portions of a ligandmolecule
and a simultaneously comparably large entropic contribution to binding.26–28 Furthermore, even
the implication of crystallographically resolved water molecules that interact with the ligand as
well as protons that are expelled or taken up upon complex formation can be elucidated.29–34
Despitemany reasonable correlations between thermodynamic and structural data,more recent
QSARs demonstrated that knowledge about thermodynamics and structure alone does not
necessarily yield conclusive insights. _is can be the case if a ligand is preorganized, i.e. if its
favored conformation in solution closely resembles the bioactive conformation in the bound
state, a scenario that is structurally diõcult to access, but oen requires the support of MD
simulations.35,36 _is circumstance can become even more cumbersome to elucidate, if the
preferred conformation in solution comprises the entrapment of a water molecule, which is
released before binding to the protein. _is ûnding for themost exible in a series of congeneric
ligands of protein kinase A (PKA) caused a counterintuitively favorable entropic signature of
binding, which refuted the traditional view that highly exible ligands usually bind entropically
penalized due to the immobilization of rotatable bonds.37 Additionally, thermodynamics can also
help to rationalize ûndings that lie beyond the physicochemical properties, e.g. the formation
ofmutation-induced resistances by identifying positions on amolecular scaòold that allow for
enough exibility of the scaòold to enable binding to the target despitemutations.38,39 Moreover,
a strong enthalpic signature has also been associated with enhanced selectivity.25 Importantly,
13
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the thermodynamic partitioning of ∆G enables the elucidation of the origin of enthalpy-entropy
compensation (subsection 1.2.4), a phenomenon in which enthalpic and entropic contributions
developing along a series of congenericmolecules cancel each other out and which, if actually
present in the studied system and not caused by inaccuracies in themeasurements, can seriously
impede the aspired increase in aõnity during lead optimization.15,40 _e only method capable
of directly providing ∆H for a given binding event is isothermal titration calorimetry (ITC),
which measures the apparent heat signal of the overall binding process including, importantly,
all associated sub-processes as addressed in section 1.1, which makes the choice of a suitable
model system important in order to circumvent the overlay ofmultiple eòects.15,21 But despite
clear empirical correlations between structure and thermodynamic binding signatures, it is
reasonable to assume that even themost thoroughly designed series of congenericmoleculeswill
always bear a residual risk of additive or compensating eòects which render the studied system
more complex than initially intended.41 _erefore, it has been argued that themere enthalpic
contribution of the interaction between protein and ligand is not at all accessible experimentally
and that experimental values can only aid in the overall understanding of ligand binding and
should preferably be complemented with computer simulations to take into account as much
as possible of the complexity of ligand binding.41 Recently, it was revealed that especially the
eòect of enthalpy-entropy compensation was oen prematurely assumed to be present in certain
studies without taking into account deûciencies in the experimental setups ofmicrocalorimetric
measurements, an issue that has increased awareness for the need of high microcalorimetric
data quality.40 Furthermore, it inspired the reasoning to desist from absolute terms such as
‘enthalpically driven’ and ‘entropically driven’, as the presence of systematic errors may not
impact the general trends derived from individual experimental series, but does complicate
the absolute comparison of experimental results of diòerent protein-ligand systems on an
absolute scale.20,21 Additionally, despite examples for the correlation of favorable properties of
amolecule with strong enthalpic binding, the increasing appreciation for the complex nature
14
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of ligand binding has rendered the view, that simply a large enthalpic contribution makes
for a better drug candidate, an outdated one.16,21,24,25,41 But although it has been argued that
computer-assisted design aimed directly at increasing aõnity without initial consideration
of individual thermodynamic contributions is putatively more productive due to the lack of
universally applicable correlations between structure and the thermodynamic contributors to
∆G, the ability to partition aõnity into its contributors remains an indispensable tool, as it has
the power to disclose eòects andmechanisms that cannot be elucidated easily otherwise and has
the advantage of being experimentally evidenced.21,40,42
1.2.2 Kinetic Partitioning
While the initial perception of the signiûcance of enthalpy has been relativized, the kinetic
contributions governing aõnity have gained in attention. Since the works of Swinney et al.
and the introduction of the concept of residence time (τrd) by Copeland, the importance of
the kinetics of biomolecular recognition has gained in appreciation.23,43 For a simple one to
one interaction, Kd can be calculated by the association rate constant (k1) and dissociation rate
constant (k−1), which, in this scenario, equal the overall association rate constant (kon) and








As τrd is the inverse of koff, it can be directly derived from experiments providing the latter.23
_e importance of τrd, which is measured in vivo lies in the fact that it oen resembles a ligand’s
in vivo eõcacy a lot better than aõnity per se.23,44 An impressive example for this phenomenon
was given by Gooljarsingh et al., who showed that, despite low micromolar in vitro aõnities,
inhibitors of the heat shock protein 90 (HSP90) exerted a distinct antiproliferative eòect in cell
cultures, which was attributable to a pronouncedly long residence time.45 _e rationale for the
validity of the residence time concept lies in the fundamental diòerence between an equilibrium
15
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state under which many in vitro experiments are carried out as opposed to the open system
of a human body.44 In the latter case, the drug molecules are exposed to the pharmacokinetic
processes of absorption, distribution,metabolism and excretion, which prevent the formation
of an equilibrium state upon which the deûnition of Kd is based.44 A prolonged residence time
provides for a longer target occupation and thereby prolonged action at the receptor, irregardless
of the concentration of free inhibitormolecules in the vicinity.23,44 _e importance of this concept
becomes even more distinct, if the presence of an induced ût (section 1.3) is considered.46 In this
scenario, the initially formed complex or intermediate state PL, kinetically characterized by k1
and k−1, is considered loosely bound, and successively isomerizeswith the forward isomerization









_e binding model of induced ût leads to the more complex dependence of koff shown in
equation (7) and can be utilized for the design of koff, if the structural features of protein
isomerization and themeans to modulate these are known.23
koff =
k–1 ⋅ k–2
k–1 + k2 + k–2
(7)
Exemplarily, Cramer et al. succeeded in demonstrating the paramount importance of an in-
teraction between the side chain of Asn112 of themodel metalloprotease_ermolysin and a
bound ligand. Movement of this side chain determines the open and closed state of the protease
and ûxing it in the closed state by hydrogen bonding to a bound ligand was suggested to be
a crucial determinant for a prolonged residence time.48 Moreover, additional blockage of the
movement of this side chain by the known ligand ZFPLA was suggested to majorly contribute to
the extraordinarily long residence time of 168 d by impeding the transition from the closed to
the open state.48 A further example for the relevance of the residence time concept is the case of
16
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inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase. An inhibitor with
a prolonged residence time suppressed EGFR tyrosine phosphorylation and thereby activity
signiûcantly longer and to a larger extent than inhibitors with pronouncedly shorter target
occupancies.49 Furthermore, koff can be used to manipulate selectivity proûles, e.g. in the case
of isozyme-selective inhibition of cyclooxygenases, or indicate the tendency ofmolecules to
induce resistances, as shown for marketed drugs targeting the human immunodeûciency virus
(HIV)-1 protease.50–52 Despite the plausible argumentation for residence time, it should be noted
that the design eòorts aiming at the prolongation of residence time are futile in cases in which
residence time does not exceed the pharmacokinetic lifetime of a drug molecule.53 Despite the
more intuitive character of τrd or the argument that themaximum value achievable for kon is the
rate of diòusion, kon can still be utilized in the concept of rebinding.53 It relies on an exceedingly
large association rate constant which provides for a rapid renewed engagement of the same
target or other target molecules within the same eòect compartment aer dissociation from
its initial target and can thereby overcompensate an insuõcient residence time.23,53 Sykes et
al. demonstrated that the extrapyramidal side eòects of atypical antipsychotic drugs correlate
with kon rather than koff, a ûnding that was rationalized by amodel of rebinding.54 A practical
obstacle to the rational design of overall association rate constants is the fact that processes like
desolvation and diòusion, which are necessary prerequisites for the eventual complex formation,
are non-trivial to approach as there is little systematic knowledge about the correlation between
structure and kinetics to guide organic synthetic eòorts.23 A contribution in this regard was
made by Schuetz et al. who demonstrated the deliberate deceleration of inhibitors ofHSP90 by
increasing the energetic barrier of desolvation.55
1.2.3 The Hydrophobic Eect
_e eòect of spontaneous self-assembly of hydrophobicmolecules or hydrophobic portions of
amphiphilicmolecules in water has long-since been accepted as vitally important for the forma-
tion of three-dimensional biological structures such as proteins or membranes and biomolecular
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recognition events such as binding between a drug and its target.56–59 _e driving force for this
is assumed to be the discrepancy between the strength of interaction between the hydrophobic
solute and water molecules on the one hand, and the strong bonding between water molecules.
_e interactions formed between a hydrophobic solute and water are relatively weak, as they
occur between induced dipoles of the solute molecule and the permanent dipoles of water
molecules, while the hydrogen bonding between water molecules is solely based on the in-
teraction of permanent dipoles. Based on the ‘iceberg’ model postulated by Frank and Evans,
water molecules in the ûrst hydration shell surrounding the solute are considered to be or-
dered in hydrogen-bonding networks which are similar to those formed in ice in geometry
and strength and more highly ordered than in bulk water.60 _is view has been relativized
to some degree with respect to the extent at which order is increased in the ûrst hydration
layer.58,60 As a consequence of this non-optimal binding situation of the water molecules, the
hydrophobic solute is released from its water envelope to assemble with another solutemolecule
of its kind. _us, the assembly of hydrophobic solutes seems to bemainly driven by the strong
attraction between water molecules.61 Simultaneously, the number of water molecules required
to cover the hydrophobic assembly and thereby involved in weaker interactions with the solute
is reduced compared to the number required to cover the individual hydrophobic entities.56,62
Based on thismodel, the ‘classical’ hydrophobic eòect predicts that the release ofwatermolecules
resulting from the binding between two hydrophobicmolecules will entail a favorable entropic
contribution to the diòerence in Gibbs free energy as the released water molecules will form an
increased number of hydrogen bonds with the surrounding bulk water.61,62 Nowadays, however,
the view of a single hydrophobic eòect is outdated, as an additional observation can bemade for
certain host-guest interactions. _e ‘non-classical’ hydrophobic eòect includes the existence
of highly mobile high-energy (‘frustrated’) water molecules present in hydrophobic binding
pockets.63 Displacement of these water molecules into the bulk solvent will result in hydrogen
bonds stronger than those formed around the hydrophobic surface, which in turn results in an
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enthalpic gain.62 _e diòerentiation is complicated by the circumstance that the shape of the
hydrophobic solute inuences the energetic state of thewatermolecules surrounding it.59,64 _us,
it can be assumed that diòerentiating only these two possible extremes will not give suõcient
consideration to the issue. _e nature of the hydrophobic eòectwill always depend on the system
under investigation, especially with respect to the geometric characteristics of the investigated
system, which strongly inuence the nature of water molecules that are assembled around these
regions.62 In consequence, the complex role that water plays in protein-ligand binding is diõcult
to grasp, especially because detailed systematic studies addressing the issue will always bear a
context-based bias.59,65,66
1.2.4 Enthalpy-Entropy Compensation
_e eòect ofmutual compensation of enthalpy and entropy, termed enthalpy-entropy compen-
sation (EEC), which entails aminimal value of ∆G for a spontaneous reaction despite strong
enthalpic and entropic signatures, has long-since been recognized as a widely occurring feature
of biochemical processes such as protein folding.67 Furthermore, the formation of protein-ligand
complexes investigated for the establishment of QSARs can be subject to the phenomenon,
which can seriously impede the eòort to improve a given lead scaòold and has been shown to
occurr to various extents by several studies.26,33,68,69 _emost intuitive reason for the occurrence
of this phenomenon is the opposed nature of motion and bonding.42 Stronger, i.e. more en-
thalpic bonding reduces mobility and therefore entropy,whileweaker, i.e. less enthalpic bonding,
maintains a higher mobility and higher entropy.20,42 Furthermore, the rearrangement of solvent
molecules can be the source of this eòect.40 However, the origin and detailed characteristics of
compensation are usually system-dependent and the generalization of universally applicable
rules is therefore diõcult.42 Despite the evidence for the phenomenon of EEC, it is also known
that the derivation of thermodynamic data by ITC is not without aw. It has been suggested
that deûcient experimental setups, especially with respect to reactant concentrations, are the
major source ofmeasurement errors in the directly measured quantities of Ka and ∆H, which
19
1 Introduction
consequentially translate into an error in ∆S as shown in subsection 1.2.1.40,70 _erefore, EEC is
oen likely to be an attribute of erroneous measurements, rather than a genuine feature of the
investigated sytem.20,40
1.3 Main Types of Interactions in Protein-Ligand Binding
_e complementary nature of an enzyme’s binding pocket and a ligand, termed ‘lock-and-key’
principle by Fischer, can be seen as the initial, intuitive approach for the design of a ligand.71 If a
ligand is to bind to a target, a basic requirement is a certain degree of shape complementarity
between ligand and target. _is concept was expanded by Koshland to the theory of ‘induced
ût’, which takes into account the exibility ofmolecules and the resulting possibility of a con-
formational adaptation of protein and ligand upon binding.46 In addition to the indispensable
knowledge about the three-dimensional shape of a protein binding site that enables assumptions
about the required three-dimensional shape of a putative inhibitor, the directed design of small
molecule inhibitors also requires information about the physicochemical properties of the bind-
ing pocket. _e knowledge about the orientation of polar functional groups and the locations
of hydrophobic as well as aromatic hot spots is necessary to devise the interaction pattern to
be emulated by a ligand in order to potently and selectively bind to its target.25,46,72,73 A recent
systematic investigation of protein-ligand complexes deposited in the Protein Data Bank (PDB)
provides insight into the relative abundance of diòerent types of intermolecular interactions
between small-molecule ligands and proteins.72 Hydrophobic interactions were found with the
highest abundance, hydrogen bonds constitute the secondmost abundant kind of interaction.72
_e fact that hydrophobic interactions occupy the ûrst position in this ranking corroborates the
medicinal chemistry dogma of the relative simplicity of the installation of hydrophobic groups
on amolecular scaòold. _e fact that the desolvation of apolar residues requires less energy than
that of polar moieties as well as the direction-independent nature of hydrophobic interactions
renders the installation of apolar functionalities on amolecular scaòold themost prominent
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and convenient, because comparably simple, starting point for a design eòort.72 However, an
increased hydrophobic character inevitably entails a reduced bioavailability due to reduced
solubility in an aqueous environment.72 Moreover, due to the lack of polar functionalities that
interact in a spatially speciûcmanner, an enhanced hydrophobic character is usually accom-
panied by a decrease in selectivity and thereby an increased oò-target toxicity.73 In contrast,
polar interactions such as hydrogen bonds underlie high geometric restraints. Hydrogen bonds
were found to be the secondmost abundant form of interactions between proteins and ligand
molecules. _ey resemble themain form of directed interactions in biological systems and the
determining factor in biomolecular recognition, impressively demonstrated by the pairwise
assembly of guanine and cytosine on the one hand and adenine and thymine on the other hand
in the formation of the double helicalDNA strand.72,74,75 As useful as they are, the nature of polar
chemical functionalities bears an inherent dilemma which is especially detrimental to drug
design. Not only is it comparably diõcult to install hydrogen bond donors and acceptors on a
molecular scaòold in a way that satisûes the geometric requirements of the binding pocket.72
Polar groups also come at a relatively high energetic cost of desolvation. _erefore, in order to
contribute favorably to the overall diòerence in Gibbs free energy, the bond formed between the
polar functionality and receptor must be suõciently strong to overcome the energy required
for desolvation.55 _emagnitude of the problem is additionally increased, if a charge-assisted
hydrogen bond is to be designed. A charged polar functionality on the ligand scaòold can form
a salt bridge with a charged residue on the protein, but it will also increase the energetic cost
of desolvation. Furthermore, it is necessary to distinguish the location of the hydrogen bond,
as a higher degree of solvent exposure was found to correlate with a lower contribution to the
overall aõnity, compared to that of hydrogen bonds buried deeply within the binding site.72
Naturally, hydrophobic interactions and hydrogen bonds are not the only interactions relevant
to biomolecular recognition, but clearly themost abundant.72
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1.3.1 Fluorine in Medicinal Chemistry
A common substitution in lead-likemolecules is that of a hydrogen atom for a uorine atom.
But despite the similar steric demands, which entails considerable electronic consequences.76
Fluorine is the elementwith the highest electronegativity electronegativity (χ). As a consequence
of the diòerences in χ, the charge distribution changes distinctly upon exchange of H for F.
While the C H bond has a distinctly apolar character (∆χC H = 0.4), the C F bond is notably
polarized, with uorine bearing the negative and carbon bearing the positive partial charge
(∆χC F = −1.5).76 _e C F bond thus has a partly ionic character and dipole moment and
therefore can be interpreted as a strong electrostatic interaction between Cδ+ and Fδ–.76 _is is
exemplarily reected in the successive shortening of all C F bonds upon the iterative exchange
of oneH-atom for one F-atom at a time in the transition from CH4 to CF4, which correlates with
the increasing positive polarization of the C atom with an increasing degree of uorination.76
Furthermore, due to the combination of its van der Waals radius (rvdW) of 1.47Å and nine
electrons, uorine bears amuch denser, and thus less polarizable, electron cloud than a hydrogen
atom (rvdW = 1.2Å, one electron) which assigns uorine a distinct role in the ûne-tuning of
physicochemical properties in organic molecules.76 _e manner in which these are altered,
however, is context dependent. _e peruorination of hydrocarbons leads to uorocarbons. Due
to the increased size of F, the arrangement of the CF2 units follows a helical fashion, opposed to
the straight but alternating (zig-zag type) arrangement of CH2 groups and, in addition to low
polarizability, accounts for the increased hydrophobicity as a result of the enlarged cross-section
area of the uorocarbons.77,78 Fig. 1 shows the structural diòerence between n-decanoate and n-
peruorodecanoate from Cambridge Structural Database (CSD) entries LUNZUP and GUSTIZ,
respectively.79,80
Futhermore, uorocarbons feature the unique property of lipophobicity, a term that expresses the
tendency of uorocarbons to form a phase of their own instead ofmixing with hydrocarbons.77
Moreover, the highly polarized C F bond leads to a stabilization of the C C bond by a reduction
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A B
Fig. 1: Structural consequences of peruorination of an alkyl chain. A Stick model of n-decanoate from CSD entry LUNZUP. B Stick model
of n-peruorodecanoate from CSD entry GUSTIZ.
of the size of the carbon orbitals,which furthermore entails a decrease in reactivity due to a lack of
energetically suitable orbitals.77 Furthermore, the slightly larger uorine atoms cover the carbon
backbonemore eõciently than hydrogen, which, in combination with reduced orbital energies,
renders uorocarbons one of themost inert groups of chemicals known to date.77 In contrast,
in a lead development eòort, usually not all C H units are converted into C F bonds. Rather,
speciûc sites of themolecular scaòold aremodiûed by the introduction of a single uorine atom
or uorinated structural motifs. _e interest in selectively installing uorine atoms in various
types of organicmolecules is reected in the vast number of uorination agents and strategies
and the plethora of uorine-containing structural motifs.81,82 Reasons for the incorporation
of uorine in drug molecules aremanifold. With respect to the conformational properties of
uorocarbons, the selective incorporation of single uorine atoms can be applied to ûne-tune
conformational preferences of alkyl chains,which can be important for the design ofmacrocyclic
drug molecules to preorganize them so as to enforce the conformation of the bound state in
themolecule in solution.82,83 Furthermore, uorine can alter the pharmacokinetic stability of a
molecule by aòecting rate and path ofmetabolism with respect to diòerent uorination sites
and alter the distribution of a drug in tissue.84 In this latter respect, uorine is advantageous
in so far, as the tissue distribution of the only natural isotope 19F can be traced nonivasively
bymagnetic resonance spectroscopy.84 _is principle has also been employed in NMR-based
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fragment screening.85 Furthermore, uorine can have an impact on the nature of protein-ligand
binding itself as described e.g. for the ûrst approved uorinated drug udrocortisone.82,86 As
opposed to the peruorination-induced non-polarizable, hydrophobic and lipophobic nature of
uorocarbons, the incorporation of a single uorine atom or a uorine-containing structural
motif can distinctly inuence the charge distribution of a molecule. A prominent example
for the utilization of uorine is the systematic replacement of C OH bonds for C F bonds
because of the similarly polar character of both and the lack of the hydrogen bond donor ability
of the latter. _e probing of the binding site of a carbohydrate-binding protein with uorinated
carbohydrate analogues demonstrated that the C F bond formidablymimics the polar character
of the C OH bond, and, due to the lack of the hydrogen bond donor ability, revealed positions
of the carbohydrate scaòold at which this ability was required for binding.87 Furthermore, the
investigation of collagen stability by the substitution of 4R-hydroxyproline for 4R-uoroproline
showed that the polar character of the C OH bond is necessary for helix stability, rather
than the hydrogen bond donor functionality.88 To sum up this combination of the practically
non-polarizable nature of a uorine atom and its strongly polarizing eòect, the term ‘polar
hydrophobicity’ was coined.89 Given the low polarizability of uorine itself, the introduction
of uorine-bearing motifs intuitively leads to an increased hydrophobicity of themolecule.82
However, such groups are oen associatedwith an increased polarity due to their strong electron
withdrawing nature.82 _is shi in charge distribution has consequences for proximal functional
groups. _e 2-monouorination or the 2,6-diuorination of a phenol distinctly decreases the
acidity constant (pKa) of the OH group, which can be used to increase binding aõnity or
install the diuorinated motif as a bioisostere for a carboxylic acid function.90–94 An oen
employed strategy is the replacement of a functional group with uorinated groups that not
onlymimic the geometry, but also the dipolemoment of the respective functionality. E.g., CF2H
can be used isosterically for OH, as the uorine atoms mimic the lone pairs of the oxygen
atoms and furthermore render the alkyl proton comparably acidic and thus enable it to act as
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hydrogen-bond donor.82 In addition to the implications for speciûc interaction patterns formed
between protein and ligand, uorination can also increasemembrane permeability and thereby
bioavailability due to an increased hydrophobic character of either the uorinatedmotif itself,
or e.g. a proximal basic functionality with reduced basicity due to the inductive eòect of uorine.
A uorinatedmotif can nonetheless bear a strong dipolemoment itself and therebymaintain
the ability to form polar interactions (compare OH and CF2H).82,95 Another example is the CF3
group. Intuitively, it seems reasonable to assume that the non-polarizable uorine atom and
isotropically uorinated structural motifs such as CF3 oen occupy hydrophobic pockets.82
_is is reected in the fact that the interaction between a receptor and either a uorine or
chlorine atom of a ligand is the secondmost abundant hydrophobic interaction in the PDB.72
Nonetheless, CF3 is also capable of interactingwith a carboxylate function due to the high positive
polarization of the carbon atom (‘tetrel bonding’).82 Another important aspect is the uorination
of aromats, which does not onlymodulatemetabolism or membrane permeability, but distinctly
changes the aromatic quadrupole moment and in consequence distinctly alters aromatic π-
π interactions. _is principle was used exemplarily to ûne-tune π-stacking interactions for
ligands of Carbonic Anhydrase (CA), the protease human Cathepsin L and the bacterial adhesin
FimH.96–98 Furthermore, various uorination patterns of the phenyl core of BSA inhibitors of
CA showed an increased aõnity compared to their non-uorinated counterparts.99–101 Beside
themeremodulation of overall molecular properties, uorine is capable of forming bonds to
amacromolecular target. An approach to assess the uorophilicity of a target’s binding site is
the systematic variation of the uorination pattern of a phenyl ring (‘uorine scan’).102 Fluorine
is known to engage in other polar interactions, albeit in putatively weak ones, for example
the interaction with the carbonyl group of a backbone amide bond in a Bürgi-Dunitz type
trajectory.76,103,104 Whether ligand-bound uorine forms hydrogen bonds with amacromolecule
is still matter of debate.76 However, there is crystallographic precedence for the involvement
of uorine in hydrogen bonds, most simply with itself in an HF-trimer motif , even though
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these are assumed to be weak compared to more commonly found hydrogen bondmotifs.76,105
Furthermore, due to its small size and the resulting low polarizability, uorine diòers signiûcantly
from its higher homologues. Unlike chlorine, bromine and iodine, uorine is capable of weakly
engaging in ‘side-on’ interactions with its lone-pairs, but does not engage in ‘head-on’ halogen
bonding, which refers to the interaction between the positively polarized cap of a halogen atom
(‘σ-hole’) with an aromatic π-system or a lone pair.106 Fluorine only shows a σ-hole in extreme
cases with little relevance to the design of drugs.106
1.4 Alkyl Chains inQSAR Studies
Due to the relative chemical simplicity of installing alkyl chains on amolecular scaòold and
the strictly systematic fashion in which their attachment can produce chemical variety, they
were employed in many studies aimed at establishing QSARs. Malham et al. found a favorable
development of standard free energies of binding along with an enhancement of the standard en-
thalpy of binding throughout a series of increasingly hydrophobic primary alcohols as inhibitors
of themajor urinary protein.107 _e entropic contribution became increasingly unfavorable with
increasing chain length, which could be traced back to dispersive protein-ligand interactions,
while the classical hydrophobic eòect fell short of explaining these ûndings.107 _e expansion
of cyclic hydrocarbons as subunits at the center of a Grb2-SH2 domain inhibitor scaòold was
observed to entail an increase in aõnity based on the burial of hydrophobic surface area and,
contrarily to the classical hydrophobic eòect, with increasingly favorable enthalpic contribu-
tions by Myslinski et al..108 Furthermore, it was found, that a gain in the standard enthalpy
of binding was compensated by a decreasing contribution of the entropic term by aliphatic
derivatives of this ligand series.109 Krimmer et al. succeeded in the design of water networks
around solvent-exposed parts that contribute favorably aõnity to the overall binding aõnity, by
decorating a thermolysine inhibitor scaòold with hydrophobicmoieties of various lengths and
degrees of branching.17,18 Cramer et al. demonstrated, that it can even be detrimental for aõnity
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to expose polar groups to the bulk solvent, rather than hydrophobic ones, due to solvation
phenomena.19 Jain et al. and Krishnamurthy et al. investigated hydrophobic tails of CAIs with
oligoethylene glycol-, oligoglycine- and oligosarcosine tails, by which the presence of EEC could
be demonstrated for these systems, whereas growing alkyl- and peruoroalkyl tails were shown
to increase aõnity for CA.68,110,111
1.5 Isothermal Titration Calorimetry
ITC is themethod of choice for the determination of the thermodynamic parameters governing
a (bio)molecular recognition process. _e reacting species in the sample cell is titrated step-
wise with a reactant from a syringe under constant stirring. A thermal element maintains the
temperature of the reference cell. A heat sensor reports the temperature diòerence between
sample cell and reference cell caused by the reaction heat (Fig. 2). _e power (PQ) required by
or withdrawn from the thermal element in order to keep the temperature of the sample cell at












Fig. 2: Schematic representation of a microcalorimeter, adapted from references [112],[22] and [20].
_e signals of the resulting thermogram are integrated and plotted against the molar ratio
of titrant to titrand, which enables the extraction of ∆H, Ka and stoichiometry of binding
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(ns) (Fig. 3).22 _us, by applying equations (2), (3) and (4), ITC provides all thermodynamic
parameters characterizing the binding reaction. More recently, the scope of extractable data
was augmented by themethod of kinITC, which provides information about kon and koff.113,114
_ereby, a full characterization of a binding event under one set of experimental conditions
becomes possible without the need to resort to other techniques with diòerent experimental
prerequisites or the need for the labelling of samples. For this purpose, the equilibration time
(τeq), i.e. the time the reaction solution in the sample cell requires to equilibrate (visible by the
return of the signal to baseline level in a thermogram) is calculated with koff as ût parameter.115
Hence, kon is accessible via equation (5). _e presence of kinetic information in the experimental
data becomes apparent in an equilibration time curve (ETC), which depicts the dependence of
an injection’s equilibration time on themolar ratio (rm). Fig. 3 shows the connection between an
experimental thermogram, the integrated heat values and the occurrence of kinetic information
in an ITC experiment.
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Fig. 3: A Thermogram measured for the interaction between hCAII and 4-nitrobenzenesulfonamide with an early injection colored in
blue and the injection closest to the inection point colored in orange. PQ denotes the applied power. B Integrated heat values from
the thermogram in Awith a green t function andmarked data points representing themarked injections inA. ∆H is represented by the
dierence between both plateaus, ns is the value of rm at the inection point. C Close-up view of the superimposed marked injections
in A. A broadening of the signal with proceeding titration is visible. D ETC derived from the broadening of injections with proceeding
titration.
1.6 Macromolecular X-ray Crystallography
X-rays interact with matter by scattering on the electron clouds of atoms.116 Crystallinematerial
is constructed periodically, i.e. composed from a multitude of unit cells in all three spatial
directions.116 _e reection of X-rays from a crystal in an X-ray diòraction (XRD) experiment











Fig.4: AUnit cellwith arbitrarydimensions a, b and c and the semi-transparent intersecting (234) planes in orange. B Side-on viewof a set
of planes in orangewith scattering atoms in black. The incident beams are diracted and enclose the Bragg angle θ with the respective
plane. As a consequence of geometrical considerations, θ is also present between the dashed line orthogonal to the set of planes and
lines between a scattering atom in the upper plane, which intercepts the middle incident and reected wave orthogonally. The green
lines represent the oset ∆ = 2 ⋅ δ. By Bragg’s law, constructive interference, and thus a reection, occurs, if ∆ is an integral multiple of λ.
From Fig. 4B it becomes evident, that the middle ray travels an additional distance of 2δ
compared to the uppermost ray. It can furthermore be deduced that δ can be calculated by
equation (8).
δ = dhkl ⋅ sinθ (8)
Father and Son Bragg showed, that in order for a reection to occur, θ must fulûll the following
condition, known as Bragg’s law:
2 ⋅ dhkl ⋅ sinθ = n ⋅ λ (9)
in which θ represents the incident angle of the impinging ray, λ the wavelength and n an
integer, known as the diòraction order. Constructive interference between rays reected from
diòerent planes within a set, and thereby eventually a recordable reection, can only occur for
values of θ that enable the diòerence in travelled distance ∆ = 2 ⋅ δ between two rays to be
an integral multiple of λ.118 Rotation of the crystal through the X-ray beam arranges several
sets of planes in an orientation that fulûlls equation (9) and the recording of one image per
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orientation thereby produces a dataset that contains information about the three-dimensional
distribution of electrons in a unit cell.118 _e dataset can thus be used to produce an electron
density map, that, combined with chemical knowledge about the crystal’s components, can be
used to assign atomic coordinates and thereby build a molecular model.118,119 Fig. 5 shows a
diòraction image recorded at beamline (BL) 14.1 at the BESSY II electron storage ring operated
by theHelmholtz-Zentrum Berlin and a snapshot of the crystallographicmodelling soware
Coot that shows an electron density map with modelled protein and ligand, produced from the
respective dataset.120,121
A B
Fig. 5: A Diraction image of an hCAII crystal. B Electron densitymapwith modelled protein and ligand generated from an XRD dataset
of an hCAII crystal soakedwith saccharin sodium salt.
_e investigation of crystalline materials by XRD has profoundly shaped the understanding
of the spatial organization of matter in that it provides information about the positions of
atoms relative to one another and hence enables the deduction of atomic radii, bond lengths,
the inuence of the chemical environment on these, or the characteristics of various types of
noncovalent interactions between chemical entities.72,118,122 Scattering of X-rays occurs on the
electrons surrounding an atom. Hence, the result of a successful XRD experiment is a three-
dimensional electron densitymap which resembles the shape of the chemical matter responsible
for the scattering.116 Assuming that the unit cell, from which the crystal can be constructed by
repeated addition of unit cells in all three spatial directions, does not have strictly the same
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orientation and thermal motion in every asymmetric unit, the ûnal electron density map will
always depict the average of electron distribution over all the asymmetric units in the whole
crystal.116 _us, it is intuitively understandable, that protein crystals usually feature a higher
degree of disorder than small molecules or peptide crystals, given the considerably larger size of
proteins.123 _e derivation of atomic properties such as radii and bond lengths are not as exactly
determinable from protein crystals as from small molecule crystals, especially not at resolutions
lower than common bond lengths in small molecules, and thus the subsequent building and
reûnement of amolecular protein model highly depends on restraints and constraints derived
from small molecule structures.116 Aer crystallization and incubation with a ligand of interest
and X-ray data collection, themain problem in the process of structure determination is the step
of phasing. _e XRD experiment delivers the intensities of the recorded reections from which
the structure factors (i.e. the amplitudes of the detected X-rays) can be calculated. However, the
phases of the recorded X-rays bear a considerably higher information content, but are lost in the
process of detection and thus need to be recovered subsequently.117 _is circumstancewas termed
‘phase problem’.117 As amplitudes and phases are not linked by a formal relationship, their only
mutual connection is themolecular structure or electron density.117 _us, if there is some initial
knowledge about either of these, it can be used for the determination of phase values.117 Under the
prerequisite of atomic resolutions < 1.2Å, directmethodsmostly used for small molecule crystals,
e.g. the utilization of known heavy atom sites, can lead to a solution to the phase problem.117
However, resolutions in this range are rarely observed for protein crystals, except for crystals
of intensively studiedmodel proteins such as CA. Molecular replacement with a structurally
similar model is a convenient, because simple and fast,method for phasing, but comes at the
disadvantage ofmodel bias.117 Furthermore, isomorphism of crystals (i.e. the circumstance that
both crystals comprise the same unit cell), can be used. Derivatizing one crystal by soaking it
in a solution of a heavymetal compound can alter the intensities of the reections compared
to those of the non-derivatized crystal. _e diòerences in intensities between both datasets
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can be used to infer the positions of the heavy atoms.117 A disadvantage of this approach is,
that metal species can putatively change the local environment in which they bind and hence
reduce isomorphism in the derivatized crystal. Furthermore, the phenomenon of anomalous
dispersion can be employed to derive the coordinates of the so called anomalous scatterers in
experiments such as single-wavelength anomalous dispersion (SAD).117 _is approach exploits
the inherent ability of atoms to absorb X-rays of speciûc wavelengths dependent on the atomic
number.118 _e absorbed photon excites an electron, which, upon falling back to its ground state,
emits a photon with a phase diòerent from that of the incident photon.118 Although an inversion
center is not necessarily present in a crystal, every diòraction pattern is centrosymmetric.122
Friedel’s law states, that the intensity (Ihkl) is the same for centrosymmetrically related reections
(equation (10)).122
Ihkl = Ih̄k̄l̄ (10)
In the presence of anomalous scatteres, however, this parity is broken due to the phase diòerence
between absorbed and emitted photon and the resulting disparity can be used to determine the
locations of the anomalous scatterers.122
1.7 Carbonic Anhydrase
_e enzyme family of Carbonic Anhydrases (CAs) has long since been subject of intensive
research. Since the discovery of the inhibitory acitivity of sulfanilamide towards CA and the
clinical investigation of the ûrst marketed CAI acetazolamide in 1954, CAs have been under
extensive investigation for the treatment of various diseases.101,124–126 Of the seven genetically
diòerent CA families (α-, β-, γ-, δ-, ζ-, η-, θ-CAs) known to date, α-CAs represent the only
family present in humans. It comprises 15 isoforms with diòerent organ and tissue distributions,
catalytic activities and susceptibilities to diòerent inhibitor classes.126,127 _e main function
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of α-CAs is the interconversion of carbon dioxide and water and bicarbonate and a proton
(reaction (11)).
CO2 + H2O HCO3– + H+ (11)
Consequentially, α-CAs are involved in pH regulation and more generally, electrolyte secre-
tion. Futhermore they are linked to several vital biological processes such as the synthesis of
d-glucose or lipids and themetabolism of bones but also in the pathogenicity of tumors and
neurodegeneration.127,128 _us, CAs oòer a broad range for the treatment of various diseases by
activation or inhibition. _e second reason for the high proûle of CAs in biophysical and biomed-
ical research are the physicochemical properties,which render especially the best-known isoform
II a highly convenient model for studies of the underlying principles of ligand binding.59,129 CAII
is a comparably rigid protein, is usually assumed to remain virtually unchanged upon ligand
binding.15 _is is especially convenient for the study of protein-ligand binding as diòerences
in binding behavior must originate from the structure of the ligands, rather than from confor-
mational changes of the protein.15 Furthermore, the conically shaped binding site comprises
two halves, one characterized by hydrophobic amino acid side chains (‘hydrophobic wall’), the
other by hydrophilic amino acid side chains.59 Furthermore, the binding of sulfonamides with
the catalytically active ZnII ion is well understood.59 Additionally, CAII is easily expressed and
crystallizes readily.59
1.7.1 Sulfonamides as Inhibitors of human Carbonic Anhydrase II
Aromatic sulfonamides are the classical pharmacophoremotif for the inhibition of CA since the
discovery of the inhibitor sulfanilamide.125,130,131 _e signiûcance of the sulfonamidemotif lies
in mimicry of the transition state of CO2 hydration (reaction (11)).132 A transition state analog is
generally assumed to be boundmore tightly than either substrates or products of the enzymatic
reaction.133–136 _erefore, the design of transition-state analogs aims at creating a stable chemical
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moiety with a van der Waals geometry and electrostatic surface potential as close as possible
to that of the transition state to be mimicked.136 _e neutral nature of the ZnII-bicarbonate
complex is maintained by the circumstance, that sulfonamides coordinate the ZnII cofactor
anionically.137,138 Fig. 6 depicts the similarity between a ZnII-bound bicarbonate ion resulting













Fig. 6: CO2 (2VVA,139 A), bicarbonate (2VVB,139 B) and benzenefsulfonamide (6GDC,140 C) bound in the active site of hCAII. Carbon atoms
are shown in orange, oxygen atoms in red, nitrogen atoms in blue and the sulfur atom in yellow. The ZnII cofactor is shown as grey
sphere, the coordinating hydroxide ion/water molecule as red sphere. Dashed lines represent the coordinating bonds between the
ZnII cofactor (grey sphere) and the side chains of His94, His96 and 119 (grey), coordinating bonds between the ZnII cofactor and the
respective ligand as well as hydrogen bonds between ligand and Thr199 (orange) and the bond to be formed between the ZnII bound
watermolecule/hydroxide ion (red sphere) and CO2 (red). Unless otherwise stated, this coloring code applies to all images.
_e sulfonamide group mimicks the geometry and polar interaction pattern of a bicarbonate ion.
In addition to the coordination to the ZnII cofactor, the coordinating oxygen or nitrogen atom
donates a hydrogen bond to the side chain of_r199 while an oxygen atom of either molecule
accepts a hydrogen bond from the nitrogen atom of said protein residue.129 A determining
feature for the binding of arylsulfonamides is the additional hydrophobic interaction between
the aromatic core of the inhibitor and the side chain of Leu198.141
1.7.1.1 The General Structure of Carbonic Anhydrase Inhibitors
_e general composition of classical sulfonamidic CAIs comprises a primary sulfonamide head
group, an aromatic ring, a tail region and a secondary recognition element (SRE).129 Grzybowski
et al. designed ligand 1 (Fig. 7) which features all four design elements of the general structure of
CAIs for the binding site of hCAII in a computer-assisted approach and showed a Kd of 30 pm in
35
1 Introduction








Fig. 7: CAI 1 developed in silico containing all four classical design elements of BSA CAIs. The sulfonamide head group is shown in green,
the aromatic ring in red, the tail in blue and the SRE in orange.
and tail portion, termed ‘ring approach’ and ‘tail approach’, have led to amultitude of CAIs.127
_e ring approach entailed a wide variety of diòerent ring systems that were investigated for
their usefulness in CAIs and refuted the former dogma that aromatic rings are essential for the
inhibitory performance of CAIs.143 _is became especially useful, as it was found that CAIs
incorporating saturated ring systems strongly inhibited the supposedly sulfonamide-resistant
human isoform III. Ultimately, the ring approach led to the development of themarketed drugs
dorzolamide and brinzolamide.143 However, a large number of the resulting compounds did
show inhibitory power against the ubiquitously expressed isoform II in the human body, but
were also potent allergens, and thereby unsuited for the use as therapeutics.143 _e tail approach,
introcuded by Supuran, increased the chemical variability of CAIs in a convenient way, seeing
that the attachment of electrophilic functionalities to nucleophilicmoieties on the ring scaòold is
chemically simpler than the construction of ring systems. _e tail approach aims at ûne-tuning
physicochemical properties of already known CAIs by the introduction of residues that are
ionized under physiological conditions and thereby improve solubility as well as therapeutic
performance and reduce side eòects.143
1.7.1.2 Thermodynamics of the Carbonic Anhydrase II – Benzenesulfonamide System
Taking into account the relatively high rigidity of Carbonic Anhydrase II (CAII), Krishnamurthy
et al. sought to separate the individual contributions of individual parts of CAIs to the overall free
energy of binding.129 Based on the assumption, that the electrostatic interactions mainly depend
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on the ligand’s pKa and that the dispersive interactions between aromatic ring and protein are
merely a function of hydrophobicity (measured by the logarithmic partition coeõcient (logP)),
semiquantitativeQSARwere established for a series of diversely uorinated BSAs.144 _e ûndings
allowed the conclusion, that electrostatic interactions are themain driving force for bindingwith
a contribution of 65% by the interaction between the ZnII cofactor and the sulfonamide anion,
and 10% added by the hydrogen network formed between the sulfonamide inhibitor and_r199
in the active site.144 Hydrophobic interactions between the aromatic ring and the protein account
for the residual 25%.144 Despite the relative physicochemical simplicity of the concept of acidity,
it entails many eòects that are diõcult to separate: An increased acidity of the ligand provides
for a higher fraction of anionic sulfonamide for binding, but also reduces the anion’s Lewis,
which counterbalances the former eòect.144 _us, it was argued that the optimal pKa value for a
BSA CAI is equal to the pH value of the surrounding medium.144 In addition, the authors also
issued a note of caution with respect to the general applicability of these values, seeing that the
investigated ligandmolecules were comparably small, and thus should not be considered a valid
model for larger BSA ligandswhich, e.g., bear a large hydrophobic tail.144 In general, an enhanced
ability to form hydrophobic contacts with the protein, usually achieved by the attachment of
hydrophobic tails, correlates with an increase in aõnity. However, a non-optimally designed
hydrophobic tail can frustrate an increase in aõnity due to steric repulsion.129 Apart from either
favorable or unfavorable contributions, non-optimally designed tails can furthermore entail EEC
(subsection 1.2.4), as demonstrated by Krishnamurthy et al. by the use of BSA inhibitors with
oligoglycine, -sarcosine and -ethylene glycol tails.68 Microcalorimetry revealed indiòerence of
∆G to the tail lengths as enthalpic and entropic contributions cancelled each other out.68 A later
study byMecinović et al. demonstrated that alkyl- and peruoroalkyl chains did indeed show
an increase in ∆G with increasing tail length.145 Interestingly, ligands investigated in the latter
study show shape complementarity between the tail and the hydrophobic wall. In combination
with the work by Krishnamurthy et al. this gives rise to the assumption, that not merely the
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accumulation of hydrophobicmatter on a hydrophobic surface is of importance to binding, but
that shape complementarity between the interacting entities plays a distinct role.
1.7.1.3 Kinetics of the Carbonic Anhydrase II - Benzenesulfonamide System
Not only has CAII been employed as a model system for the investigation of protein-ligand
binding thermodynamics but also for the establishment of kinetic selectivity proûles of diòerent
BSAs for CA isoforms and the demonstration of the concept of intrinsic kinetics.146,147 _e latter
aimes at the determination of kinetics without superimposed protonation eòects and reveals
the inherent kinetic properties of a ligandmolecule.147 Earlier studies aimed at elucidating the
fundamental mechanics underlying the association and dissociation processes and thereby the
determinants of kon and koff. In general, the following observations weremade with respect to
the kinetics governing the CA – BSA complex formation and disassembly:
a) kon is pH dependent137
b) koff is pH independent137
c) BSAs with large hydrophobic substituents can have faster association rates than smaller
ligands.129
Especially themechanism of association has been subject to debate for a long time. In general, it
is necessary to diòerentiate observations a) and c) in the argument. With respect to the chemical
species it was postulated, that association between CA and a BSA can occur via either of the
following reactions.129
ArSO2NH2 + CA ZnII OH2+ ArSO2NH ZnII CA + H2O + H+ (12)
ArSO2NH2 + CA ZnII OH ArSO2NH ZnII CA + H2O (13)
ArSO2NH– + CA ZnII OH2+ ArSO2NH ZnII CA + H2O (14)
ArSO2NH– + CA ZnII OH ArSO2NH ZnII CA + OH– (15)
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It was found that only reactions (13) and (14) can reproduce the experimental data based on
the fractions of reactive species considered in the respective equation.129 Already in the 1970s,
King et al. argued, based on experimental evidence, that an encounter between the uncharged
BSA and CA species is the likely premise for the association process. Later, although not
experimentally evidenced, Krishnamurthy et al. assumed the charged species to be the intially
reactive forms.129,144,148,149 Based on the experiment-derived assumption that the initial approach
occurs between the neutral species, it was argued that the mechanism of association must
comprisemore than one step, given the necessity to release one sulfonamidic proton and that,
furthermore, a preequilibrium governed by hydrophobic interactions is likely to account for the
increasing kon along a series of BSAs with increasing hydrophobicities.148,149 _is is especially
important to consider with respect to observation c). Based on the reasoning of Taylor et al.,
Gaspari et al. conûrmed the kinetic signatures of binding of a subset of increasingly hydrophobic
compounds already investigated by Taylor et al. in a complementary approach comprising
surface plasmon resonance (SPR),MX andMD simulations. _e latter comprised a four-state









_e hydrophobicity-based intermediate (F) represents a state, in which protein and ligand
interact merely hydrophobically. It is then commuted into the advanced intermediate (S), which
describes a polar coordination of the ligand with polar functionalities in the active site and the
ZnII-bound hydroxide ion prior to the ûnal, crystallographically observable binding pose, into
which it is convertedwith the ûnal forward rate constant (k3). _is step furthermore includes the
transfer of the sulfonamide proton to the hydroxide group, which supports reaction 14.150 Unlike
reaction (6), k2 and k−2 here refer to the isomerization of the ligand’s state rather than that of
the receptor. With respect to the question of proton transfer, it was furthermore suggested that
deprotonation of the sulfonamide function is unlikely to occur before approaching the active site,
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given that the pKa only changes negligibly along the path of association.150 _is raises a doubt
about the theory of the interplay between the fraction of free sulfonamide anion and its Lewis
basicity. Based on the insights provided by Gaspari et al., the free species of ligand should not be
of concern for the rate of interaction, seeing that initially the uncharged sulfonamide approaches
the active site. While these ûndings paint a plausible picture of the association mechanism,
they do not consider the circumstance, that it was shown by means of neutron diòraction, that
the oxygen species coordinating the ZnII cofactor is a water molecule in the crystalline state,
even at pH 9.151 _us, the association mechanism, despitemany eòorts to elucidate it, is still not
doubtlessly explicable, while the dissociation mechanism remains even more obscure.
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_e storage of protein crystals and the execution of XRD experiments at cryogenic temperatures
has a distinct impact on the outcome ofXRD experiments.152 An early perception of the inuence
of X-rays on protein crystals was, that the chemical matter within the crystal can be, to some
extent, radiolyzed. _e products of these reactions are free radicals and ionic species, which
themselves are capable of initiating chemical reactions, that ultimately lead to chemical modi-
ûcations of the crystallizedmolecules, and thereby putatively the disintegration of the crystal
itself.152 Measurement at cryogenic temperatures (oen 100K in practice) distinctly reduces
the occurrence of radiolysis events and furthermore slows down themotion of their reaction
products through the crystal.152 An inherent problem of the freezing of protein crystals, usually
grown in aqueous media, is the formation of ice. _e density of water ice is lower than that of
water, which leads to an increase in volume of water aggregates within the solvent channels.152
_is will either lead to a change of the crystal’s lattice due to the displacement of its molecules,
or may even cause a breaking of the crystal to release the mechanical strain imposed by ice
formation.152 Ice crystals formed on the surface of the protein crystal can have similar eòects.152
Furthermore, ice crystals themselves diòract X-rays, and thereby cause a powder diòraction
pattern of rings, that will impede the analysis of Bragg reections that happen to be located close
to or underneath these rings.152 A suitable cryoprotectant forestalls the formation of crystalline
ice by promoting vitrifaction of the sample.152 If the crystallization or soaking conditions do not
already provide for suõcient cryoprotection, the choice of the cryoprotectant is of paramount
importance for the success of the planned XRD experiment. _ere is, however, a putative disad-
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vantage to the use of cryoprotectants, if crystals are to be soaked with small organicmolecules.
Given that many cryoprotectants are small organicmolecules themselves, they can also bind
in a protein’s active site and thereby change, impede or even prevent the binding of the small
molecule of interest. _is is possibly the case with hCAII and glycerol. Glycerol is a common
cryoprotectant for the hCAII–BSA system, and is found in numerous of such complexes in the
PDB, e.g. in entry 5LL8 (Fig. 8).
Fig. 8: Glycerol in the active site of hCAII in orangewith an adjacent BSA ligand in purple.
To enable soaking experiments without the inuence of glycerol, a new cryoprotectant was
sought. Tab. 1 lists the investigated solutions.
Tab. 1: Investigated cryoprotectants.






d-Fructose (anhydrous)a 25% w/v
d-Glucose (anhydrous)a 25% w/v
d-sucrose (anhydrous)a 25% w/v
d-Sorbitol (anhydrous)a 25% w/v
Trisodium citrateb 1.6m
Potassium sodium tartrateb 2.5m
a Dissolved in a solution containing 3.0M ammonium sulfate, 0.1M TRIS
at pH 7.8. b Dissolved in demineralizedwater.
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Crystals of similar size and grown from the same batch of protein in 2.7m ammonium sulfate,
0.1 m TRIS at pH 7.8were incubated in the solutions listed in Tab. 1 for 30min and ash-frozen in
liquid nitrogen. Images were recorded on aMAR345 image plate detector with Cu-Kα radiation.
Fig. 9 shows diòraction images for all tested conditions.
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Fig. 9: Diraction images of hCAII crystals incubatedwith dierent cryoprotectants. A rac-1-aminopropan-2-ol. B Betaine hydrochloride.
C Glycine. D L-Proline. E Sarcosine. F D-Fructose. G D-Glucose. H D-Sucrose. I D-Sorbitol. J Trisodium citrate. K Potassium sodium tartrate.
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Trisodium citrate solution caused streaked reections and the incubation with d-fructose,
aqueous potassium sodium tartrate, d-sorbitol and d-sucrose entailed ice rings. Based on visual
inspection,many conditions yielded similarly strong diòraction, e.g. rac-1-aminopropan-2-ol
and d-glucose. It was found, however, that the (R)-enantiomer of the former coordinates to
the ZnII cofactor (Fig. 10), similar to already reported CA-inhibiting polyamines spermine and
spermidine.153 d-glucose was not found near the active site, but only in three remote binding
sites between crystal mates (Fig. 10), and was thus chosen as cryoprotectant for the preparation













Fig. 10: (R)-1-aminopropan-2-ol (2) in the acitve site of hCAII and D-glucose (3) in the hCAII crystal packing. Omit composite electron
density maps are shown at 1 σ in blue and dierence electron density maps at 3 σ in green. A Valence bond formula of 2 and 3. The
anomeric carbon atom of the latter is marked with an asterisk. B (R)-1-aminopropan-2-ol (2) in the hCAII active site. C Overview of D-
glucose binding sites on the hCAII asymmetric unit. D Highly populated binding site of β-D-glucose molecule, which interacts with the
side chainsof Lys39, Gln255 and Lys257. Eα-D-glucosebinds to thebackbone carbonyl atomof Thr177. Fβ-D-glucosebinds to thebackbone
carbonyl atom of Thr177.
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3 Investigation of Varying Alkyl Tail
Lengths and Geometries
A question that has not yet been answeredwith respect to the hCAII–BSA system is the inuence
of diòerent geometries of the alkyl chain relative to the phenyl core. _erefore, n-alkyl and n-
alkyloxy substituted BSAs 4 – 13 (Tab. 2)were investigated bymeans ofMX and ITC to elucidate
the inuence of diòerent tail geometries on the thermodynamics and kinetics of binding.
















Compound R PDB Compound R PDB
4 H 6GDC 10 Me 6I0W
5 Me 6GM9 11 Et 6I1U
6 Et 6HQX 12 Pr 6I2F




3 Investigation of Varying Alkyl Tail Lengths and Geometries
3.1 Crystallographic Results
_e necessary prerequisite for the detailed investigation and comparison of the inuence of the
n-alkyl and n-alkyloxy tails is that the non-tail moieties of themolecules maintain the binding
pose of the unsubstituted BSA 4, which is shown in Fig. 11.
A B
C D
Fig. 11: A Superposition of n-alkyl derivatives (4 light green, 5 orange, 6 red, 7 violet, 8 light blue, 9 cyan) in the hCAII active site with
solvent excluded surface representation. Side chain atoms forming the hydrophobic patch are colored in light red. The ZnII cofactor
is shown as grey sphere. B Superposition of n-alkyloxy derivatives (10 light cyan, 11 green, 12 beige, 13 blue) according to A. C n-alkyl
derivatives in the active site in stick represenation. Residues forming polar interactions with either ligands or ZnII cofactor are shown.
D n-alkyloxy derivatives in the active site in stick represenation. Residues forming polar interactions with either ligands or ZnII cofactor
are shown.
Omit electron densitymaps of all ligands in Fig. 11 are shown in Fig. 12. All ligands reûned to an
occupancy of 1.0. _e alkyl tails of compounds 4 – 8 are accommodated on the hydrophobic
wall in an all-trans conformation. Ligand 9, deviantly, adopts a gauche conformation. _e
change in composition of both molecular series entails a distinct structural eòect:Whereas the
torsion angle between the phenyl-bound ethylene unit and the aromatic ring approximates 60°
for n-alkyl derivatives, it only slightly diverts from 0° for the n-alkyloxy derivatives.
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A 4 B 5 C 6
D 7 E 8 F 9
G 10 H 11 I 12
J 13
Fig. 12: n-alkyl and n-alkyloxy substituted BSAs bound in the active site of hCAII. 4 (A), 5 (B), 6 (C), 7 (D), 8 (E), 9 (F), 10 (G), 11 (H), 12 (I),
13 (J). Omit 2mFo–DFc and mFo–DFc maps are contoured in blue at 1 σ and green at 3 σ, respectively.
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_e structural diòerence is a consequence of steric and electronic eòects of the aliphatic carbon
or oxygen atom bound to the phenyl moiety. It is thus only possible for molecules 12 and 13
to interact extensively with the hydrophobic patch, whereas this is possible ‘earlier’ within the
n-alkyl series for specimens with more than one tail atom (6 – 9). A quantiûcation of these
characteristics was approached by the calculation of solvent excluded surface areas (SESAs),
which are better suited for the correlationwith thermodynamic paramters than solvent accessible
surface areas (SASAs).154 Solvent excluded surface areas were estimated by equation (17).
SESA =
SESAP + SESAL − SESAPL
2
(17)
Tab. 3 shows SESAs of all compounds in their bound conformation, calculated contact area with
the protein, the increments in contact areas of ligands with successive chain lengths and the
ratio of contact area to the surface of the respective ligand.
Tab. 3: Investigated n-alkyl and n-alkyloxy BSAs.
Compound Chain length Ligand / Å2 Contact / Å2 Incrementa Ratiob
4 n = 0 151.3 127.9 0.85
5 n = 1 162.6 130.9 3.0 0.81
6 n = 2 178.8 139.3 8.4 0.78
7 n = 3 196.0 144.4 5.1 0.74
8 n = 4 213.2 160.2 15.8 0.75
9 n = 5 229.2 168.8 8.6 0.74
10 n = 1 178.0 137.1 0.77
11 n = 2 196.1 140.6 3.5 0.72
12 n = 3 213.1 162.4 21.8 0.76
13 n = 4 224.1 165.9 3.5 0.74
a Increments refer to the dierence between ligands of successive lengths. b The Ratio column provides the fraction
of the contact area of a ligandwith the protein in comparison to the ligand’s surface area.
Notably, ligands 7 and 9 exert a lower eõciency at burying surface area in the n-alkyl series.
_e geometric setting of the n-alkyloxy series caused by the conjugation between an oxygen
lone-pair and the aromatic π-system entails a pairwise development of contact area within the
ether series. _e interface area is similar for compounds 10 and 11 on the one hand, and for 12
and 13 on the other, whereas there is a pronounced diòerence between ligands 11 and 12. _e
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notion to bury surface area recedes within the n-alkyl series until compound 7, increases for 8
and recedes again for 9.
3.2 Isothermal Titration Calorimetry
A novel titration protocol was applied to enable reliable extraction of both thermodynamic and
kinetic information from ITC data. It is based on the variation of injection volumes to shi
injections to the ûrst half of an ITC thermogram (before the inection point) and a reduction in
the number of injections in the saturation region.
3.2.1 Thermodynamic Results
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Fig. 13: Globally tted values of ∆H°(green), values for ∆G° (blue) calculated from the globally determined values of Kaand values for
–T∆S°(red) calculated from the former two. Standard errors of three individual measurements are given to present experimental uncer-
tainty. As 9 was characterized in a displacement setup against 4-carboxybenzenesulfonamide (20), error bars resemble the tting error
for the global tting of ∆H° and the propagated errors of ∆G° and –T∆S°.
3.2.1.1 n-Alkyl Series
A linear increase in the free energy of binding can be observed from 4 to 6. Notably, 7 seems to
represent a ‘pit’ of EEC:40,62 ∆H° recedes from the trend of linear growth, whereas the decrease
of the unfavorable entropic contribution culminates in a virtually favorable contribution and
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thereby prevents a loss in ∆G° compared to 6. Compound 8 shows a renewed increase in ∆G°,
which results from a distinct increase in the enthalpic contribution, as the entropic contribution
becomes distinctly unfavorable again, opposed to the increasingly favorable enthalpic and
decreasingly unfavorable entropic developments for ligands 4 – 6. Notably, compound 9 exerts
a similar thermodynamic behavior as 7 compared to the respective preceding compound, as
its binding is enthalpically weaker, while the entropic term becomes favorable. _is coincides
with the same eõciency at burying surface area of 7 and 9. However, compound 9 still gains in
the overall free energy of binding, which is easily explained by themere burial of surface area.
However, residual mobilities derived from high-resolution MX models can partly shed light on
the issue. Fig. 14 shows the numberedmodel of 9 taken from the respectiveMXmodel and plots



















































Fig. 14: A Numbered model of 9. B Atomic B-factors normalized on the average B-factor of all atoms (including protein and other ligand
atoms)within a radius of 6.5 Å around the respective atom. C Like B, but only taking into account protein atoms for normalization.
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4 – 6 are similar in this respect, pronounced diòerences become apparent for compounds 7
and 9. Notably, the relation between these ligands is the same with both methods applied for
normalization. Ligand 7 is the ligand with the highest residual mobility, which coincides with
its entropically favorable contribution to binding, whereas the loosening of the interface area is
reected in the receding enthalpic term. Intuitively, the renewed entropic loss and enthalpic
gain of 8 can be seen as a result of its stronger immobilization. Importantly, this reasoning does
not apply to the thermodynamic development from 8 to 9, as 9 is themost strongly immobilized
ligand in the series. _e binding of 9, however, entails the formation of a gauche conformation
about the bond between atoms 13 and 14, which appears to be necessary for an optimal burial
of surface area, but simultaneously counterbalances the enthalpic gain resulting thereof. _e
thermodynamic similarity of 7 and 9 thus seems to have diòerent origins due to the changing
topography of the protein surface.
3.2.1.2 n-Alkyloxy Series
As with the pairwise development of interface areas, also a pairwise development of the ther-
modynamic signatures was observed. _e diòerence between 11 and 12 (∆∆G° = −3.1 kJmol−1)
is larger than either of the diòerences for the pairs 10/11 (∆∆G° = −2.2kJmol−1) and 12/13
(∆∆G° = −1.0kJmol−1). A similar development was found for the diòerence in ∆H°. It dif-
fers by smaller amounts between the pairs 10/11 (∆∆G° = −2.0kJmol−1) and 12/13 (∆∆G° =
−1.0kJmol−1) than between compounds 11 and 12 (∆∆G° = −3.6kJmol−1), which is reected in
the larger diòerence in interface areas of compounds compounds 11 and 12 (Tab. 3). Opposed
to the n-alkyl series, the interface area formed between ligands and hCAII does not correlate
with the entropic development for the n-alkyloxy derivatives, as 13 is entropically more heavily
penalized than 12. In this case, however, it needs to be considered, that 13 is structurally diòerent
in so far, as it is the only compound whose last chain atom protrudes from the binding pocket,
a circumstance which might give rise to this ûnding. Interestingly, also residual mobilities
reect the pairwise geometric development already explained (Fig. 14). _e tails of the larger
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compound of each pair (11 and 13 show a higher residual mobility than those of the respective
smaller compounds, although a larger amount of surface area is buried by the larger ligands. _is
resembles the relationship between compounds 7 and 5/6 and contrasts that between molecules
7 and 8/9. Compounds 7, 11 and 13 all orient the terminal methyl group toward the entrance
of the binding site. Opposed to this arrangement, all other compounds except for the shortest
tail-bearing compounds in each series (5 and 10) accommodate the terminal ethyl moiety on
the hydrophobic wall in a vertical fashion and, despite a smaller amount of buried surface area,

















































Fig. 15: B-factor analysis for the n-alkyloxy series analogous to Fig. 14.
Interestingly, both series diòer overall in the partitioning of ∆G° into ∆H° and ∆S°. Binding
of compounds in the n-alkyl is enthalpically distinctly stronger than binding of compounds
in the n-alkyl series, but is also more heavily penalized entropically. A reason for this might
the arrangement of water molecules in surrounding the complex. Water molecules are hardly
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discernible above the active site, which renders an argument based on the formation of water
networks hypothetical in this case. Desolvation of small-molecule inhibitor and protein is a
process that must necessarily occur before the actual binding between both, but is diõcult to
grasp experimentally. Fig. 16 depicts the development of the calculated solvation free energy
(∆Gsolv, bearing the inverse sign of the desolvation process) for both series, computed quantum
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Fig. 16: Solvation free energies for both molecular series (not including compound 9).
Intuitively, ∆Gsolv recedes with increasing hydrophobicity and reects the increasingly favorable
aõnity for the n-alkyl derivatives. _e special position of 7 within the series, however, cannot be
explained. Neither can solvation (and thereby desolvation) account for the pairwise development
within the n-alkyloxy series, as∆Gsolv also develops in a linear fashion in this series. However, the
distinctly larger values of ∆Gsolv for the n-alkyloxy compounds may conribute to the enthalpic
and entropic discrepancies between both series.
As the changing physicochemical characteristic in both series is an increasing hydrophobic
surface, it can be reasonably assumed that the hydrophobic eòect is responsible for the thermo-
dynamic ûndings.62 Given the paired enthalpic development in the n-alkyloxy series, however,
which correlateswith the paired development in surface burial, it seems more likely that the ther-
modynamic ûndings are attributable to the dispersive interactions between ligands and protein,
rather than the hydrophobic eòect. It is therefore also more likely, that the pit of compensation
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in the n-alkyl series is a consequence of the nature of the ligands, rather than a consequence of
the hydrophobic eòect.
As shown in Tab. 3, the ligands 7 to 9 bury successively more surface area on the protein, which
becomes visible in the close-up of the tail regions of these compounds (Fig. 17).
Fig. 17: Close-up of the tail regions of compounds 7 (violet), 8 (light blue) and 9 (cyan).
It can be inferred, that the pit of compensation seems to be reected in the residual mobilities
of atoms. 7 shows distinctly larger normalized B-factors than any of the preceding n-alkyl
derivatives, which can be seen as a hint to the origin of the compensatory thermodynamic
behavior and the favorable entropic contribution. It is furthermore worth noting, that the tails
of 8 and 9 both show decreased residual mobility compared to 7. _is raises the assumption,
as for the n-alkyloxy derivatives, that the transition from three to four tail atoms resembles a
partitioning into two groups ofmolecules within the n-alkyl series, considering the ability to
bury surface area. Contrarily to the above, a correlation between the eõciency at surface burial
and decreasing entropic contribution, does not hold in this case. _e fashion, in which the tail is
accommodated on the hydrophobic patch, is changed aer compound 8. Compound 9 deviates
from its predecessors in the series in that it adopts a gauche conformation instead of an all-trans
conformation, which seems to be reected in the thermodynamic data. _e again favorable
entropic contribution of 9, however, cannot be easily explained.
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3.2.2 Kinetic Results
With themethod of kinITC it was possible to extract the kinetic parameters for both molecular
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Fig. 18: Kinetic data for both molecular series except compound 9 recorded by kinITC. Error bars represent the standard error for three
measurements.
3.2.2.1 n-Alkyl Series
Association rates become increasingly higher with growing chain lengths for compounds 4 – 8.
However, pairs of ligands with similar kon values were observed (4/5, 6/7). Dissociation rates
develop diòerently. Compound 4 diòers distinctly from 5, which in turn is not discernible from
the succeeding molecules in the series. Compound 9 was characterized in a displacement setup,
which does not allow for the extraction of kinetic information.
3.2.2.2 n-Alkyloxy Series
An increase in the association rates was found across the series, while the dissociation rates
develop in a pairwise recession. Compound 10 and 11 dissociate distinctly faster than com-
pounds 12 and 13, which follows the pairwise trend in which these compounds bury surface
area on the protein.
A revealing comparison is that between 8 and 12 as both compounds have the same tail length
and bind to hCAII with virtually the same free energy of binding of ∆G° = −42.6kJmol−1.
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However, the kinetic signatures of both compounds diòer distinctly. 8 binds with a higher ve-
locity (kon = 1.46 ⋅ 105 m−1 s−1) than 12 (kon = 6.40 ⋅ 104 m−1 s−1), but the latter is themore slowly
dissociating compound (koff = 2.2 ⋅ 10−3 m−1 s−1) compared to the former (koff = 4.9 ⋅ 10−3 m−1 s−1).
_e rationale of Gaspar et al.for the hCAII–BSA system, that increased hydrophobicity accel-
erates the association step between ligand and protein, can be reasonably applied in this case,
assuming that the ether oxygen atom renders 12more polar than 8.150 _e reason for the reduced
dissociation rate of 12 can be explained by the a comparison of the burial of surface area. At
almost the same surface area, 8 buries less surface than 12 due to an increased distance between
the terminal methyl group and the hydrophobic wall, which is depicted in Fig. 19
Fig. 19: Close-up of the tail regions of compounds 8 (light blue), and 12 (beige).
_e increased proximity between the tail of 12 and the hydrophobic wall compared to 8 provides
for stronger hydrophobic interactions and thereby impedes the dissociation, rendering 12 a
more ‘shape-eõcient’ binder than 8. _is circumstance furthermore demonstrates, that aminute
chemical alteration can be used to shed light on the determinants of binding kinetics.
Interestingly, the increasingly less unfavorable desolvation for both series agrees with the con-
tinous increase in kon. Desolvation is a necessary prerequisite to complex formation between
protein and ligand, and needs to be taken into account as contributing factor. _is furthermore
supports themechanism of association elucidated by Gaspari et al.(subsubsection 1.7.1.3).150
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3.2.3 Comparisonwith Surface Plasmon Resonance
A noteworthy observation in the course of this work is the observation, that the kinetic values
of the n-alkyl series show the same trends as the data recorded by SPR for compounds 4 – 7 in





















































































Fig. 20: Comparison of kinetic data from ITC experiments (left ordinates)with SPR data from an earlier study (right ordinates).
Despite the resemblance of trends, the values for kon and koff obtained from ITC experiments are
approximately one order ofmagnitude lower than those derived from SPR experiments. It can
be reasonably assumed, that protein molecules in solution show a diòerence in ligand binding
behavior compared to protein molecules that are immobilized on a chip as in the case of SPR.
Molecules in solution are unhindered in their mobility. On an SPR chip, diòerent orientations
fo the opening of the active site entrance relative to the immobilization matrix can be conceived.
Depending on the amino acid residue that participates in immobilization by chemical coupling,
the binding sitemay be oriented either toward thematrix or the solvent. Either ‘specimen’ can
be assumed to show diòerent ligand binding behavior. SPR thus delivers information about an
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‘average’ binding site. Furthermore, ITC is an equilibrium-basedmethod, whereas SPR records
data based on a steady state in a ow chamber. Despite these putatively crucial diòerences
between both methods, the reason for the ûnding that ITC records lower kinetic rate constants
for these series ofmolecules must remain unresolved herein.
3.2.4 Further InvestigatedMolecules
In addition to the characterization the compounds discussed in this chapter, additional com-
pounds were investigated both crystallographically and bymeans of ITC.Within the n-alkyl
series, these compounds were the hexyl 14, 6SBL), heptyl (15), ethylhydroxy (16, 6RG5) and
butylhydroxy (17, 6SEY) derivatives. Pentyl (18, 6SBM) and hexyl (19) derivativeswere excluded
from the n-alkyloxy series. Fig. 21 shows the crystallographicmodels of hCAII in complex with
these compounds.
A 14 B 15 C 16
D 17 E 18 F 19
Fig. 21: Further n-alkyl and n-alkyloxy BSA CAIs 14 (A), 15 (B), 16 (C), 17 (D), 18 (E) and 19 (F)with omit electron densitymaps.
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Models of hCAII in complex with compounds 14, 16, 17 and 18 were deposited in the PDB.
Complexes hCAII–15 and hCAII–19 were not deposited, as the last two tail atoms of either
ligand were not resolved in the electron density and could not bemodeled (Fig. 22).
A B
Fig. 22: Close-ups of the tail region of compounds 15 (A) and 19 (B)with 2mFo – DFc density at 1 σ in blue andmFo – DFc density in green
at 3 σ after renement. The latter indicates one further tail atom for each ligand, but is toweak to be modeled.
ITCmeasurements revealed a comparably high level of noise and occurrence of artifacts for
ligands 16 and 17, which is especially detrimental to kinetic analysis (Fig. 23). Compounds 14,
15, 18 and 19 had to bemeasured in a displacement setup due to their high potencies. However,
analysis of the data showed comparably high uncertainties that did not allow for structure-
correlated intrepretation. Furthermore dilution titrations suggested interactions between the































Fig. 23: A Exemplary processed thermogram of a titration of compound 16 into hCAII. A distinctly uneven baseline and artifact signals
are visible. B Close-up of A for the rst 1000 s of the titration experiment.
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3.3 Conclusions
_is study shows the importance ofminute systematic chemical alterations in the investigation
ofmolecular series for the establishment of detailed QSARs. Despite the argument, that studies
of this kind produce results which are unique and only relevant for the investigated system,
the concepts they deliver are needed, in combination with the results of similarly detailed
studies, to incorporate them in computer programs that can be applied to rationalize ûndings
in systems that have not yet been examined in a strictly systematic fashion.21 Moreover, the
results presented herein demonstrate, that the stringent development of a chemical scaòold
need not necessarily exert linear thermodynamic or kinetic binding proûles. It additionally
reveals, how the change of a ligand’s preferred conformation by aminute chemical change can
manipulate thermodynamic and kinetic signatures of binding, which gives rise to the ûnding,
that the n-alkyl and n-alkyloxy analogs with identical tail lengths swap their binding kinetic
properties at an unchanged binding aõnity. It furthermore demonstrates, that a novel ITC
measurement protocol yields both thermodynamic and kinetic data, the latter of which shows
the same trends as data derived from SPR, the current gold standard for the retrieval of kinetic
information.
62
4 A NewMeasurement Protocol for the
Reliable Extraction of Thermodynamic
and Kinetic Data from Isothermal
Titration Calorimetry Experiments
Many adjustable parameters are available in the design of an ITC experiment. _e applied
concentrations of protein (cP) and ligand (cL), which determine themolar ratio (rm) at every step
of the titration experiment, that value of rm, that resembles the stoichiometry of binding (ns) of
the complex formed between protein and ligand, the number of injections (N i), the injection
volume (V i), the injection time (ti) (with the injection rate (vi) resulting of the former two), the
delay between injections (ts, which most strongly inuences experimental runtime), the stirring
speed (vr), theWiseman parameter (c), the heat of injection (Q) and the parameter for the total
heat (h), introduced by Tellinghuisen.112,155
Considerable theoretical and experimental eòort has gone into the ûne-tuning of ITC experi-
ments to ensure reliable thermodynamic results at minimally required experimental eòort.20,156
Less know-how is available for the application of kinITC. In addition to a plot of integrated heat
values it provides the ETC, which shows the dependency of the equilibration time (τeq) on the
ratio of injected species and the species in the cell.113,114 Beginning from the so called ‘standard
protocol’, the aim of this chapter is to provide amanual for the execution of high-quality kinITC
experiments for the reliable extration of both thermodynamic and kinetic parameters.156
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While the standard protocol will yield the thermodynamic information about a binding event,
data precision can be improvedwith a smaller N i and a largerV i, which is particularly important
for the comparison of congeneric ligand serieswith onlyminimal changes of the lead scaòold, and
was substantiated by theoretical and experimental studies.18,19,156 _is approach becomes even
more important, if subsequent computational studies rely on the experimental values.20 Fig. 24
shows thermograms, integrated heat values and ETCs for diòerent simulated experimental setups
for a one to one binding reactionwith the following constants: Kd = 620nm, ∆H° = 15kcalmol−1,
cP = 20µm, cL = 200µm and ts = 180 s. Fig. 24A show the outcome of an experiment following
the standard protocol (typically 20 – 30 injections).156 It yields a thermogram with suõciently
strong injection heats and allows the determination of ∆H° and Kd. _ese data were simulated
under the assumption of 100% active protein sample,which yields a stoichiometry of ns = 1.0. In
practice, however, ns = 1.0 is rarely found. Because of partial degradation and denaturation of the
protein, ns < 1.0 is themore commonly found scenario. Under the assumption, that the purity
of the small molecule sample is exactly known, the stoichiometry of the binding event provides
information about the fraction of active protein (i.e. protein competent to bind the ligand)
present in the whole sample. Fig. 24B shows values for a titration experiment with a fraction of
70% of active protein, which leads to an inection point of the isotherm at ns = 0.7. Notably,
the peak of the ETC is also shied to the same stoichiometry. _is point is worth pondering
before spending valuable protein and ligandmaterial for a kinITC experiment. _e signiûcance
of the diòerences between ETCs A and B lies in the number of kinetically analyzable data points
(i.e. injections). _e ETC’s le part (smaller rm-values before the peak is reached) is of particular
importance for kinetic analysis. Injections in this range of the curve diòer signiûcantly from the
instrument noise. As the injection signals determining the right part of the ETC diòer much less
from noise, they bear a comparably high uncertainty. Given this aspect, it becomes obvious that
titration of a protein sample with a low fraction of binding-competent protein material with the
standard protocol will lead to less data points in the kinetically crucial region of the ETC, while
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most data points fall in the ETC’s right half. _is scenario culminates in the application of a
thermodynamically optimized protocol with few large injections.155 Fig. 24C demonstrates, that
in this scenario the ETC contains almost no information in the region prior tomid-titration, and
even less if an imperfect protein sample is used. Fig. 24D shows the outcome of a simulated ITC
experiment optimized to measure both thermodynamic and kinetic values despite the practical
reality of an imperfect protein sample. For kinetic analysis, as many injetions as possible are
desirable before themid-titration injection (for which τeq is the highest). Injection protocols
in Fig. 24A – C will thus not provide a solution to the problem. Accordingly, it is necessary to
relocate data points to the region prior to mid-titration by varying the injection volumes, while
keeping the same (or a similar) number of injections to maintain the same overall run time as a
standard protocol and thereby eõciency. Consequently, the corresponding injections need to
be smaller in volume than injections deûning the same region of thermogram 1A. _is in turn
requires larger injection volumes for the fewer ûnal injections that deûne the saturation region
in the right part. Both, an increase of the species in the cell at a given ligand concentration in the
syringe or a decrease of the syringe concentration at a given cell concentration would shi more
injections to the le part beforemid-titration is reached, but at the same time prevent saturation,
which is an important determinant for thermodynamic data quality.156 One could account for
the inactive fraction of protein by adjusting its concentration in a way that the solution in the
cell will contain an apparent 100% active protein. However, this will additionally increase the
amount of exposed inactive protein, and the danger exists that unspeciûc interactions with the
ligand occur and will deûnitely requiremore protein material. _e experiment in Fig. 24D can
thus be seen as a combination of titration protocols in A and C to ensure best possible titration
data for thermodynamic and kinetic information despite the practical obstacle of a partially
inactive protein sample.
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Fig. 24: Plots for simulated titration experiments. Plots on the left contain thermograms (left ordinate and abscissa inD) and the resulting
integrated heat values as dots (right ordinate, abscissa in A). Plots on the right show the corresponding ETCs (abscissa inD). A ‘Standard
protocol’ with V i = 2.0 µL and ns = 1.0. B Like A, but with ns = 0.7. C Thermodynamically optimized protocol with V i = 3.8 µL and ns = 1.0.
D Kinetically optimized protocolwith varying V i and ns = 0.7.
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4.1 Experimental Design
To validate the approach, ITCexperimentswere conducted, following the diòerent titration proto-









Fig. 25: A Valence bond formula of compound 20. B 20 bound in the active site of hCAII. Omit electron densitymaps are shown in blue
(2mFo–DFc , 1 σ) and green (mFo–DFc , 3 σ).
To maintain comparability among protocols, the same concentrations of protein and ligand
were used throughout all protocols to maintain the quantities c, h and rm, which predominantly
determine the thermodynamic readout of ITC experiments.155
4.1 Experimental Design
Experiments were carried out based on the following quantities: cP = 20µm, cL = 210µm
(considering the purity of the ligand), ts = 180 s, T = 298.15K, vr = 1000 rpm, initial diòerential
power PQ = 5.0µcal s−1 and a ûlter period of 1. Additionally, a protocol was tested, which
combinesV i of the standard protocolwith ti from the kinetically improved protocol to investigate
the impact of the injection speed on the results. _e applied injection schemes are shown in
Tab. 4.
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Tab. 4: Applied injection schemes for the assessment of thermodynamic and kinetic data quality.
Protocola V i / µLb ti / s vi / µL s–1
Standard 19 × 2.0 4.0 0.5
Kinetically optimized
15 × 1.5 3.0 0.5
1 × 2.0 4.0 0.5
3 × 4.5 9.0 0.5
Mixed
15 × 2.0 3.0 0.7
1 × 2.0 4.0 0.5
3 × 2.0 9.0 0.2
_ermodynamically optimized 10 × 3.8 7.6 0.5
a Color coding for the following plots. b An additional injection of 0.3 µL preceded every experimental
run.
Titrations were carried out in degassed 40mm HEPES buòer at pH 7.8. _e purity of com-
pound 20 was determined to 95.2% by analytical HPLC by Khang Ngo. _e concentration of
the DMSO stocks of 20 used for the preparation of the syringe solution were corrected for this
impurity so that the ûnal concentration of 20 in the syringe was cL = 210µm. Measurements
for each protocol were carried out ûvefold. Raw and processed thermograms, integrated heat
values and ETCs are provided in the experimental part.
4.2 Results
4.2.1 Thermodynamic Results
Fig. 26 shows thermodynamic results for titration experiments of the hCAII–20 system with
the above protocols.
All protocols yield comparable aõnity values within themargin of error although themixed
protocol suggests a deviation from the other protocols. While the mixed protocol shows a
notable diòerence between average and globally ûtted value, these are virtually the same for the
other protocols, respectively.
Furthermore, the standard protocol shows a larger error margin than the thermodynamically
optimized one. Notably, the error margin of the kinetically optimized protocol lies in between

























Fig. 26: Thermodynamic data of the hCAII–20 complex obtained with dierent titration protocols. The color coding is adapted from
Tab. 4. Filled bars represent the sample mean values, empty bars represent the globally tted value. Error bars represent the extremes of
a condence interval of 95% for ve measurements under the assumption, that the experimental values are T-distributed.
of ∆H° and –T∆S°, showing that the kinetically optimized protocol even provides a beneût for
the collection of thermodynamic data compared to the standard protocol. _emixed protocol
virtually yields the same thermodynamic signature as the kinetically optimized protocol, however
with even lower error margins. It also seems to produce reliable thermodynamic data.
Naturally, the previously published systematicwork on the CAII–20 systemneeds to be acknowl-
edged, especially the diòerent experimental outcomes between the present and previous studies.
While the diòerent protocols applied here all yield aõnity values between 640 nm and 680 nm,
an exhaustive study reported values around 690 nm and 1400 nm.70,157,158 Furthermore, ∆H° was
communicated to be between −18 kJmol−1 and −60 kJmol−1 while the measurements herein
present an enthalpic signature of −60±1 kJmol−1. _emost prominent diòerences between those
studies and the present one are that diòerent enzymes were used (bovine Carbonic Anhydrase II
(bCAII) instead of the human isoform herein) and diòerent measurement buòers (phosphate
buòered saline (PBS) as opposed to HEPES herein). Whether these are themain reasons for the
observed deviations is diõcult to answer without further independent experiments.
4.2.2 Kinetic Results
An essential quantity for the evaluation of the kinetic data is the instrument’s response time
(τITC). _e τexp is a ût parameter and needs to fall in close proximity of the actual physical,
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calorimeter-speciûc value (which strongly depends on the cleanness of the cell).159 _e response
time of the ITC200 was determined with ethanol in triplicate as described in the experimental














Fig. 27: Mean values (lled columns) and values after consideration of the globally determined thermodynamic parameters (empty
columns) for τexp in s. Color coding as in Tab. 4.
All protocols seem to enable reasonable ûtting of τexp with a deviation from τITC of approximately
0.5 s. Notably, the kinetically optimized protocol (green) provides the smallest error margin.
































Fig. 28: Globally tted and mean values for koff and kon for the applied titration protocolswith the same coloring schemes as in Tab. 4.
Expectedly, the kinetic parameters derived from the thermodynamically optimized protocol
diòer signiûcantly from those extracted by the other three protocols. While koff is in good
agreement among the latter, kon agrees between standard and kinetic protocol by themargin of
error, but themixed protocol results in a deviation. As only koff is ûtted for the determination
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of the equilibration time but not kon, the diòerencemust result from the diòerence in Kd. kon
results from the quotient of koff and Kd (equation 5, p. 15).113 _e diòerence between the three
protocols lies in themid-titration region, from which Kd is determined, and where diòerent
injection rates are applied. Whether they are responsible for the deviation in Kd and thus in
kon cannot be ultimately concluded herein. However, caution is advisable for the comparison
of ITC-derived kinetic data obtained at varying injection rates. One should not bemisled by
the comparably sized error values for the thermodynamically optimized protocol. _e kinetic
values are well comparable between diòerent experiments within the series of experiments with
this protocol. However, the χ2 values between 1.5 and 3.4 for the ût of the ETC show, that kinetic
data cannot be reliably extracted from such a short protocol. Notably, the kinetically optimized
protocol yields the smallest error margins of all protocols and seems to be a legitimate approach
to obtain both thermodynamic and kinetic data from the same ITC experiment.
4.2.3 Comparisonwith Surface Plasmon Resonance
Nowadays, surface plasmon resonance (SPR) is themethod of choice for themeasurement of
biomolecular reaction kinetics. _ermodynamically, ITC and SPR seem to provide the same
values for a given protein-ligand system using the samematerials as demonstrated in a study
with bCAII and 20.158 However, ITC and SPR diòer fundamentally with respect to the state of
the protein, which is either freely oating in solution or immobilized on an SPR chip via a linker.
As Zihlmann et al. showed, kinetic data from ITC and SPR can be in good agreement, albeit
with a rather constant oòset between both methods.160 Whether a linear correlation between
both methods is always given or depends on the nature of the studied protein-ligand system
remains to be seen, as kinetic data from ITC experiments are scarce at themoment. However,
it is not unreasonable to assume that the immobilization of the protein on a chip surface can
signiûcantly inuence its ability to bind a ligand, as is described in subsection 3.2.3. With this
argument about the comparison between ITC and SPR in mind, it is reasonable to at least
question whether kinetic data from ITC and SPR do necessarily fall within the same range or
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even have to show the same trends within congeneric series of molecules, or if the inherent
properties of the protein-ligand system bear diòerently on the experimental outcome of both
methods due to the diòerent measurement conditions. _erefore, it is necessary to ensure robust
data collection for kinetic data analysiswith ITC to enable reliable comparisonwith SPR data. In
a previous study from our group, 20was used as a reference compound for SPRmeasurements.150
Kinetic values extracted from these experiments were Kd = 0.89µm, kon = 6.5 ⋅ 104 m−1 s−1 and
koff = 5.8 ⋅ 10−2 s−1. Despite falling within the same range, they do diòer by the values presented
herein by 30% (kon) and 50% (koff). _is discrepancy is distinct, but not as large as a diòerence
of one order ofmagnitude for themolecular series investigated in chapter 3, which underlines
the validity and importance of diòerentiating the diòerent experimental conditions of ITC and
SPR.
4.3 Conclusions
It was shown that a combination of the standard protocol and a thermodynamically optimized
protocol with varying injection volumes can be used to extract both thermodynamic and kinetic
information for 1:1 protein-ligand reactions from a single titration with themethod of kinITC
with lower uncertainty in the thermodynamic and kinetic quantities than with the standard
protocol. We found putative evidence for an inuence of the injection rate on Kd and thereby kon.
Obviously, the combination of standard protocol and thermodynamically optimized protocol
will double experimental runtime and increase the error in the thermodynamic parameters
compared to the latter. _is is, however, a necessary compromise, seeing that the kinITCmethod
relies on data points before and next to the mid-titration region of an ITC experiment. As
demonstrated herein, a suõcient number of data points in this region can be diõcult or even
impossible to achieve with either standard or thermodynamically optimized protocol, especially
considering that protein samples are seldom perfect and contain 100% of active protein.
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4.3 Conclusions
Whilemany theoretical considerations have advanced the ûeld ofmicrocalorimetry, only practi-
cal aspects and empirical ûndings can be described herein. For future work with themethod of
kinITC,mathematical models that predict putative dependencies of the kinetic parameters on
experimental settings would be desirable.
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5 The Inuence of Varying Fluorination
Patterns
Herein, a thermodynamic and kinetic uorine-scan of the active site of hCAII, similar to the
one carried out by Olsen et al. for the serine protease thrombin, is described.102 For this purpose,
variously uorinated and para-substituted BSA ligands were investigated. Fig. 29 shows the
general structure of these compounds, as well as the deûnition of certain geometricmeasures,
that quantitatively describe their binding in the active site of hCAII. _e respective data for















Fig. 29: A General structure of investigated compounds. Numbers refer to the uorinated positions. B Deniton of geometric measures
listed in Tab. 5
In 2007, Krishnamurthy et al. investigated BSAs 4 (chapter 3) and 21, 22, 23, 26, 27 and 32
(Tab. 5) as CAI by ITC to assess the individual thermodynamic contributions of the diòerent
kinds of interactions of these ligands to the overall diòerence in Gibbs free energy of binding to
bCAII (structurally closely related to hCAII) and concluded, that 65% were contributed by the
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interaction between the sulfonamide anion andZnII cofactor, 10% by the hydrogen bond network
established between ligand and protein and 25% by hydrophobic interactions between aromatic
ring and protein.129,144 Scott et al. later usedmolecules 4, 21, 22 and 23 among other compounds
to establish a thermodynamic QSAR of CAIs.99
Considering the circumstance, that comparably little kinetic data derived from ITC experiments
has been published so far, it seems appropriate to provide further validation for themethod,
especially under the prerequisite of an adjustedmeasurement protocol for the reliable extrac-
tion of both thermodynamic and kinetic data (chapter 4). Hence, the above compounds are
convenient in this respect as thermodynamic data for subsets of these are available from the
previously mentioned studies.
5.1 Crystallographic Results
Crystallographic models of compounds 21, 22, 23, 26 and 27 were already available in the
PDB under the accession codes 2WEG, 2WEO, 1IF4, 1IF5 and 1IF6. However, structures for
all compounds in Tab. 5 weremade to increase resolution andmaintain the same conditions
for all complexes. In general, two diòerent conformations of uorinated compounds in the
hCAII active site were observed, which orient the phenyl ring diòerently, as depicted in Fig. 30.
_e ûrst orientation is adopted by compounds 21, 22, 23, 26, 27 and 29 (mean value of torsion
angle τmean = 54.2 ° with a standard deviation of ±3.5 °)and mimics that of non-uorinated
compound 4, which will be referred to as ‘reference conformation’. _e deviating orientation
adopted by compounds 24 and 26 – 32 (τmean = 2.2 ° ± 1.9 °) will be referred to as ‘alternative
conformation’. It is worth noting, that the reference conformation enables the key interaction
between the aromatic portion and the side chain of Leu198.141 Tab. 5 lists the torsion angle (τ)
between the nitrogen atom, coordinated to the ZnII cofactor, sulfur, the ipso carbon atom C1
and C2. _e contact between the aromatic ring and Leu198 results in a short distance to one of
the terminal Cδ methyl groups, the distance between Cδ and the centroid of the ring is listed in
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Tab. 5, together with the deviation from the direction of the normal vector of the phenyl ring
plane. In the reference conformation, the angular deviation is comparably small. In the second
alternative conformation, it amounts to approximately 55°.
At ûrst, monouorinated compounds 21 – 23 will be considered. Comparable to 4 and 5,
compound 23 merely orients its para-uoro substituent toward the entrance of the active site
funnel, virtually adopting the same geometry as 4 and 5 with respect to both the ligand pose
and the orientation of the adjacent residue _r200. _e latter residue is identically oriented
as in the apo–hCAII structure (PDB entry 3KS3165). Compounds 21 and 22 (Fig. 30) orient
the uorine atoms in opposite directions. Notably, the uorine atom of 21 is located within a
distance of the hydroxy function of_r200 that allows for the inference of a hydrogen bond,
as already pointed out by Scott et al.99 Compound 22 positions the uorine atom toward the
rim of the hydrophobic wall. _is seems reasonable to expect with respect to the preference of
uorine atoms and uorinatedmotifs to occupy hydrophobic pockets.82 With this binding pose,
22 adopts a conformation very similar to 4 and 5 and_r200 also remains in an unchanged
orientation, whereas 21 pushes _r200 slightly out of position (RMSD = 0.2Å), likely due to
steric repulsion with the ortho uorine substituent. Interestingly, the combination of 21 and 22
with respect to the uorination patterns to reveal the diuoro derivatives 24 and 25 results in
diòerent orientations of the latter two compounds. Whereas 25 is virtually a superposition of the
binding modes of 21 and 22, 24 adopts the alternative orientation of the phenyl ring. Supposedly,
this shi results from steric repulsion with the terminal methyl group of Val121. With respect
to _r200, 25 induces the same geometry already observed for 21. _e binding of 24, however,
entails two diòerent movements of_r200, one of which can be described as toward the ligand,
which can be caused by an attractive interaction. Notably, compounds 26, 27 and 29 adopt both
orientations of the phenyl ring in the crystal structure. Importantly, the alternate conformations
found for compounds 26 and 27 merit the renewed production of crystal structures herein,
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A 21 B 22 C 23
D 24 E 25 F 26
G 27 H 28 I 29
J 30 K 31 L 32
Fig. 30: Binding modes of uorinated compounds 21 (A), 22 (B), 23 (C), 24 (D), 25 (E), 26 (F), 27 (G), 28 (H), 29 (I), 30 (J), 31 (K) and 32 (L)
and the respective Thr200 residue in orange. Fluorine atoms are shown in light blue, the ZnII cofactor as gray sphere. 4 and the according
Thr200 residue are shown in purple. Omit 2mFo–DFc and mFo–DFc maps are contoured in blue at 1 σ and green at 3 σ, respectively.
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seeing that no alternate conformations could be resolved in the already depositedmodels 1IF5
(26) and 1IF6 (27, Fig. 31).
A B
Fig. 31: Compounds 26 (A) and 27 (B) in orange in comparisonwith ligand conformations observed in PDB entries 1IF5 and 1IF6.
Furthermore, diòerence electron density of the ûnal models indicates, that a second binding
conformation seems possible also for compounds 21, 22, 28 and 30, although the diòerence
density is too weak to properly allow modeling of the second, deûnitely minor populated
arrangement. Reconsidering the interpretation of the density for 21 and 22, a second putative
binding conformation appears visible in the positive diòerence density, negative diòerence






Fig. 32: Compounds 21, 22, 28 and 30 in orangewith putative additional binding conformations. Compounds 21 (A) and 22 (B) are shown
in comparisonwith compound 24 in purple to indicate the second conformation. Compounds 28 (C) and 30 (D) are shown in comparison
with compound 29 in purple to indicate the second conformation.
5.1.1 Movement of Thr200
_e notion, that hCAII has a highly rigid binding site which is not inuenced structurally by the
binding of ligands, needs to be relativized, seeing that almost all of the diversely uorinated BSAs
examined herein cause themovement of_r200.129 _e orientation of_r200 in the hCAII–4
complex and in the unliganded protein will also be referred to as the reference state in this
respect. It was found that ligands distinctly displace_r200 with respect to its position in the
reference state in two manners (Fig. 30). A quantiûcation by RMSD analysis relative to the
hCAII–4 complex can be found in Tab. 5. _e ûrst one can be described as amovement away
from the ZnII cofactor, the second one as amovement toward it. Binding of compounds 21, 22,
25, 26 and 27 entails movement away from the zinc ion. Compounds 28, 29, 30, 31 and 32 cause
amovement toward the zinc ion. Given the comparably low degree to which 22 displaces the
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amino acid, it is still reasonable to assume the same geometry as in the reference structure. _e
same holds for 23. In case the ortho position is occupied by a uorine atom, the slightly larger
size of F compared to H results in a shi of _r200 (21 and 25) away from the ZnII cofactor.
Obviously, an additional o-uorine atom attached to the monouoro-22 results in a strong
rotation of the phenyl ring and the o-uorine atom is accommodated in a small niche next to
Val121. _r200 is shied away from the zinc ion. _e di-ortho and di-meta substituted derivatives
26 and 27 bind with two conformers simultaneously. In the di-ortho case, _r200 is shied,
whereas the di-meta derivative binds with _r200 in nearly unchanged orientation. _e series
of 28 – 32 share the 2,3,5,6-tetrauoro pattern. Apart from 31 and 32, they all share two binding
poses. However, these are diòerently populated. _e p-Me derivative 29 shows both orientations,
interestingly with reversed occupancies compared to 26 and 27. In the case of 28 and 30, the
second orientation is only found with minor occurrence (Fig. 32). Notably, 31 shows only one
orientation of the phenyl ring. Possibly, this is caused by the circumstance that the attached
n-propyl group at C4 adopts a gauche conformation and occupies some space required for the
placement of the ligand in the alternative conformation. Given the observation, that ligands
with only onemodeled orientation can have a putative second binding orientation (Fig. 32), this
can be seen as a hint for a putative second orientation of_r200 that might be caused by the
indicated, but not modeled, second orientation of the ligand. Although the RMSD values for
themovements of_r200 in the hCAII–ligand complexes are small, it is probable that these
movements are a feature of ligand binding, as the structures were solved at very high resolutions
around 1Å.
5.1.2 Accommodation of a Fluorine Atom in a Hydrophobic Pocket
As reasoned above, the diòerent orientation of 24 compared to 25 is likely the avoidance of steric
repulsion between the o-uorine substituent and the side chain of Val121. _emovement of the
ligand furthermore entails a deeper burial of them-uorine substituent in the cavity bounded




Fig. 33: Hydrophobic pocket in orange, that accommodates meta and ortho uorine substituents, exemplarily depicted with com-
pounds 22 (A) and 24 (B),which adopt either the reference (τ ∼ 55°) or alternative conformation (τ ∼ 0°).
_is suggestion is supported by the circumstance, that also compound 26, which bears no meta
substituent, partially adopts the alternative orientation. Tab. 5 shows values for the interface
area between the uorine atom accommodated in the hydrophobic pocket deûned above. It
is noteworthy, that for the alternative orientation (24, 27 – 32) the interface values for the
accommodation of either ortho or meta substituent are larger than for the standard orientation
(22, 25) and in a similar range across either themeta or ortho substitutedmolecules. Although
the elucidation of universal structural rules is impeded by the presence of an alternative binding
mode, the binding of compounds 21, 22, 24 and 25 reveals, that the preference of a uorine
atom in meta position to bind to the hydrophobic pocket exceeds that of a uorine atom in ortho
position to be oriented toward_r200.
_e comparison of compounds 24 and 25 furthermore allows for the conclusion, that the
preference for a uorine atom in meta position to bind to the hydrophobic pocket is stronger
than that of a uorine atom in ortho position to be oriented toward_r200.
Given the complex picture painted by various substitution patterns, itwas furthermore sought to
establish structures of hCAII complexes ofmerely para-substituted BSAs 34 – 37, which would
putativelymaintain the same binding pose as unsubstituted BSA 4, and furthermore not displace
_r200 (Fig. 34). However, given that compound 37 is protolytically active at themeasurement
pH of 7.8 with the phenolic OH functionality, it was not taken into account for thermodynamic
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and kinetic analysis. _e same was argument was considered for compound 20. Compound 36
was characterized thermodynamically, but did not yield reliable kinetic parameters.
A 34 B 35 C 36
D 37
Fig. 34: para-substituted BSAs 34 (A), 35 (B), 36 (C) and 37 (D) in orangewith omit electron densitymaps in blue at 1 σ (2mFo – DFc) and
3 σ (mFo – DFc) and the respective side chain of Thr200. Compound 4 is shown as reference in purple.
5.1.3 AnUnexpected Dimerization Product
Electron density for hCAII in complex with compound 32 revealed, that not only the catalytic
center next to the zinc ion is occupied by a ligand but that a further intriguing molecule, that
represents a dimer of 32 is found in the crystal structure. It features intramolecular edge-to-
face π-stacking interactions. Fig. 35 shows dimer 33 and its crystallographicmodel geometry
suggested by omit electron density maps.
Considering the van der Waals radii of a carbon atom in benzene (rvdw(Car) = 1.77Å) and a
phenyl bound uorine atom (rvdw(Far) = 1.47Å) , the sum of 3.24Å is larger than the intramolec-




















Fig. 35: Valence bond formula of dimerization product 33 (left) and crystallographic model from the hCAII complex with 2mFo–DFc map
contoured at 1 σ and mFo–DFc map in green and 3 σ (right). Carbon atoms are shown in orange, uorine atoms in light blue. Carbon
atoms used to display intramolecular π-stacking are shown in purple. π-stacking interactions are indicated as purple dashed lines with
the respective distances between atomic dispositions of F and C.
of the aromaticmoieties, which leads to a decreased electron density around the carbon atoms.
Compound 33 binds in a second, surface-exposed binding site, covered by a second crystal mate.
_ere, it engages in both, classical hydrogen bonds and interactions oen observed between
uorine atoms and proteins. Fig. 36 shows an overview of two hCAII symmetrymates clamping
molecule 33 and a close-up view of the binding site. With respect to the catalytic center, a fair
amount of diòerence density indicates binding of a ligand. _e dimer 33, however, could not be
modeled in the active site, although pronounced residual mFo – DFc density above themodeled
monomer 32 suggests, that 33 also populates the active, albeit with a very low occupancy.
A B C
Fig. 36: A Surface representation of two hCAII crystal mates,which enclose dimer 33 between them. B Closeup of the binding site of 33
between two hCAII crystal mates. C Residual mFo–DFc density at 3 σ (green) and −3 σ (red) above the active sitewithmodeledmonomer
32 (for dierence electron density of 32, s. Fig. 30L).
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It was not clear, whether dimer 33 was formed in the soaking drop or had already been present
in the commercially available solid. Consequentially, it was desisted from further usage of 32 for
ITC experiments, given the unclear quality and purity of the sample.
5.2 Thermodynamic Results
Titrations of hCAII with a diòerent batch of 4 resulted in amolar amount of transferred protons
of np = −0.1mol L−1 (subsection 14.10),meaning that on molar scale, 0.1 protons are transferred
to the surrounding buòer per formed hCAII–4 complex. As sulfonamides are known to bind
hCAII as anions, a proton from the sulfonamide group must be released into the surrounding
buòer. Under the assumption, that the ligand associates with the protein in the uncharged state
as described by Gaspari et al., the proton needs to be transferred to the surrounding medium
from within the active site. _e reason for the small detected amount of 0.1 moles L−1 supports
the assumption, that, prior to sulfonamide binding, the fourth vertex of the tetrahedral ZnII
complex is occupied by a hydroxide ion. _e hydroxide ion can react with the proton to form
water, which does not react with a buòer molecule, and thus does not alter the overall reaction
heat in a buòer-dependent manner. _us, the thermodynamic signatures, depicted in Fig. 37,
which describe the entire complex formation process of the investigated compounds, can be
assumed to not be overlaid by a protonation step.
_e addition of a uorine atom in para position of 4 entails amoderate increase in binding free
energy (∆∆G°4→23 = −1.3 kJmol−1), whereas the addition of a uorine atom in ortho position
leading to compound 21 entails a distinct change in the thermodynamic binding proûle compared
to that of 4, with a distinctly stronger enthalpic advantage and entropic penalty, which lead to
a slightly larger gain in ∆G° (∆∆G°4→21 = −2.2 kJmol−1). A similar development holds true for
meta-uorinated compound 22 to a lesser extent in the enthalpic and entropic parameters, but a
further increase in overall aõnity (∆∆G°4→22 = −4.2 kJmol−1). Interestingly, the combination
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Fig. 37: Thermodynamic signatures of compounds 4, 5 and 21 – 31 measured in 10mM HEPES buer at pH 7.8 with ∆G° in blue, ∆H° in
green and –T∆S° in red. The values for 4 and 5 are taken from chapter 3. For 4, 5 and 21 – 31, globally tted values of three direct titrations
are given. Error bars represent the standard error of measurement for these compounds, based on three measurements. Compounds
29 – 31were characterized by a displacement experimentwith subsequent global tting, as they could not be characterized directly due
to their high anities. For these compounds, values of Ka and ∆H° from globally tted displacement experiments and the values of ∆G°
and –T∆S° calculated from the former two are given. Error bars represent the error of global tting for Ka and ∆H°. Error values for ∆G°
and –T∆S°were calculated from the former two under assumption of propagation.
binding pose as the former three (21, 22 and 23) and orients both uorine atoms accordingly,
amounts to more than the sum of its parts in the thermodynamic signatures. Both enthalpic
beneût and and entropic penalty are larger than for either of the former three compounds and
yield an overall gain in binding free energy (∆∆G°4→25 = −6.8 kJmol−1). Mono-ortho andmono-
meta uorination as well as 2,5-diuorination seem to be the enthalpically favored substitution
patterns in the investigated series,whereas the para uorination in 23 has no enthalpic advantage.
However, the alternative combination of 21 and 22 to form the ortho-meta 24 entails a distinct
diversion from the enthalpic and entropic signatures of the parent compounds. Hardly any
entropic contritbution is observable in HEPES buòer, rendering 24 amerely enthalpic binder
within the investigated series ofmolecules, with a similar value of ∆G° as 25. Notably, a second
ortho uorine atom as in compound 26 reduces the entropic penalty of compound 21, but also
the enthalpic beneût, which leaves the free energy of binding virtually unaltered compared to
21. Di-meta uorination in 27 has a similar eòect, given the diòerent enthalpic and entropic
signatures ofmonouorinated 22 and diuorinated 27 and their highly similar values of ∆G°
(∆∆G°22→27 = −0.7 kJmol−1). Tetrauorination of 4 to aòord 28 does not provide a distinct
increase in aõnity over related compounds, seeing that the addition of two uorine atoms to
24 yields an almost negligible increase in ∆G° of (∆∆G°24→28 = −0.5 kJmol−1). In this particular
87
5 The Inuence of Varying Fluorination Patterns
case, it is obvious that the addition of two additional uorine atoms is thermodynamically futile.
_e addition of amethyl (29) or ethyl group (30) in 4-position, however, provides an increase
in aõnity for the tetrauorinated scaòold. Given the second possible binding mode of the
ethyl derivative 30 (Fig. 32), however, it is questionable, whether an increased ability to form
interactions with the hydrophobic wall, as shown in previous studies, is the only reason for
the increase in aõnity.140,150 It must certainly play a role, however, given the circumstance, that
compound 31, which does not show a second binding mode that would allow for an interaction
between the n-propyl chain and the hydrophobic wall, has a slightly decreased aõnity compared
to 30 (∆∆G°31→30 = −0.5 kJmol−1).
A comparison of para-substituted compounds 23 and 34 – 36 and unsubstituted prototype 4
shows, that for electronwithdrawing groups, a gain in aõnity ismainly enthalpy-driven,while an
electron-donating group in 36 causes a loss in aõnity due to an entropic penalty. para-substituted
compounds 20 and 37 were not considered for this comparison, as they show protolytic activity
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Fig. 38: Comparison of globally tted thermodynamic signatures of compounds 4, 23 and 34 – 36. Error bars represent the standard error
of measurement, based on three measurements.
5.3 Kinetic Results
_e kinetic kon and koff rates were determined by the newly developed titration protocol us-
ing kinITC (chapter 4). _e obtained data are summarized in the Appendix (p. 188). Overall,
values of kon scatter over four orders ofmagnitude (∆kon = 15.5 ⋅ 104 m−1 s−1) and koff less with
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∆koff = 1.7 ⋅ 10−2 s−1. Given the circumstance, that the variety of diòerent substituents and substi-
tution patterns investigated herein inevitably entail varying acidities of the BSA ligands, their
pKa values weremeasured by Björn Wagner from Roche (Tab. 6).
Tab. 6: pKa values of uorinated and para-substituted BSAs.
Compound pKa
4 9.96 ± 0.01
5 10.15 ± 0.01
21 9.38 ± 0.01
22 9.57 ± 0.01
23 9.84 ± 0.01
24 8.98 ± 0.01
25 8.99 ± 0.01
26 8.90 ± 0.01
27 9.18 ± 0.01
28 8.08 ± 0.01
29 8.20 ± 0.01
34 9.13 ± 0.01
35 9.06 ± 0.01
36 2.12 ± 0.01, 10.55 ± 0.01
Compared to the non-uorinated ligands 4 and 5, no clear-cut correlation is obvious, and a











































Fig. 39: Plot of kon and koff against the pKa value for compounds 4, 5, 21 – 28, 34 and 35.
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5.4 Discussion
5.4.1 Comparison of Thermodynamic Datawith Earlier Studies
As mentioned above, ligands 4, 21, 22, 23, 26 and 27 had already been investigated previously by
Krishnamurthy et al. and furthermore by Scott et al., who included compounds 4, 21, 22 and 23
in a study of variously substituted CAIs.99,144 Fig. 40 shows a comparison of the thermodynamic


























































Fig. 40: Comparison of thermodynamic values recorded in this work (blue) with data from studies by Krishnamurthy et al. (green) and
Scott et al. (red).
_e values for∆G° closely resemble each otherwith the largest diòerence of ∆∆G° = −2.1 kJmol−1
found for compound 23 between the value presented herein and that of Scott et al.99 It needs to be
noted here, thatKrishnamurthy et al. used bCAII instead of hCAII,which are, at least structurally,
largely similar.129 Whether this similarity translates into the thermodynamic signatures is diõcult
to estimate. _e enthalpic contributions diòer by amounts up to almost 20 kJmol−1. _is can be
expected, considering that the studies were conducted in diòerent buòers at diòerent pH values,
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and that the previously mentioned small amount of protons can be expected to be transferred
between a CA–BSA complex and the surrounding buòer.30,167 Generally, the enthalpic trends
are roughly maintained. However, given that the oòsets are not constant, other diòerences
between the studies must be expected. _e deviations between all three studies become even
more pronounced in the entropic term, given that only some trends can be crudely reproduced.
However, considering that the entropic term is calculated from the directly measured values
of Ka and ∆H°, errors in these quantities will strongly inuence the entropic term. Seeing that
the trends for the directly measured quantities Ka (and thereby ∆G°) could be reproduced, this
study is a further example for the validity of the measurement protocol, that was improved
for kinetic analysis of ITC data. Krishnamurthy et al. investigated the above compounds in
order to partition the contribution of electrostatic and hydrophobic interactions on the ligand’s
structural elements, arguing that this was possible due to the same orientation of the BSA cores
of all ligands.144 Given the ûnding, that 26 and 27 do, however, adopt two binding modes, and
that a second conformation can also be inferred for 21 and 22, it is questionable, whether a
partitioning in this manner can be conducted this easily. Also, the argument does not take into
account the special nature of uorine, which greatly diòers from that of hydrogen. _e various
orientations of uorine atoms in the active site by diòerent ligands enable diòerent interaction
patterns, and they cause structural changes of the protein and diòerent binding modes of the
ligands. It therefore seems questionable, that the overall free energy of binding can be simply
partitioned on the individual structural motifs, given the large variety of interaction patterns
across the ligand series.
5.4.2 Comparison of Crystallographic Resultswith Thermodynamic
Data
Overall, two conformers are observed in the studied complexes. _e phenyl moiety adopts
an eclipsed arrangement with respect to the attached sulfonamide group, giving rise to two
conformational families. Either the S N bond (τ = 0°) or one of the S O bonds is in coplanar
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arrangement with the phenyl ring (τ = 55°). _e two additional substituents at sulfur adopt an
orientation with approximately 60° above and below the phenyl plane. _e two binding-pose
orientations correlate eitherwith an occupancy of the uorine substituent in a small hydrophobic
niche next to Val121 and Leu141 or seemingly more deeply buried in a pocket below Phe131 and
adjacent to Val143. _e two orientations also correlate with an angular deviation of the terminal
Cδ-methyl group of Leu198 from the normal vector perpendicular to the phenyl ring. _e
4-substituent is oriented toward the opening of the funnel-shaped active-site pocket and is partly
exposed to the solvent environment. Likely due to steric conicts in some of the complexes,
signiûcant spatial shis are recorded for the placement of_r200, taking the apo-protein as
reference.
Assuming that the crystallographically observed binding modes reect geometries relevant for
the thermodynamic signatures of the binding ligands, our data suggest that the occupancy of
the hydrophobic niche next to Val121 by a uorine substituent is enthalpically favored compared
to the placement in the alternative pocket below Phe131. Opposing trends are found for the
entropic signature, slightly compensating the enthalpic advantage. _e seemingly deeper burial
of the uorine substituent may be compensated by a more costly steric placement with an
increased contact surface to the protein (Tab.5). However, these opposing eòects are diõcult to
translate directly into changes of the thermodynamic proûles. Remarkably, the placement of an
ortho-uoro substituent next to _r200 results in a shi of the latter residue, however, without
an enthalpically detrimental eòect. _is might be compensated for by a putative hydrogen bond
between the uorine atom and the hydroxy side chain function of_r200, already suggested by
Scott et al.
5.4.3 Comparison of Crystallographic Resultswith Kinetic Data
An inherent problem in the process of establishing structure-kinetic relationships is the contrary
nature of structure on the one hand, and the processes of association and dissociation on the
other. While structural knowledge is mostly elucidated in the solid state, the association and
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dissociation ofmolecules comprises several subsequent states, whose time-dependency cannot
be elucidated in the solid state. For the interpretation of kinetic data, structural information
about the time-limiting step along the association and dissociation process must be known.
While in the case of 4-alkyl substituted BSAs, amodel for the associationmechanismwas derived
by in silico methods, some deductions about the dissociation might be inferred from the bound
state, given that it necessarily represents the starting point for the dissociation mechanism.
For the 4-alkyl substituted BSAs, an intermediate pre-binding state governed by hydrophobic
interactions is the initial and rate-limiting step in the association between hCAII and BSAs.150
Subsequently, on the way to the ûnal binding pose, the ligand forms hydrophobic interactions
with the hydrophobic wall, but additionally engages in hydrogen bonding with _r199,_r200
and the ZnII-bound hydroxide ion.150 Given the increased hydrophobic character that is oen
entailed by uorination, a similar scenario can be envisaged for the compounds investigated
herein.76 However, the rate-limiting step need not necessarily be the same in this case. To assess,
whether hydrophobicity is important for binding kinetics, kon and koff were correlated with








































Fig. 41: A plot of kon and koff against logP shows, that hydrophobicity is not a determining factor for the binding kinetics of uorinated
BSAs.
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It is reasonable to assume, that the reprotonation of the ligandmay play a role in the rate-limiting
step of the dissociation process, given that BSAs bind as anions. In this scenario, the pKa values
should correlate with the dissociation rates (koff). However, Fig. 39 deûnitely indicates amore
complex correlation for koff. Notably, for compounds 4, 23, 34 and 35, which do not causemajor
structural perturbations in the active site or feature diòerent substitution patterns, a correlation



































































Fig. 42: Plots of kon and koff of compounds 4, 23, 34 and 35 and plot of ∆G° of compounds 4, 23, 34, 35 and 36 against the pKa value.
Opposed to the para-substituted derivatives, ligands bearing ortho or meta uoro-substituents
seem to contribute additional features that modulate the correlation of structural with biophys-
ical data. Exemplarily, compounds 22, 24, 25 and 27, which share the common feature of a
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hydrophobically accommodated uorine substituent in meta position along with solely one
major binding pose of the phenly ring are comparably fast binders and simultaneously relatively
slowly dissociating compounds. With some care, this ûnding seems to assign a uorine atom
in this position a special role in for the binding kinetics of the studied series. Moreover, the
comparison of compounds 24 and 28 reveals, that, in addition to the thermodynamic similarity
shown above, the kinetic signatures are almost identical. _is provides further support for the
assumption, that uorination in meta position along with the accommodation of the uorine
substituent in a hydrophobic pocket is favorable for the binding to hCAII. _is observation is
further supported by the kinetic data of the uorinated ligands 21 and 26, which only feature an
ortho uoro substituent but lack ameta uorine atom that could be favorably accommodated
in the hydrophobic niche. Both, together with 23, which lacks ortho and meta substituents,
show higher dissociation rates and lower association rates compared to the remaining uoro
derivatives (Fig. 39).
5.5 Conclusions
Herein, high-resolution crystallographic and ITC data for a series of variously uorinated and
4-substituted BSAs are presented. _e applied substitution patterns have signiûcant inuence
on the ligands’ acidities (Tab. 6). While it is diõcult to establish a straight-forward structure
activity relationship because of the complex and multifaceted nature of the binding of these
compounds, there is evidence that a meta uorine substituent is favorable for both, overall
aõnity and furthermore high association and low dissociation rates. Moreover, it could be
shown, that the incorporation of an additional second uorine atom (compare compounds 21
and 26) or two additional uorine atoms (compare compounds 24 and 28) can be futile, at least
with respect to the biophysical properties.
A small set of chemically diverse, only para-substituted, BSAs shows, that an increasing acidity
provides for a faster association process. As was demonstrated previously, the association
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between para n-alkyl substituted BSAs beneûts from a hydrophobic contact between the ligands
and hCAII.150 It can be expected, that the alkyl series features highly similar acidities across all
compounds. In combination with the ûndings presented herein, it can be reasoned, that, as
long as acidity is maintained for structurally similar para-substituted BSAs, the formation of
a hydrophobic contact likely represents the rate-limiting step. However, if acidity is strongly
modulated while structural similarty is largely preserved, the transfer of one of the sulfonamide
protons to the ZnII-bound hydroxide ion prior to active-site binding becomes the rate-limiting
step. _is ûnding is clearly indicated by the 4-substituted BSAs of deviating acidity (Fig. 42).
_is correlation still seems to hold for the entire series of studied ligands (Fig. 39), although
deviations from this trend as for compounds 21 and 26 are diõcult to explain structurally or
eletronically on the basis of availablematerial. Likely, a series of ortho-substituted ligands needs
to be studied further elucidate thematter.
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Human Carbonic Anhydrase Inhibitor
In 2002,Grzybowski et al. devised CAI 1 (Fig. 43A) by computational means,which comprises the
four classical design elements of BSA CAIs.129,142 It showed an aõnity of 30 pm in a competitive
assay and was deemed the most potent CAI at the time of its development.142 To obtain an
estimate of the performance of 1 compared to alkylated compounds without SRE investigated
in chapter 3, a new crystallographicmodel was produced to improve data quality, given that
the previously availablemodel of the hCAII–1 complex (1IF7) dates back to the year 2002.142 In









Fig. 43: A Valence bond formula of compound 1. B Superimposition of the hCAII–1 complex 6SDL (orange)with the previousmodel 1IF7
(purple) published by Grzybowski et al., forwhich electron density is not available. Only the active site of 6SDL is shown. Formodel 6SDL,
the omit 2mFo–DFc map is shown at 1 σ in blue and the omitmFo–DFc map at 3 σ in green.
Furthermore, 1 was subjected to ITCmeasurements. Surprisingly, a titration of 1 into hCAII did
not yield a curve characteristic for a 1 : 1 binding event, but revealed at least 2 events. To probe
whether ligand degradation in the frozen DMSO stock solution was the cause, a new stock was
97
6 Renewed Investigation of a Potent Human Carbonic Anhydrase Inhibitor
prepared and titrated into a solution of hCAII. Fig. 44A shows the processed thermograms (t
denotes the time) and integrated heat values from titration experiments with diòerent DMSO
stocks of 1.


































































Fig. 44: A Comparison of ITC data for two stock solutions of 1 in purple (old stock) and orange (new stock). Thermograms are shown as
lineswith the power signal associatedwith an injection (PQ) on the left ordinate and based on the experimental run time on the bottom
abscissa. The orange thermogram is shifted by 40 s for clarity. Integrated heat values are represented as circles with the injection heat
Q on the right ordinate and rm on the top abscissa. Data points are connected for clarity. B Comparison of dierent injection protocols
for three measurementswith the older stock solution. The blue and red thermograms are shifted by 40 s and 80 s, respectively, and data
points of integrated heat values are connected for clarity.
Importantly, the observed shape of the curves cannot be caused by a 2 : 1 binding stoichiometry of
1 to hCAII, as the two inection points are found at values of rm of 0.45 and 1.2, and are thus not
integral multiples of each other,whichwould be expected for such a scenario. _e high similarity
between both thermograms and integrated heat values, respectively, proves, that the ûrst DMSO
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Tab. 7: Applied injection schemes to investigate compound 1. Colors according to Fig. 44.
blue green red
19 × 2.0 µL 6 × 1.0 µL 6 × 1.5 µL
16 × 2.0 µL 13 × 2.0 µL
1 × 3.0 µL
V t 38.0 µL 38.0 µL 38.0 µL
stock solution (purple data), which had been prepared one year before the second (orange data),
remained stable and that the second event visible in the integrated heat values does not arise as a
result of decomposition of 1 inDMSO. Furthermore, a dilution titration of 1 into buòer suggests,
that molecules of 1 seem to interact in solution, seeing that the resulting heat signals are not
equally sized, as would be expected. However, subtraction of the dilution titration data from the
titration data for the reaction between 1 and hCAII does not alter the progression of the resulting
integrated heat values. An impact on the shape of the resulting integrated heat value curves,
however, was noticed for diòerent injection schemes with the same V t of 38.0 µL to elucidate
other putative events (Tab. 7). Given the circumstance that the shapes of the titration curves vary
with the injection protocol (Fig. 44B), it was deduced that the visible events are time dependent,
as the diòerent titration protocols lead to diòerent concentrations of L and consequentially
PL at a speciûc instant during the experimental run. _us, additional experiments with the
same V t, V i and N i with diòerent ts were carried out (Fig. 45A). Furthermore, the temperature
dependence was investigated, given that the dependence of ∆H° is oen observed (Fig. 45B).22
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Fig. 45: A Comparison of dierent time intervals of 180 s (blue), 360 s (green) and 720 s (red) for the titration of 1 into hCAII. The blue and
red thermograms are shift by 100 s and 200 s, respectively, for clarity. BComparison of dierent temperatures of 25 °C (blue), 15 °C (orange)
and 35 °C (purple) for the titration of 1 into hCAII. The orange and purple thermograms are shifted by 40 s and 80 s, respectively, for clarity.
Given the unusual, and in literature likely unprecendented observation, that the two inection
points found for the binding of 1 to hCAII are not integral multiples of each other, a binding
model of two binding sites could be abandoned. Chemically, the sample was shown to be 99.5%
pure by quantitative NMR spectroscopy by Hans-Dieter Gerber, which rules out an impurity
as a cause for the above. It was furthermore assumed, that the lack of coherence between the
values of ns of the inection points is caused by a non-homogeneous ligand sample in the sense,
that compound 1 adopts a second conformation in solution, which is also capable of binding
to hCAII, which is symbolized by the superscripts 1 and 2 in equation (18). Furthermore, the
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protein can adopt two diòerent states that bind 1 diòerently (equations (19). _e latter is unlikely,
however, given the high structural rigidity of hCAII, but cannot be fully excluded because of the
ûnding of themobility of_r200, which, however, only seems to occur aer a ligand has bound,
not before (chapter 5).
PL1 P + L1/2 PL2 (18)
P1L P1/2 + L P2L (19)
Itwas tried to ûtmodels described either by equation (18) or (19) to the data under the assumption,
that either the fractions of the respective ligand species add up to one (equation (20)), or that
those of the respective protein species add up to 0.7 (equation (21)).
rL1 + rL2 = 1 (20)
rP1 + rP2 = 0.7 (21)
Condition (20) is based on the assumption, that the ligand has a purity of 100% for simplicity.
Condition (21) is based on the observation, that for 1 : 1 interactions reported herein, hCAII
usually possessed an active fraction of approximately 0.7. Tab. 8 shows the thermodynamic
parameters obtained from the ûtting procedures.
Notably, both models enable a reasonably high goodness of ût (GoF) of 86.7%. Moreover, the
enthalpic values are in good agreement between both models, although ∆H° is relatively large
for the ûrst reaction of both models compared to other enthalpic signatures for the binding of
BSAs reported herein. Also, the values of Ka of the respective ûrst reactions, although notwithin
error margin, are similar. _e value of Ka for the respective second reaction shows, that it is
thermodynamically less favored than the ûrst reaction. Despite this diòerence, bothmodels show
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Tab. 8: Thermodynamic parameters for the tting of models (18) and (19) to the titration data of the interaction between 1 and hCAIIwith




of ligand Complex Ka / m
–1 ∆H°/kJ mol–1
(18) 0.35 0.37 PL
1
(5.52 ± 0.85) ⋅ 108 −86.1 ± 4.9
0.65 0.63 PL2 (7.99 ± 2.93) ⋅ 105 −32.3 ± 2.3
(19) 0.40 0.43 P
1L (3.85 ± 0.31) ⋅ 108 −91.7 ± 1.5
0.63 0.57 P2L (1.95 ± 0.18) ⋅ 107 −35.1 ± 0.6
a partitioning of the formed two possible species of about 40% and 60%. _e circumstance,
that themore stable complex is formed to a lower extent than the less stable one, leads to the
conclusion, that the latter must feature a higher association rate. Under this prerequisite, the
change of titration proûles with an increased time span between injections (Fig. 45A) can be
rationalized by the transformation of the kinetically favored hCAII–1 complex (hCAII–1kin) into
the thermodynamically favored hCAII–1 complex (hCAII–1td). _is is possible, theoretically,
in two ways. Either the hCAII–1kin species disassembles in favor of a subsequently formed
hCAII–1td species, or via conversion of the former into the latter without complete disassembly,
although a rebinding scenario is also conceivable (subsection 1.2.2).
6.1 Conclusions
_e ûndings in this chapter describe, to the best ofmy knowledge, the calorimetrically unprece-
dented observation, that two conformations of one ligand have diòerent thermodynamic and
kinetic binding signatures. Structurally, these ûndingswill be diõcult to elucidate on the basis of
MX by either soaking or cocrystallization, given the usual time spans for crystallization of hCAII
(1 d) and soaking (12 h) of hCAII crystals,which are long time spans compared to the longest ITC
run performed herein with 720 s of spacing between injections. Amore promising method in
this respectmight beNMR, as it is capable of providing information in the solvated state. Further
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information might be gained by the investigation of the (S)-enantiomer. If the enantiomer shows
similar integrated heat values as the (R)-enantiomer 1, this could indicate an eòect in solution to
exert inuence on the binding, as both enantiomers can be expected to show the same behavior
in solution. Furthermore, the achiral derivative of 1 without the CH3 group might shed light
on whether the chiral center is a prerequisite to the assumed conformational characteristics
of 1 and its complex with hCAII. Additionally, a small molecule crystal structure of 1 might
provide insight into the preferred conformation for this ligand. While the preferential binding
of bioactively preorganized ligands is a well-accepted principle in SBDD, it usually compares
diòerent chemical entities as opposed to the ûndings for compound 1 presented herein.36
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7 A Chiral ZnII Binder
In 2017, Chrysanthopoulos et al. reported on the discovery of an until then unknown ZnII-







Fig. 46: Structure of 5-phenyloxazolidine-2,4-dione discovered by Chrysanthopoulos et al. as novel CAI motif.
Notably, only the (R)-enantiomer of 38 was found in the crystal structure.168 Herein, it was tried
to assess, whether the (S)-enantiomer also binds to hCAII both by crystallography as well as by
means of ITC. _erefore, the racemicmixture of 38 synthesized by Khang Ngo was subjected to
chiral HPLC by Sebastian Hickert from Merck KGaA, Darmstadt, to separate the enantiomers.
_e chromatogram (Fig. 47) shows apparent separation of the two enantiomers.
Operator:b17278  Timebase:HPLC_A19_333_39_48   Sequence:20180727 Page 1-1
7/30/2018  3:46 PM
default_new/Integration
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU15a Build 4693 (253073)
Sample Name: Marburg Injection Volume: 2.0  
Instrument: HPLC_A19_333_39_48 Channel: UV_VIS_2
Sample Type: unknown Wavelength: 210
Aquisition Method: HP-EOH_60-40_1ML_20MIN Sample ID: Saeule7
Integration Method: Default Flow: 1.0
Recording Time: 2018.07.30 15:15 Vial Number: 102
Säule: Daicel CHIRALPAK IA / 250x4.6 / 5µm
No. Ret.Time Height Area Rel.Area Type 
min mAU mAU*min %
1  2.93      1.363 0.116 0.07    Ru
2  3.22      7.355 0.764 0.46    BMB
3  4.73      3.639 0.583 0.35    Ru
4  5.08      18.556 3.861 2.34    BMB
5  7.78      203.020 80.241 48.61    BMB
6  12.76      174.051 79.491 48.16    BMB
Total: 165.056 100.00    










































Fig. 47: Chromatogram of the separation of the racemic mixture of 38.
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Soaking of both enantiomers overnight, however, resulted in only the (R)-enantiomer being
observed in the crystal structure, also in the crystallographicmodel of crystals soaked with the
(S)-enantiomer. Considering that both structures showed an increased resolution compared to
the already available crystallographicmodels 5TXY and 5TY8, the structure from the crystal
soaked with the (R)-enantiomer was deposited in the PDB as entry 6SFQ. _e observation,
that only the (R)-enantiomer was found even for the crystal structure of the crystal soaked
with the (S)-enantiomer gave rise to the assumption, that the binding to hCAII might promote
epimerization. _us, the concentrations of the enantiomers in the soaking drop were increased
by increasing the amount of DMSO to decrease soaking time and thereby prevent putative
racemize. However, even aer 1min of soaking, only the (R)-enantiomer was observed bound
to the (S)-soaked crystal. Fig. 48 shows the comparison of the depositedmodel 6SFQ and the
structures derived from crystals that were soaked shortly at high ligand concentrations of either
(R)- or (S)-enantiomer.
A B C
Fig. 48: Crystallographic model of compound 38 bound to hCAII. A Fully rened and deposited model 6SFQ with omit 2mFo–DFc map
in blue at 1 σ and mFo–DFc map at 3 σ. 6SFQ is shownwith electron densitymaps of the crystal soakedwith (R)–38 (B) and (S)–38 (C).
Clearly, the crystal soaked with the (S)-enantiomer exhibits the (R)-enantiomer in the active
site. It is unlikely, however, that racemization occurs in buòer at pH 7.8, given the pKa of 38
of 11.96 ± 0.09. _is allows for two possible scenarios, by which (R)–38 ûnds its way into the
crystal initially soaked with (S)–38. Either, the enantiomers were not fully separated by the
HPLC run. _ereby, presuming a distinctly larger aõnity of the (R)-enantiomer, even a small
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impurity of (R)–38 in the (S)–38 sample can lead to themere observation of the former bound
in the active site of hCAII. _e second possible scenario is the racemization of either enantiomer
aer binding to the ZnII cofactor. _e plot of integrated heat values from an ITC experiment





























Fig. 49: ITC thermograms for the titrations of (R)-38 (A) and (S)-38 (B) into hCAII.
Fig. 49A clearly shows binding between (R)-38 and hCAII. Notably, however, the stoichiometry
of the reaction amounts to ns = 1.4. _is is twice the approximate value of ns usually found in
the course of this work, and indicates an impurity of the ligand. _is impurity might be, in
fact, the non-binding (S), that is generated throughout the experiment from the (R)–38, which
delays saturation of the protein. It is also conceivable, that the impurity was present in the ligand
sample before the experiment. However, the chromatogram in Fig. 47 does not suggest a highly
abundant impurity. Fig. 49B shows the titration of hCAII with (S)–38. Clearly, (S)–38 does not
bind to hCAII. Given the argument, that (R)–38 racemizes within the active site, this is also
conceivable for the (S)-enantiomer. However, seeing that the injection heat values in Fig. 49B do
not distinctly change in magnitude, it is unlikely, that (S)–38 racemizes rapidly to yield themore
potent (R)–38. _is can be seen as a further indicator for the theory, that only coordination to
the ZnII cofactor enables racemization, putatively because of increased acidity of the CH unit.
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It was furthermore tried to assess the propensity of 38 to racemize in presence of hCAII by
polarimetry. However, despite the degassing of the aqueous buòer that was used for the prepa-
ration of the experimental solution, formation of gas bubbles was still observed in the cuvette,
which makes the investigation of the above problem infeasible under these conditions. _e
usage of amodel system, such as a solution of a ZnII salt and imidazol in a polar organic solvent
as replacement for hCAII might bemore preferable in this case.
108
8 Concentration-dependent Soaking to
Assess theOccupancy of a Second
Binding Site
_e prediction of binding sites of proteins can facilitate the discovery of starting points for a
drug design project, especially if the target of interest does not crystallize readily and renders an
experimental structural approach diõcult. In the group of Antonella Di Pizio, the prediction of
a second binding site of a known CAI was envisaged. A complex of hCAII with compound 39
had previously been characterized crystallographically and deposited in the PDB as entry 4FVO










Fig.50: A Structureof compound 39. BCrystallographicmodel of thehCAII–39 complex fromPDBentry 4FVOwith twooccupied binding
sites.
It was thus tried to assess the occupancy of the ligand in the second binding site as a function of
concentration by soaking similarly sized crystals of hCAII over night in diòerent concentrations
of 39. However, no concentration provided suõcient electron density to merit themodeling of
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39 in the second binding site. Fig. 51 shows a close-up of the second binding site in PDB entry
4FVO with 2mFo–DFc maps andmFo–DFc maps from crystals soaked in solutions containing
compound 39 in concentrations of 5mm and 0.1 mm.
A B
Fig. 51: Closeup of the second binding site of PDB entry 4FVO with electron densities of complexes of hCAII with compound 39 soaked
at concentrations of 5.0mM (A) and 0.1mM (B).
Although diòerent concentrations did not lead to results that could acutally be used for crystal-
lographicmodeling of the second binding site, diòerences in the occupation of the active site
could be observed. Tab. 9 shows the applied concentrations and crystallographically observed
occupancies of the second binding site.







aCompound 39 recrystallized from the soaking
drop at an initial concentration of 10mM.
Given the small to negligible diòerences in occupancies for soaking concentrations of 0.5 to
5 mm, it was decided to deposit models originating from 5.0mm and 0.1 mm in the PDB as
entries 6SDH and 6SDI, respectively (Fig. 52).
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A B
Fig. 52: Crystallographic models of the hCAII–39 complex produced from soaking at concentrations of 5.0mM (A, 6SDH) and 0.1mM (B,
6SDI).
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9 Investigation of Furosemide Analogs
_e loop-diuretic furosemide (40) binds to the sodium-potassium-chloride transporter present
in the thick ascending limb of the loop ofHenle preventing the reabsorption of sodium, chloride
and water.169 It is known, that this sulfonamide-bearing drug also inhibits hCAII.170 Because
of its substitution pattern it adopts a diòerent binding mode than unsubstituted BSA to inter-
act with the sidechain of His64 and orient the chlorine substituent in a hydrophobic pocket
(Fig. 53A). Given the distinct role ofHis64 as proton shuttle in the catalyticmechanism, it was
hypothesized, that it might also be engaged in the dissociation of inhibitors, seeing that these
need to be reprotonated aer dissociation from the ZnII cofactor.171 For this purpose, it was
tried to assess, whether simpler and commercially available derivatives of 40 could be used to
assess the inuence ofHis64 on the dissociation velocity. _erefore, complexes of hCAII with
compounds 41 and 42 were produced to determine, whether the nitro functionality is capable of
hydrogen bonding to the side chain of His64, and shows a distinct diòerence in the dissociation
rate compared to 41. _e choice for a nitro compound was made to remove a protolytically
active functionality, that would potentially inuence thermodynamics and kinetics of binding
to hCAII.147 However, crystallography revealed, that the nitro moiety is accommodated on a
part of the hydrophobic wall, rather than engaged in hydrogen bonding, and thus adopts the
same binding mode as 41 (Fig. 53B and C).
Given these observations, compounds 41 and 42 are not suitable for the elucidation of the
inuence ofHis64 in the dissociation mechanism. Scott et al. already observed, that a chlorine
substituent adjacent to the sulfonamide group leads to a binding mode similar to that of 40.99
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Fig. 53: AComplex of hCAIIwith furosemide (40). The carboxylate function interactswith the side chain of His64, the chlorine substituent
points into a hydrophobic pocket. B hCAII in complex with furosemide derivative 41. C hCAII in complex with compound 42. The nitro
moiety does not engage in hydrogen bonding to the side chain of His64.
_us, the introduction of a chlorine substituent in compounds 41 and 42 in ortho-position to
the sulfonamide, and in the case of 42 para to the nitro compound, is likely to induce binding
geometries similar to that of 40, which would then enable hydrogen bonding between hCAII
andHis64.
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10 Investigation of the Eect of a
Remote-Binding Sulfoxide on
Active-Site Inhibitor Binding
D’Ambrosio et al. reported sulfoxide 43 to bind to the side chain ofHis64 outside the active site of
hCAII and demonstrated, that it exerts inhibitory action (Fig. 54A).172 Crystallography revealed,
that, instead of coordinating to the ZnII cofactor, it engages in a water-mediated contact with







Fig. 54: A Remote-acting sulfoxide CAI 43. B Binding of 43 to the side chain of His64, mediated by awatermolecule (4QY3).
D’Ambrosio et al. reported an inhibitory constant for 43 of 150 nm. Based on this ûnding, it
was tried to assess the aõnity of 43 for hCAII by means of ITC. _e resulting thermogram,
however, did not show any binding event. Given that this can be caused by small heat signals
(entropy-driven binding) and does not exclude binding per se, itwas then tried to assess,whether
43 has an impact on the binding of the known ligand 37 (Chapter 5). _e titration of 37 into 43
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did not show an interaction of a deûned stoichiometry, which excluded interaction between
both compounds, rendering them suitable for an experiment to test cooperativity. _us, hCAII
was mixed with an excess of 43 and titrated with 37. Unexpectedly, the presence of 43 reduced
the aõnity of 37 (Tab. 10).
Tab. 10: Values of Kd and ∆H° for the characterization of the hCAII–37 complex with andwithout sulfoxide 43.
Compounds Kd / nm ∆H°/ kJ mol–1
37/43 790 ± 60.9 −53.9 ± 2.7
37 685 ± 40.7 −51.7 ± 0.8
Despite the circumstance, that no deûned interaction between 37 and 43 could be observed,
unspeciûc interactions might still be the cause for the reduced aõnity of BSA 37.
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11 Growth of Crystals Suitable for
Neutron Diraction






Fig. 55: A Structure of the articial sweetener saccharin 44. B Saccharin in the active site of hCAII (2Q1B).
As saccharin features an N-acyl sulfonamide function instead of a primary sulfonamide, the
nitrogen atom has only one valence le to neutrally bind a hydrogen atom. Under the premise,
that sulfonamides usually coordinate the ZnII cofactor in the anionic state, saccharin likely
looses a proton as well before complexation, given its comparably high acidity (pKa = 1.6).174
However, this does not have to hold true necessarily, considering the fact that the supposedly
simple question of the protonation state of the ZnII-bound oxygen species has not yet been
doubtlessly answered. Whilemost estimations conclude, that the pKa value of the ZnII-bound
water molecule is 6.8, there is also experimental evidence that suggests a pKa of 5.129 _is would
entail that the ZnII-boundwater molecule is deprotonated in solution for pH > 5, or from pH 6.8
onwards. However, neutron diòraction studies of hCAII showed, that the fourth vertex of the
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tetrahedral coordination sphere of the ZnII species is, in fact, occupied by a water molecule
in the crystalline state, even at pH 9.0.151 It is thus not unlikely, that also saccharin, despite its
comparably high acidity, binds to hCAII in the protonated state.
11.1 Screening of Already Known Crystallization
Conditions
It was thus tried to obtain hCAII crystals suõciently large for neutron diòraction, as both
protons and deuterons scatter neutrons, andmight thereby answer the question for saccharin’s
protonation state in complex with the ZnII cofactor. _is was to be done with perdeuterated
hCAII provided by Himanshu Singh from the group of Rasmus Linser. To assess feasibility,
already reported crystallization conditions based on trisodium citratewere investigatedwith non-
deuterated hCAII.175 Given that these conditions produced large crystals without the addition
of PCMB in literature, it was desisted from its usage for the initial trials. Fig. 56 shows, however,
that PCMB was necessary for the production of voluminous crystals with hCAII from own
production, that have a clear expansion in all three spatial dimensions, as the lack of PCMB only
produced shard-like two-dimensional crystals.
A B
Fig. 56: HCAII crystals grown in 1.40M trisodium citrate solutionwith PCMB (A) andwithout (B).
Notably, the crystallization with PCMB not only provided for voluminous three-dimensional
crystal growth, but also enabled suõciently fast crystallization, which prevented the formation
of additional nuclei. Considering that larger crystals require a larger amount of protein than
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crystals commonly used for XRD, the protein concentration was increased from 5mgmL−1 to
16.9mgmL−1 to providemore protein material for crystallization. Additionally, crystallization
was carried out in both H2O-based as well as D2O-based buòer at various concentrations of




Fig. 57: Crystals of hCAII grown in dierent precipitant conditions. A 1.40M trisodiumcitrate, H2O after 24 h. B 1.40M trisodiumcitrate, D2O
after 24 h. C 1.40M trisodium citrate, H2O after 48 h. D 1.40M trisodium citrate, D2O after 48 h. E 1.25M trisodium citrate, H2O after 6d.
Due to the increased protein concentration,more crystals formed at a concentration of trisodium
citrate of 1.40m. _is is counterbalanced by a decreased precipitant concentration of 1.25m
trisodium citrate, which yielded one large crystal. Notably, deuterated buòer decelerated crystal
growth. Furthermore, the diòraction power had to be assessed. Fig. 58 shows diòraction images
of crystals grown in H2O-based and D2O-based conditions recorded with Cu-Kα radiation on a
MAR345 image plate detector.
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A B
Fig. 58: A Diraction image of an hCAII crystal grown in H2O-based 1.25M trisodium citrate, exposed for 3min. B Diraction image of an
hCAII crystal grown in D2O-based 1.40M trisodium citrate, exposed for 5min.
Due to the prolonged exposure time of the crystal grown in deuteratedmedium, the diòraction
image shows a high number of overloaded spots, discernible as light spots in the bulk diòraction.
It can therefore be assumed that deuteration does not distinctly alter the diòraction power.
Subsequently, crystal growth was tried on a larger scale. _erefore, drops were set up in plastic
culture dishes with a precipitant concentration of 1.35m, a drop volume of 400 µL, a protein
concentration of 5mgmL−1 and a reservoir volume of 3.0mL. _is approach did not turn
out satisfactory, however, given the large number and small size of crystals (Fig. 59A and B).
Furthermore, crystallization was tried with protonated protein in aHampton Research 9 well
glass plate sandwich box setupwith a precipitant concentration of 1.30M, with a drop volume of
400 µL, a protein concentration of 16mgmL−1 and a reservoir volume of 25mL, which yielded
crystals with a length of up to 2mm in the longest dimension (Fig. 59C andD).
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A B
C D
Fig. 59: Crystallization trials in A a culture dish in protonated medium and B deuterated medium, C, D in a sandwich box setup in proto-
nated medium.
11.2 A Joint X-ray and Neutron Diraction Structure of a
Carbonic Anhydrase IXMimic
In 2019, Koruza et al. published the crystallographicmodel of amimic of the cancer-associated
hCA isoform IX (hCAIX), which was constructed from hCAII by seven point mutations and
was characterized by joint neutron and X-ray diòraction data.176 Interestingly, also complexes of
the hCAIX-chimera in complex with saccharin and a derivative were reported with a picture
of the nuclear density of the active site, and it was argued, that saccharin coordinates the ZnII
cofactor in the deprotonated form.176 However, considering the circumstance, that nuclear
density of the remaining hydrogen atoms of saccharin is weak to non-existent, the argument for
binding in the deprotonated form is not doubtlessly proved. Under the prerequisite, that for
high-resolution MX models of hCAII hydrogen atoms can be observed in well-ordered regions,
the solution of the phase problem was tried by SAD and directly at a resolution of 0.99Å to
obtain electron densitymaps without model-bias in order to ûnd a clue for putative protonation
of saccharin in complex with hCAII. _erefore, SAD phasing was conducted with the programs
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SHELXC/D/E as combined in the hkl2map soware suite and was additionally tried directly
with the program ACORN from the CCP4i suite.177,178 Fig. 60 shows the electron density maps
from the experimentally determined phases of the SAD experiment (A) and from the phases
determined directly from known starting coordinates (B).
A B C
D E F
Fig. 60: A 2mFo–DFc map as output by SHELXD at 3 σ. B 2mFo–DFc map of the active site as output by ACORN at 3 σ. C Electron density
maps after renement. 2mFo–DFc map in blue at 1 σ, mFo–DFc maps in green at 3 σ and in red at −3 σ. D Comparison of the active sites
of the hCAII–44 complex in orange and the hCAII–4 complex (6GDC). (Putative) hydrogen bonds are indicated as dashed orange lines.
E Saccharin and the side chain of Val143 shown as sticks with mFo–DFc density in at 3 σ. F Saccharin and the side chain of Val143 shown
as stickswith mFo–DFc density at 3.6 σ.
Protons did indeed become visible in the active site during reûnement. Fig. 60C shows electron
density maps aer the last reûnement run without hydrogen atoms. A small peak of diòerence
density was found at the position where a proton might be found. A comparison of the binding
mode of saccharin with that of compound 4 (Fig. 60D) shows, that the hydrogen-bond dis-
tance (dhb) between the nitrogen atom of the ligand and the hydrogen bond accepting hydroxy
function of_r199 is increased in the complex with saccharin (dhb = 3.3Å) compared to the
hCAII–4 complex (dhb = 2.9Å), which allows for the inference of a weak hydrogen bond in the
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hCAII–44 complex. Fig. 60E and F furthermore show, that the positive diòerence density peak
close to the nitrogen atom of 44 has approximately the samemagnitude as the peaks caused by
hydrogen atoms of the side chain of the structurally well conserved residue Val143, which can
be seen as an argument for the validity of the assumption, that this peak is indeed caused by a
proton. _is is furthermore complemented by the approximate distance of 0.9Å between the
density peak and the nitrogen atom of the saccharin molecule is close to the distance of 0.92Å
observed for the distance between the nitrogen hydrogen atoms in a small-molecule crystal
structure of saccharin.179
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12 Introduction to Fragment-Based
Drug Design
_e initial step that has to be taken for the development of a small-molecule drug is the de-
termination of a starting molecule, which can be elaborated into the eventual drug molecule.
In the early 1990s, large chemical libraries were established for high-throughput screenings
(HTSs) to accelerate this step by screening millions of drug-like compounds in biochemical
and biophysical assays against a target of interest.180 _is resulted in marketed drugs against
cancer, theHIV and diabetes, among others.180 A shortcoming ofHTS is the narrow applicability
with respect to the nature of putative drug targets.181 Another issue, potentially causative for the
former, is the ineõcient coverage of chemical space that is available for an HTS library of com-
pounds comprising up to 30 atoms.181,182 _is resembles the typical size of drug-likemolecules,
and was estimated to enablemore than 1060 conceivable compounds.183 Fragment-based drug
design (FBDD) relies on smaller molecules called fragments, despite their chemical integrity, as
they can be seen as parts of drug-likemolecules because of an atom count smaller than 20.181
Similar to the statistical physicochemical description of drug molecules by Lipinski’s Rule of
Five (RO5), early fragment libraries were assembled under adherence to the Astex Rule of_ree
(RO3).184,185 It states that fragment-likemolecules have amolecular weight (MW) < 300Da, a
number of hydrogen bond donors and acceptors ≤ 3, respectively, and clogP ≤ 3.185 Given the
smaller chemical space of 166 ⋅ 109 molecules conceivable for molecules made up of 17 atoms
of the elements C,N,O, S, F, Cl, Br, I andH, it is clear, that fragments cover the the chemical
spacemore eõciently, which provides them with a wider applicability.182,186 _e rationale for the
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superiority of fragments compared to drug-likemolecules in the lead-ûnding process is based on
the assumption that, based on the RO3, binding of a fragment to a target can only occur through
a small number of interactions and thus with weak aõnity.182 However, the formed interactions
are usually of high quality as the low spatial complexity of the fragments enables an optimal
orientation within the binding site and thus enables supreme geometrical complementarity
between the interacting functional groups of fragment and target while the chance of repulsive
interactions of non-optimally placed moieties is reduced.72,182,185 A fragment hit can then be
used to establish a lead scaòold by the approaches of fragment growing,merging and linking.182
_e goal of fragment growing is to address additional functional groups in the binding pocket to
enhance aõnity by increasing molecular size.182 Fragment merging and linking initially require
at least two fragment hits. For merging, the two fragments need to address diòerent parts of the
binding site, but at the same time overlap with one portion. Linking requires two fragments to
occupy diòerent parts of the binding site without overlapping. _e latter two methods by trend
posemore of a challenge than themere growth of the intial fragment scaòold, as the geometric
requirements of both fragments need to be taken into account to maintain the eõcient binding
of both portions in the ûnal follow-up molecular scaòold.182 Especially the development of a
suitable linker that does not impose an entropic penalty nor induce a hydrophobic collapse in so-
lutionwith a distinct deviation from the biologically active conformation, is oen challenging.182
Although the approach of FBDD drastically reduces the number of compounds necessary to
cover as much chemical space as possible, it still requires a high screening eòort. _emethod of
SAR byNMR andMX are themost prominent techniques used in this respect.187–189 MX, despite
the high demand of protein material, the necessity to grow suitable crystals and the dependence
on the availability ofmeasurement time at synchrotron facilities, is an especially powerful tool,
as it is capable of detecting very weakly binding fragments and delivers information about the
geometry of binding poses and the nature of the formed interactions.182 In the laboratory of
Gerhard Klebe, a 361-entry fragment library targeted at themodel aspartic protease endothia-
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pepsin was established, that does not strictly adhere to the RO3, but also considers the chemical
feasibility of the generation of follow-up compounds from fragment hits.190 Furthermore, this
study revealed that a strict adherence to the RO3would have excluded several hits.190 _is library
was investigated again to compare the hit rates of diòerent biophysical assays with MX and
found, that MX elucidated binding events that would have been missed by other techniques,
and advocates for crystallography as the prime, because themost promising, tool in FBDD.191
Although the majority of clinical candidates still originates from the elaboration of already
known binders and random HTS, the advantage of SBDD in combination with FBDD is appar-
ent, given the relatively short period of six years it took to market the ûrst fragment-based drug
vemurafenib with antimelanomal activity. Fig. 61 shows the initial fragment-sized 7-azaindole
(a prominent motif in kinase-targeted fragment libraries) derivatives 45 and 46 in complex
with the Pim-1 kinase and the structurally related kinase domain of the ûbroblast growth factor

















Fig. 61: Fragment hits in structurally related kinases that led to the development of Vemurafenib. A 7-azaindole derivative 45 in the active
site of the Pim-1 kinase (3C4E). B 7-azaindole derivate 46 in the active site of the kinase domain of FGFR1 (3C4F). C Vemurafenib (47) in
complex with B-Raf kinase (3C4C).
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_e inital lead discovery with fragments does not necessarily accelerate the entire process.
_e second marketed fragment-based drug Venetoclax entered the market aer 20 years of
development.194 However, fragments are a promising approach to accelerate drug discovery,




Screening of a 96-Entry Fragment
Library
In an eòort tomake the power of fragments available to a broader public, a 96-entries fragment li-
brarywas assembled in the laboratory ofGerhardKlebe. It comprises subsets of the 361-fragments
library mentioned above, of a library of representativemolecules from the PDBeChem database
from the AGWeiss at theHelmholtz-Zentrum Berlin as well as 3D-enriched fragments.190,195
Given the fact that approximately 50% of the 96 compounds were taken from the aspartic-
protease targeted 361-entry in-house library, it is valid to ask whether the assembly is broadly
applicable in the lead discovery against targets of various functions. _is question was addressed
by screening the 96-entry assembly against various established model proteins of the Klebe
laboratory, such as hCAII. Experimental details can be found in subsection 14.3.2.
13.1 Results
Out of 96 compounds, the eight compounds depicted in Fig. 62 were found in the crystal
structure of hCAII. Four of these occupy the active site, one is found on the edge of the funnel-
shaped active site. _e remaining three fragments are positioned in between hCAII crystal
mates, with one beneûting from a contact with the crystallization agent PCMB, the other two,
surprisingly, attached covalently to the N-terminus. _e binding of fragments 48, 49, 51 and
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52 was described in a preceding Master thesis, but will bementioned here for completeness.196
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Fig. 62: Upper panel: Valence bond formulae of bound fragments. Lower panel: Overview of fragment binding sites. Fragments are
shown in orange with omit 2mFo–DFc maps in blue at 1 σ and mFo–DFc maps in green at 3 σ. Active site binders are shown with the
interacting amino acids in stick represenation. Remotely binding fragments are shown on with the surface representation of adjacent
proteinmolecules. Hydrazides 48 (A) and 52 (B) and sulfonamide 55 (C) coordinate to the ZnII cofactor, salycilic acid (51,D) coordinates to
the ZnII-boundwatermolecule. Anilide 53 (E) is accommodated in a hydrophobic cavity on the rim of the funnel-shaped active site, that
is covered by a proline residue of a symmtetrymate. Cyclic carbamate (S)-54 (F) coordinates to the C-terminus and a Trp sidechain, and
donates a hydrogen bond to the PCMB molecule of a symmetrymate. Pyrazole 50 (G) is directly covalently attached to the N-terminus,
uorinated compound 49 (H) via a linker.
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Hydrazides 48 and 52 occupy the active site of hCAII and coordinate the ZnII cofactor with the
Nβ and carbonyl O atom of the hydrazide function, which results in a pentacoordinated cofactor.
_e phenyl rings are involved in a π-interaction with the side chain of Leu198. Notably, the
coordination geometry enables a hydrogen bond between Nβ of the hydrazide group, and the
side chain hydroxy function of_r199. _is entails a diòerent orientation of the phenyl moiety
compared to BSA (4), which triggers a ip of the sidechain of Leu198, that is also present in the
complex of hCAII with N-hydroxybenzamide, discovered by Di Fiore et al. (Fig. 63).197
A B
Fig. 63: A Comparison of hydrazide fragment 48 (orange) and BSA 4 (purple) and the respective side chains of Leu198. B Comparison of
48 and the analogous hydroxamate (blue) (4FL7).197
Salycilic acid 51 binds in a fashion that was observed previously for other hydroxybenzoic
acids in complex with hCAII. _e carboxylate function interacts via a hydrogen bond with the
ZnII-bound hydroxide ion/water molecule. _e carboxylate function furthermore interacts with
the side chain of_r200, a state similar to the prebinding S-state deûned by Gaspari et al. for the
binding of BSAs and already observed by Martin and Cohen for variously hydroxylated benzoic
acid derivatives.198 Without surprise, sulfonamide 55 can be expected to bind to hCAII, and does
so with the expected geometry. Primary amine 53 was found to occupy a hydrophobic cavity on
the rim of the active site funnel. It is held in place by a charge-assisted hydrogen bond with the
side chain of Asp72 and furthermore interacts with a water molecule, which mediates a contact
between the anilide N-atom and the side chain of Glu69. Additionally, the phenyl interacts with
the side chain of Ile91 via the π-system, which is furthermore involved in an interaction with
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the sidechain of Pro237 of a symmetrymate. Moreover, an interaction between a lone pair of
the O-atom of the symmetry mate’s amide bond between Pro237 and Glu236 in a Bürgi-Dunitz
type trajectory can be inferred.103,104,199 _us, the binding of 53 is likely to be an artifact enabled
by the crystal packing, rather than by genuine aõnity for the position on the rim of the hCAII
active site itself. Fragment 54 was used as racemate. _e (S) enantiomer was found to bridge
the gap between C-terminus and the sidechain of Trp192. Furthermore, the secondary amine
interacts with the carboxylate function of the crystallization agent PCMB of a symmetry mate.
Whereas the binding of fragment 49 had been mentioned already in the preceding master thesis,
the binding of 50 was only noticed aer renewed inspection. Notably, both compounds are
covalently attached to the N-terminus. In the case of 49 this occurs via a covalent linker of
unknown identity. Given the circumstance that the soaking conditions contained polyethylene
glycol (PEG) 400, it is reasonable to assume, that the linker is a methylene unit which was
installed by incorporation of onemolecule of formaldehyde, which is known to be present in















Scheme 1: Possible mechanism for the reaction between the N-terminus of the hCAII-expression tag proteinwith 49. The N-terminal pri-
mary amine reactswith formaldehyde under loss ofwater to yield an imine. This in turn is nucleophilically attacked by 49with concurrent
proton transfer to yield the nal protein-small-molecule hybrid.
Fragment 49 itself is involved in some interesting interactions. It is known, that the S-atom of
aMet side chain is oen found in the vicinity of π-donors, such as aromatic rings and amide
bondswithwhich it engages mostly through dispersive interactions.201 Especially the nucleobase
adenine is oen found in company ofMet side chains in MX models. While the π-system of
adenine is distributed over thewholemolecular scaòold, this cannot be the case for compound 49,
given, its three CH2 units. However, the hydrazinecarboximidamide substructure and the
diuorophenlymoiety,which are connected by a Csp2 atom, provide an extended π system,which
can be expected to act as binding partner for theMet side chain S-atom. Given the comparably
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close distance of 3.3Å between the Oδ1 atom of the side chain of Asp71 of a symmetry mate and
the covalently linked N-atom of 49, an interation can be inferred which resembles that between
an Asp side chain and the positively charged aromatic scaòold of a false-positive fragment
screening hit against endothiapepsin, discovered by Schiebel et al.202 It is reasonable to assume
that it is, in fact, a charged interaction, given that the hydrazinecarboximidamide substructure
can be considered basic, thus bearing a positive charge that can be distributed over several atoms























Scheme 2: Protonation of the small-molecule moiety of the hCAII–49 hybrid and possible resonance structures. R represents the 3,4-
diuorophenyl motif.
Furthermore, the side chain of Ser73 of the symmetry matemight interact with the N3 atom of
49, that is involved in the delocalization of a positive charge. An interaction that is oen found
for uorinated compounds is the interaction between an F-atom and an amide bond.102 _e
F-atom of 49 exerts such an interaction with the amide bond between Gln185 and Lys159 in a
symmetrymate at a distance of 3.2Å. Furthermore, the distance of 3.2Å between the F1 atom
of 49 and the Cδ2-atom of Leu57 of a diòerent symmetry mate is in the same range as the sum
of the van der Waals radii of an aliphatic C-atom and an aromatically bound F-atom of 3.17Å
(see chapter 5).76 It was tried to reproduce the binding of 49 in a 1.50m trisodium citrate buòer,
both with and without DMSO. Fig. 64 clearly shows, that molecule 49 is not found in the site
described above in either condition.
Fragment 50 is also covalently attached to the N-terminus, but without a linker. Reaction
between protein and fragment might have occurred through two possible reactions. Either, the
unprotonated N-atom of the protein replaces the protonated primary amine function of 50 or




Fig. 64: Close-up of the binding site of 49. A Model of covalently bound fragment49. B Model obtained from a crystal soaked in the
above trisodium citrate conditions including 10% DMSO after automated renement superimposedwith the binding pose of 49 from A.
CModel obtained from a crystal soaked in the above trisodium citrate conditions including without DMSO after automated renement









Scheme 3: Possible mechanism for the reaction between the N-terminus of the hCAII-expression tag proteinwith 50. Under the assump-
tion of aprotonatedN-terminalprimary amine, theprimary amine of compound 50 replaces theN-terminus, putatively in an SN2 reaction
given the electronwithdrawing nature of the adjacent amide bond omitted here.
indicator for favorable accommodation of (aromatic) π-systems. Notably, the sidechain ofMet1
is not visible in the presence of 50 and might suggest that the π-system of 56 is too small to
interact favorably, or that it lacks a positive charge.
13.2 PanDDA Analysis
Weak population of binding sites results in weak density for the bound ligand, which renders its
identiûcation by visual inspection of the electron density maps ûrstly speculative, and secondly
highly tedious, if not impossible. For a suõciently large number of crystallographic datasets
of the same protein, it is nowadays possible to unveil such binding events by the Pan-Dataset
Density Analysis (PanDDA) method.203 PanDDA, in short, relies on a density ‘ground-state’,
which is generated as an average of the datasets included in the analysis.203 A proportion of the
ground-state is then substracted from each individual dataset to reveal ‘changed states’, such as
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ligand binding.203 _e hCAII datasets collected in the course of the above fragment-screening
campaign were subjected to PanDDA analysis. Surprisingly, only fragments 48, 51 and 52 out of
the eight identiûed hits and no additional binding events were found in this analysis, although
visual inspection aer a run of the in-house automated reûnement pipeline by Dr. Johannes
Schiebel clearly identiûed the residual ûve binders. A putative reason for the low success rate was
assumed to be a non-optimal averaging of the ground-state, which was putatively caused by the
fact, that soaking times ranged from 15 h at most to 3min minimum. _is became necessary, as
it was found that the exposition of crystals to several fragments led to partial or even complete
loss of diòraction power, sometimes without visible degradation of the crystal. Such a distinct
diòerence in soaking time can be expected to cause diòerences, e.g. in the degree to which a
binding site, that accommodates solvent molecules, is occupied. _erefore, a PanDDA run was
carried out only with datasets from crystals, that had been submerged in the soaking drop for
15 h, which resulted in the detection of fragments 48, 49, 51, 52, 53 and 55. _is analysis still
missed fragments 50 and 54, but supports the theory of the inuence of diòerent soaking times
on electron density. However, analysis of datasets only soaked for 3min revealed not a single hit,
but should at least have identiûed compound 57. Fig. 65 shows the PanDDA event maps for the
identiûed binding events.
13.3 Conclusions
_e active site of hCAII is occupied by four out of 96 possible compounds, three ofwhich directly
coordinate to the ZnII cofactor. Compounds 48 and 52 are, although not surprisingly found
given the inhibitory action of the structurally highly similar N-hydroxybenzamide, to the best of
my knowledge, the ûrst hydrazide inhibitors of hCAII deposited in the PDB. Although probably
not relevant for medicinal chemistry purposes, the binding of four additional fragments in
various sites enabled by crystal packing partially revealed that this fragment library is also suited





Fig. 65: PanDDA densitymaps for identied fragment binding events shown at 2 σ. A 48. B 49. C 51. D 52. E 53. F 55.
and Cys side chains and has the potential to reveal possibilities for interactions that might not
be initially apparent, such as interactions between amide bonds as for 53 or the interactions
between uorine atoms and either amide bonds or aliphatic groups.
A PanDDA analysis of all 96 datasets showed a low success rate of only three identiûed events out
of eight bound fragments, thatwere found by visual inspection of the electron densitymaps aer
performing automated reûnement. A renewed PanDDA run with a subset of datasets obtained
from crystals that were all soaked for 15 h showed an increased number of identiûed binding
events of six bound fragments, and thereby supports the notion, that diòerent soaking times
bear diòerently on the electron density distribution in crystals. An explanation for this might
be, that a soaking time of 15 h is suõciently long to enable full equilibration of all unit cells
with the surrounding medium. In this context, the unsuccessful recovery of a known binder
from a subset of datasets, that were exposed to the soaking medium for a drastically shorter
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period of only 3min means, that equilibration of the crystal with the soaking drop had not
been concluded. _is can be expected to result in distinct diòerences in the distribution of
electron density across unit cells, and is possibly themore pronounced the larger the crystal
is. _is last reasoning would furthermore entail not only drastic diòerences within one, but
across several crystals andmight well be an explanation for the unsuccessful PanDDA run with
datasets obtained aer a soaking period of 3min.
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14 Methods and Materials
14.2 Protein Expression and Purication
14.2.1 Expression
HCAII was expressed in Escherichia Coli BL21 Codon plus cells. 100 µL ethanolic Chlorampheni-
col solution (34mgmL−1) and 100 µL aqeous Amipicillin sodium salt (Ampicillin-Na) solution
(100mgml−1) were added to 100mL lysogeny broth (LB) medium, which was then incubated
with cells carrying the pGEX-4T1 plasmid with the hCAII-GST fusion protein gene overnight
at 37 °C. _e cells were taken from a glycerol stock prepared by Dr. Johannes Schiebel. To 1 L
of LBmedium was added 1mL of aqueous Amipicillin sodium salt (Ampicillin-Na) solution
(100mgml−1) and 20mL of overnight culture. Expression culture growth was monitored with a
NanoDropTM 2000c. _e expression culture was allowed to grow until an optical density (OD)
of 0.6 at a wavelength of 600 nm was reached. Expression of the hCAII-GST fusion protein was
induced by addition of 1mL 1m isopropyl-β-d-thiogalactopyranoside (IPTG) solution. 1mL
aqueous 0.94m ZnCl2 solution was added, following a procedure by Cimmperman et al., and
the expression was conducted for 4 h at 32 °C.204
14.2.2 Lysis
Cells were harvested by centrifugation (10 000 rpm, 10min, 4 °C) and either stored at −80 °C
overnight or directly used for further puriûcation. Cell pellets were resuspended in 150mL PBS
containing one protease-inhibitor cocktail pill. Cell disruption was carried out in centrifugation
vessels by sonication (Branson Soniûer 250). Every vessel was sonicated ûve times for 1min at a
duty cycle of 70 and an output control of 3. Cells were spun down by centrifugation (20 000 rpm,
45min, 4 °C).
14.2.3 Purication
_e lysis was loaded onto a Glutathione SepharoseTM High Performance column at a ow rate
of 1mLmin-1 via peristaltic pump and aerwards washed with 400mL of PBS at a ow rate of
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3mLmin-1. Cleavage of the GST tag was achieved overnight aer the column was manually
loaded by syringe with 10mL PBS containing 500 IU of thrombin at an approximate ow rate
of 1mLmin-1. _e protein was eluted in 25mL of PBS via fast protein liquid chromatography
(FPLC) at a ow rate of 1mLmin-1 and a pressure of 0.4MPa. Removal of thrombin from the
ow through was achieved by dilution with the same volume of 0.1 m TRIS buòer containing
(1 m) NaCl at pH 7.4, and running themixture through a 5mL HiTrapTM Benzamidine FF(HS)
column. _e ow throughwas puriûed by size exclusion chromatography with aHiLoadTM 26/60
Superdex200 size exclusion column and the buòer exchanged to 0.05m TRIS buòer, pH=7.8.
Protein purity was monitored by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) (Fig. 66) as described by Laemmli.205
1 2 3 4 5 6 7 8
Fig. 66: SDS-PAGE gel for the purication of hCAII. 1 Ruler (molecular weight increases from top to bottom). 2 Eluate of SEC column.
3 Eluate of benzamidine column. 4 Eluate of GSH column. 5 Application of thrombin to loaded GSH column. 6 Flowthrough of washing
GSH column. 7 Flowthrough of loading of GSH column. 8 Cell pellet after lysis.
14.3 Macromolecular Crystallography
14.3.1 Crystallization
Unless stated otherwise, crystals were grown in the following two conditions.
14.3.1.1 Ammonium Sulfate Conditions
Crystallizationwas carried out in hanging drop plates fromHampton Research in 24-well format
at 18 °C. Crystallization drops were set up by mixing 2.0 µL of protein solution in the ûnal
expression buòer (cP = 10mgmL−1) with 2.0 µL of a solution of (NH4)2SO4 2.25 – 2.70 m , TRIS
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0.1 m, pH 7.8 and saturated with PCMB on siliconized 22mm circular cover slides from Jena
Bioscience. _e reservoir contained 0.5mL of the (NH4)2SO4 solution used for the drop. Crystals
grew overnight and reached their ûnal size aer one day.
14.3.1.2 TrisodiumCitrate Conditions
Crystallizationwas carried out in hanging drop plates fromHampton Research in 24-well format
at 18 °C. Crystallization drops were set up by mixing 2.0 µL of protein solution in the ûnal
expression buòer (cP = 10mgmL−1) with 2.0 µL of a solution of trisodium citrate 1.40m, TRIS
0.1 m, pH 7.8 and saturated with PCMB on siliconized 22mm circular cover slides from Jena
Bioscience. Crystals grew within one to two days and reached their ûnal size aer three days.
14.3.2 Soaking and Cryoprotection
Crystals grown in (NH4)2SO4 conditionswere soaked overnight in a solution of 3.0m (NH4)2SO4
TRIS 0.1 m, pH 7.8, d-glucose 25% (w/v) saturated with the ligand of interest. Cryoprotection
was conducted by submerging the crystals in a solution containing 3.0m (NH4)2SO4, TRIS 0.1 m,
pH 7.8 and saturated with the ligand of interest for 30 s. Crystals grown in trisodium citrate
conditionswere soaked in a solution of trisodium citrate 1.50m, TRIS 0.1 m, pH 7.8 and saturated
with the ligand of interest, which was also suitable for cryoprotection. Crystals for fragment
screening were soaked in conditions from Dr. Kan Fu’s PhD thesis with a high PEG content and
10% DMSO for periods of 15 h or 3min.206
14.3.3 Diraction Data Collection, Processing and Renement
Diòraction data were recorded on themacromolecular crystallography beamlines of BESSY II,
ELETTRA and PETRA III.120,207,208 Data indexing, integration and scaling were performed with
the programsXDS andXDSAPP2.0.209,210 A random selection of 5%of all reectionswas used for
the calculation of Rfree. Structure solutionwas done bymolecular replacement using the program
Phaser from the CCP4i suitewith PDB entry 3KS3 as initial model, except for the hCAII–44 com-
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plex (Chapter 11).165,178 Model building inCoot into 2mFo–mFc andmFo–mFc maps at 1 σ and 3 σ,
respectively, alternating with subsequent reûnement steps with the graphical user interface of
diòerent versions of Phenix.reûne from the Phenix soware suitewas conducted until the conver-
gence of R-factors.121,211,212 Double conformations weremodeled if appropriate. _e reûnement
included atomic x, y and z coordinates as well as occupancies. Atomic B-factors were initially
reûned isotropically with subsequent anisotropic reûnement of all atoms except water. Lastly,
all atoms were reûned anisotropically. Riding hydrogen atoms were added with the program
ReadySet from the Phenix soware suite.211 _e website https://www.molinspiration.com/ was
used for SMILES-code generation and coordinate and restraint ûles for themodeled ligandswere
created with the GradeWeb Server (http://grade.globalphasing.org/cgi-bin/grade/server.cgi).
Coordinates and structure factor ûles were deposited in the PDB under the accession codes
given in the crystallographic tables. Crystallographic images were created with the program
PyMOL.161 Atoms are colored according to the following color scheme: H – white, C – diverse,
N – blue, O – red, F – light blue, S – yellow, Cl–green, Zn – gray.
14.3.4 SAD Phasing
SAD experiments were carried out on beamline 14.1 at the BESSY II electron storage ring
operated by theHelmholtz-Zentrum Berlin. Two datasetswere collected on a Dectris Pilatus 6M
detector at a wavelength of 0.9794Å at ϰ-angles of 0° and 30°. Datasets weremerged with the
programXSCALE.209 Phasingwasperformedwith theprogams SHELXC/D/E as combined in the
HKL2MAP bundle.177 _e anomalous signal (d"/σ(d") = 1.46 – 4.47) allowed the determination
of 3 out of 3 possible binding sites ofHg and Zn by SHELXD (CCall = 45.1). SAD phasing was
carried out using SHELXE. Structure factor amplitudes from XSCALE and phases from SHELX
were combined using the program CAD from the CCP4i suite.178 An initial electron densitymap
was calculated and amodel (3 chains with 3, 74 and 172 residues, respecdtively) was generated
via the program ARP/wARP as implemented in the CCP4i suite.178,213 Further model building
and reûnement were carried out as described in subsection 14.3.3.
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14.4 Isothermal Titration Calorimetry
14.4.1 Preparation of DMSO Stocks
30mm stocks of all ligands used for ITCmeasurements were prepared following suggestions by
Boyce et al.70 _e purity of compound 1 was determined by Hans-Dieter Gerber by quantitative
NMR. Khang Ngo determined the purities of all other compounds by analytical HPLC. Purities
of the solids were all larger than 95% and taken into account for the preparation of the DMSO
stocks.
14.4.2 General Sample and Experiment Preparation
Experimental solutions were prepared under the proposition of a total volume of 300 µL and a
totalDMSO content of 3 – 5% (v/v). Proteinwasmixedwith buòer and subsequentlyDMSO._e
ligand DMSO stock was further diluted with DMSO for a ûnal volume of 9 µL andmixed with
291 µL of buòer. _e samples were vortexed shortly and centrifuged. Aer washing with buòer
and drying of themeasurement cell, the protein sample was loaded and the excess removed.
_e syringe was loaded with ligand solution, purged and reûlled. A downward movement
corresponding to 0.03 µL was performed.214 Additionally, a smaller injection of 0.3 µL preceded
the titration and was discarded before analysis.
14.4.3 n-Alkyl and n-Alkyloxy Compounds
Prior to ITC measurements, protein was transferred into the measurement buòer (10 mM
HEPES, pH 7.8) by centrifugation in aVivaspin 20CentrifugalConcentrator containing a 10 kDa
molecular-weight cutoò PSEmembrane, concentrated to 15mgmL−1, aliquoted, frozen in liquid
nitrogen and stored at −80 °C. Measurements were carried out on an ITC200 (GE, compounds
4 -8 and 10 -13) and an ITC200 (Malvern, 9 and 20) at 25 °C at a stirring speed of 750 rpm
and 180 s of spacing between consecutive injections. For characterization of 9, a displacement
titration setup following suggestions by Velazquez-Campoy and Freire was applied.215 HCAII
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was incubated with 20 and titrated with 9. Compounds 16 and 17 could not be characterized by
ITC because of a comparably high noise level and artifact signals (p. 61). Compounds 14, 15, 18
and 19 could not be reliably characterized by ITC because of comparably high error values.
14.4.4 Fluorinated andOther Compounds
For compounds 1, 20 – 31, 34 – 36, 38 and 43, the following procedure was applied. Prior to
measurements, protein was dialyzed against 10mm HEPES buòer at pH 7.8 at 26 °C overnight.
_e dialyzed protein solutionwas aliquoted and stored at −80 °C. _e dialysis buòerwas ûltrated
through a_ermo ScientiûcNalgene Rapid-Flow PES Bottle Top Filterwith a pore size of 0.2 µm
and used for themeasurements. Measurements were carried out on an ITC200 (Malvern) at
25 °C with a stirring speed of 1000 rpm and 180 s of spacing between consecutive injections. For
characterization of compounds 29 – 31, a displacement titration setup following suggestions by
Velazquez-Campoy and Freire was applied.215 hCAII was incubated with 20 and titrated with the
respective ligand.
14.4.5 Data Analysis
ITC data were analyzed using the AFFINImeter soware suite.114 Raw data were processed and
thermodynamic parameters determined with the global ût approach. Kinetic data were ûtted
anew by applying the globally ûtted thermodynamic parameters to the raw data. Standard errors
were calculated from the values of the individually ûttedmeasurements. For the evaluation of
displacement experiments, direct titrations of the ligand to be characterized, direct titrations
of the reference ligand and titrations of the actual displacement titrations were included in the
global analysis. _ermodynamic and kinetic data as well as thermograms, integrated heat values
and equilibration time curves are located in the Appendix.
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14.5 Compounds andMaterials
Compounds 1, 16 and 43 were synthesized by Hans-Dieter Gerber. Compound 39 was synthe-
sized by Prof. Dr. ManfredHaake. Compounds 9, 12, 13, 14, 15, 17, 18, 19, 28, 29, 30, 31 and 38
were synthesized by Khang Ngo. All other compounds were commercially available.
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Tab. 13:Materialswith suppliers used in the course of thiswork.
Substance Supplier/synthesized by Substance
Supplier/
synthesized by
1 Hans-Dieter Ger-ber 35 Alfa Aesar
2 Sigma-Aldrich 36 Sigma-Aldrich
3 (anhydr.) Fluka 37 abcr
4 Sigma-Aldrich 38 Khang Ngo
5 Sigma-Aldrich 39 Prof. Dr. ManfredHaake
6 Apollo ScientiûcLtd. 40 Sigma-Aldrich
7 Chempur 41 Enamine
8 abcr 42 Enamine
9 Khang Ngo 43 Hans-Dieter Ger-ber
10 abcr 44 Sigma-Aldrich
11 Enamine
12 Khang Ngo Ammoniumsulfate Roth
13 Khang Ngo Ampicillin-Na Roth
14 Khang Ngo Betaine-HCl Sigma Aldrich




17 Khang Ngo DMSO Roth
18 Khang Ngo d-Fructose Sigma Aldrich
19 Khang Ngo Glycine Sigma Aldrich
20 Sigma-Aldrich HEPES Roth
21 Fluorochem IPTG Roth
22 Alfa Aesar KCl Sigma Aldrich
23 Alfa Aesar K-Na-Tartrate Grüssing
24 Khang Ngo Na3-Citrate Roth
25 Alfa Aesar NaCl Roth
26 Fluorochem PCMB Sigma Aldrich
27 Alfa Aesar Peptone Roth
28 Khang Ngo l-Proline Roth
29 Khang Ngo Sarcosine Alfa Aesar
30 Khang Ngo d-Sorbitol Sigma Aldrich
31 Khang Ngo d-Sucrose Sigma Aldrich
32 Fluorochem TRIS Roth
34 Fluorochem ZnCl2 Sigma Aldrich
14.6 Calculation of Interface Areas
14.6.1 n-Alkyl- and n-Alkyloxy-Benzenesulfonamides
SES for the respective species were calculated with the program MSMS included in the Python
Molecular Viewer from theMGLTools suite version 1.5.6.216 _e protein part was reduced to
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residues Gln92, His94, His96, His119, Val121, Phe131, Val135, Leu141, Val143, Leu198, _r199,
_r200, Pro202, Leu204, Val207, Trp209 and the ZnII cofactor.
14.6.2 Fluorinated Benzenesulfonamides
Interface areas were calculated with the Linux version of the program dr_sasa in mode 4 with
the uorine atom as ligand. For meta-uorine substituents, the pocket was deûned with residues
Val121, Phe131, Leu141 and Leu198. For ortho-uorine substituents, the pocket was deûned with
residues Val121, Phe131, Val143 and Leu198.
14.7 Normalization of B-factors
Atomic B-factors were calculated in two ways to exclude the putative inuence of ligand atoms
on one another. Hydrogen atoms on the protein were removed before the calculation. In
general, the individual atomic B-factors were divided by the average B-factor of all atoms
protein atoms surrounding the respective atom in a radius of 6.5Å. One approach additionally
involved all ligand atoms in the process, the other excluded those to remove putative bias due
to the overall ligandmobility. All normalization operations were performed with the in-house
python script normalize_B.py written by Dr. Tobias Hüfner, which can be obtained free of
charge from https://github.com/wutobias/normalize_B. _e python script uses the ParmEd
library as of AmberTools17 for ûle parsing and the NumPy and SciPy libraries for numerical
operations.162,217,218
14.8 Ab initio Solvation Calculations
Calculations were carried out by Dr. Christoph P. Sager by the following procedure.
Ab initio solvation free energies ofmolecules 4 – 8 and 10 - 13 were calculated aer geometrical
optimization using the density functional theory (DFT) with the M06-2X functional by the
154
14.9 Calculation of α
Truhlar group and the 6-31G(d,p) basis-set implemented in Gaussian 16.219–221 _e SMD solvation
mode was used with water (ε = 78.3553) as solvent to derive the presented ∆G of solvation.222
14.9 Calculation of α
_e deviation angle from the normal vector (n⃗) of the phenyl ring plane (α) indicated by the
deviation vector (⃗d) was measured for the reference conformation of Leu198 using PyMOL
with the NumPy library for vector construction and the vg library for vector operations.161–163
Directional vectors for the phenyl ring plane (p⃗, q⃗) were calculated by subtracting the position
vector of the phenyl centroid from the respective position vectors of the ortho carbon atoms (Co1,
Co2). n⃗ of the phenyl ring plane was determined via the cross product of the resulting vectors
with the cross function from the vg library. ⃗d was calculated by subtraction of the position vector








Fig. 67: Calculation of angle α.
14.10 pKaMeasurements
pKa values were determined by Björn Wagner from Roche by the SiriusT3 Fast UV pKa method,
which is based on the spectrophotometric (UV-metric) titration method reported in reference
[223].
155




_e following tables show the compounds used experimentally in the course of this work.
157
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Tab. 14: Overview of compounds 1 – 10.













































Tab. 15: Overview of compounds 11 – 19.





















































Tab. 16: Overview of compounds 20 – 27.











































Tab. 17: Overview of compounds 28 – 34.







































































Tab. 18: Overview of compounds 35 – 42.



































































Tab. 19: Overview of compounds 43, 44 and 48 – 55.


















































Crystallographic data were recorded at beamlines 14.1 and 14.2 at BESSY II, P13 at PETRA III
and XRD1 at ELETTRA. Values in brackets refer to the highest resolution shell unless speciûed
diòerently. _e Matthews coeõcient was calculated with the program Phaser Cell Content
Analysis from the CCP4i suite.178 Model validation was based on the free R-factor (Rfree).212
Ramachandran plots were calculated using the program PROCHECK.224 Average B-factors
were calculated with the program MOLEMAN.225 ‘n. d.’ indicates that a structure has not been





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































_ermodynamic and kinetic parameters for individual measurements as well as globally ûtted
values are provided. For the studies concerning the ITC measurement protocol, also mean
values of the individual measurements are provided. ‘°’ refers to the standard state. χ2 denotes
the goodness of ût.
n-Alkyl and n-Alkyloxy compounds










0.12 -36.1 -39.5 3.4 2.15 465
4 0.18 -35.8 -39.2 3.4 1.86 539
0.51 -36.1 -39.9 3.8 2.08 479
0.17 -38.1 -41.0 2.9 4.76 210
5 0.15 -37.6 -40.6 3.0 3.84 260
0.71 -38.8 -40.2 1.4 6.2 161
0.68 -40.9 -41.1 0.2 14.71 68
6 0.36 -40.2 -41.43 1.19 11.21 89.23
0.52 -39.8 -42.2 2.3 9.46 105
0.26 -40.8 -38.0 -2.8 14.05 71
7 0.28 -40.4 -39.5 -0.8 11.76 85
0.43 -41.0 -39.2 -1.7 14.95 66
0.39 -42.2 -44.7 2.6 24.41 41.0
8 0.28 -42.3 -43.4 1.0 26.04 38
0.37 -43.4 -44.7 1.3 40.83 24
0.15 -37.3 -46.0 8.7 3.40 293
10 0.27 -37.1 -45.2 8.0 3.20 312
0.29 -37.6 -45.4 7.8 3.78 264
0.59 -39.6 -46.7 7.1 8.77 114
11 0.25 -39.8 -46.4 6.6 9.22 108
0.24 -39.1 -46.4 7.3 7.10 140
0.56 -42.1 -50.0 8.0 23.29 42
12 0.54 -42.8 -49.3 6.5 31.24 32
0.51 -43.4 -50.1 6.8 39.1 25
0.40 -44.5 -51.8 7.3 62.09 16
13 0.30 -44.3 -51.5 7.2 57.81 17











































































































































































































































































































































































Tab. 35: Kinetic parameters for individual ITC experiments for compounds 4 – 8 and 10 – 13 before (left) and after (right) application of
globally adjusted thermodynamic parameters.
Before global adjustment Aer global adjustment







0.55 1.71 0.79 0.54 1.62 0.81
4 0.95 2.08 1.12 1.39 2.17 1.09
1.35 2.28 1.09 1.29 2.22 1.11
0.98 2.24 0.47 0.89 2.17 0.49
5 0.84 2.84 0.74 1.06 3.02 0.68
0.69 2.48 0.40 0.81 2.15 0.48
1.50 7.53 0.51 1.47 6.90 0.59
6 2.48 5.27 0.47 2.54 5.41 0.46
0.68 7.04 0.74 0.74 7.71 0.65
0.34 8.56 0.61 0.32 8.41 0.63
7 0.81 4.82 0.41 0.84 5.00 0.37
1.31 8.43 0.56 1.18 8.08 0.60
0.69 12.43 0.51 0.71 13.3 0.45
8 1.33 16.74 0.64 1.36 17.4 0.59
0.47 14.18 0.35 0.52 13.0 0.44
1.22 2.31 0.68 1.22 2.33 0.67
10 2.01 1.91 0.60 2.15 2.02 0.58
0.83 2.74 0.72 0.74 2.61 0.75
1.30 6.75 0.77 1.28 6.62 0.79
11 3.93 5.65 0.61 4.60 5.27 0.63
1.38 5.99 0.84 1.46 6.62 0.79
2.35 6.01 0.26 2.74 6.58 0.23
12 2.50 7.76 0.25 2.38 7.47 0.26
2.10 5.64 0.14 1.80 5.15 0.18
0.95 36.16 0.58 0.96 31.6 0.74
13 1.59 10.90 0.19 1.47 9.67 0.23
2.15 12.01 0.37 2.26 13.3 0.31
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Tab. 36:Mean values for kineticparameters from individual ITCexperiments after applicationofgloballyttedparameters for compounds











4 2.00 1.00 0.19 0.10
5 2.45 0.55 0.29 0.06
6 6.68 0.57 0.67 0.06
7 7.16 0.53 1.08 0.08
8 14.6 0.49 1.43 0.05
10 2.32 0.67 1.72 0.05
11 6.17 0.73 0.45 0.05
12 6.40 0.22 0.68 0.02
13 18.2 0.43 6.81 0.16
a Kinetic data were obtained after renewed processing of the raw data with ∆H° and
Ka values from global tting. b Standard error of measurement after adjustment with
global data.
ITC Protocol










0.25 -35.0 -63.3 28.2 1.38 724
0.20 -35.5 -61.3 25.7 1.69 594
Standard 0.27 -35.7 -63.8 28.1 1.80 555
0.21 -35.3 -59.8 24.5 1.54 649
0.28 -35.1 -63.9 28.9 1.41 710
0.15 -35.5 -59.3 23.8 1.65 608
0.18 -35.4 -59.0 23.7 1.56 641
Kinetic 0.29 -35.2 -59.5 24.3 1.47 679
0.34 -35.2 -61.2 26.1 1.44 694
0.20 -35.0 -61.8 26.9 1.36 738
0.17 -35.1 -61.0 25.9 1.39 719
0.15 -35.1 -59.6 24.6 1.39 717
Mixed 0.42 -35.1 -61.9 26.8 1.40 714
0.30 -35.2 -60.1 24.9 1.47 682
0.49 -34.9 -60.3 25.4 1.28 784
0.09 -35.3 -59.6 24.3 1.52 659
0.18 -35.6 -58.2 22.6 1.73 579
_ermodynamic 0.05 -35.2 -59.0 23.8 1.47 679
0.20 -35.4 -58.7 23.3 1.57 637
0.06 -35.1 -59.5 24.4 1.44 697
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Standard, raw datamean -35.3 -62.4 27.1 646
Standard, globally adjusted -35.4 -62.6 27.2 638
Kinetic, raw datamean -35.2 -60.2 24.9 672
Kinetic, globally adjusted -35.2 -60.1 24.9 669
Mixed, raw datamean -35.1 -60.6 25.5 723
Mixed, globally adjusted -35.0 -60.2 25.3 673
_ermodynamic, raw datamean -35.3 -59.0 23.7 650
_ermodynamic, globally adjusted -35.3 -59.1 23.7 650
Tab. 39: Values for the left and right errormargin of a 95% condence interval of the thermodynamic values for ve experiments, based








Standard 0.4 2.2 2.3 90.5
Kinetic 0.2 1.6 1.8 61.9
Mixed 0.2 1.1 1.1 46.0
_ermodynamic 0.2 0.7 0.9 56.9
Tab. 40: Kinetic parameters for individual ITC experimentswith dierentmeasurement protocols for compound 20 before (left) and after
(right) application of globally adjusted thermodynamic parameters.
Before global adjustment Aer global adjustment







0.79 4.35 3.2 0.81 4.87 3.1
0.18 5.00 3.0 0.18 4.74 3.0
Standard 0.49 3.92 2.2 0.49 3.51 2.2
0.46 4.20 2.7 0.50 4.28 2.7
0.93 4.18 3.0 0.87 4.54 2.9
0.36 4.58 2.8 0.34 4.19 2.8
1.08 4.34 2.8 1.08 4.16 2.8
Kinetic 0.44 4.40 3.0 0.44 4.43 3.0
0.55 3.90 2.7 0.53 3.98 2.7
0.88 4.10 3.0 0.84 4.36 2.9
0.48 4.40 3.2 0.48 4.25 3.2
0.68 3.57 2.6 0.73 3.45 2.6
Mixed 0.11 3.81 2.7 0.11 3.67 2.7
0.22 4.14 2.8 0.24 3.86 2.9
0.61 3.49 2.7 0.59 3.62 2.7
1.75 2.93 1.9 1.74 2.95 1.9
3.08 3.09 1.8 3.15 2.84 1.8
_ermodynamic 1.52 2.91 2.0 1.54 3.03 2.0
3.33 2.94 1.9 3.37 2.91 1.9
1.78 2.27 1.6 1.74 2.42 1.6
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Tab. 41: Individual-measurement derived mean values and globally tted/adjusted kinetic values for the fourmeasurement protocols.







Standard, raw datamean 4.33 2.80 3.9 36.4
Standard, globally adjusted 4.39 2.80 3.9 36.2
Kinetic, raw datamean 4.26 2.86 3.7 35.1
Kinetic, globally adjusted 4.23 2.84 3.7 35.2
Mixed, raw datamean 3.88 2.80 3.6 35.9
Mixed, globally adjusted 3.77 2.82 3.6 35.7
_ermodynamic, raw datamean 2.83 1.83 3.7 55.0
_ermodynamic, globally adjusted 2.83 1.84 3.7 54.8
Tab. 42: Values for the left and right errormargin of a 95% condence interval of the kinetic values for ve experiments, based on the
assumption of T-distributed individual experiments.







Standard 4.33 2.80 3.9 36.4
Kinetic 4.39 2.80 3.9 36.2
Mixed 4.26 2.86 3.7 35.1
_ermodynamic 4.23 2.84 3.7 35.2
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Fluorinated and para-Substituted Compounds










0.17 -37.6 -48.2 10.6 3.92 255
21 0.28 -38.4 -48.2 9.8 5.28 189
0.10 -38.6 -48.1 9.6 5.73 174
0.28 -40.1 -47.2 7.1 10.69 93
22 0.20 -40.6 -46.8 6.2 12.81 78
0.34 -40.0 -48.1 8.1 10.36 96
0.24 -36.9 -38.8 1.9 2.94 340
23 0.58 -37.2 -41.8 4.5 3.33 300
0.12 -37.3 -39.5 2.2 3.43 291
1.47 -41.8 -43.5 1.7 21.06 47
24 0.18 -42.0 -42.9 0.9 23.04 43
0.33 -42.5 -41.9 -0.6 28.09 35
0.43 -43.0 -54.6 11.6 33.53 29
25 0.37 -42.0 -55.4 13.3 22.81 43
0.59 -43.0 -53.9 10.9 34.16 29
0.19 -38.2 -43.1 4.9 4.91 203
26 0.16 -38.1 -41.9 3.7 4.79 208
0.50 -38.6 -42.1 3.5 5.68 176
0.19 -40.7 -41.5 0.7 13.63 73
27 0.37 -41.1 -42.3 1.1 16.17 61
0.19 -41.0 -41.7 0.7 15.42 64
0.46 -42.6 -44.0 1.4 29.59 33
28 0.31 -42.6 -44.1 1.6 28.45 35
0.25 -42.7 -44.5 1.8 30.41 32
0.71 -41.1 -44.2 3.1 15.96 62
34 0.28 -41.0 -43.3 2.2 15.40 64
0.77 -40.9 -43.9 3.0 14.69 68
0.29 -41.4 -45.1 3.8 17.59 56
35 0.47 -41.9 -45.5 3.6 21.58 46
0.30 -42.1 -44.9 2.8 24.02 41
0.13 -31.5 -41.8 10.3 0.33 2999
36 0.20 -30.9 -46.9 16.0 0.26 3817



































































































































































































































Tab. 45: Kinetic parameters for individual ITC experiments for compounds 21 – 28, 34 and 35 before (left) and after (right) application of
globally adjusted thermodynamic parameters.
Before global adjustment Aer global adjustment







0.74 6.84 1.7 0.85 8.10 1.6
21 0.39 7.13 1.4 0.40 6.95 1.4
0.36 7.54 1.3 0.37 7.04 1.4
0.74 11.07 1.0 0.65 11.25 1.0
22 0.39 12.05 0.9 0.55 11.21 1.0
0.36 10.50 1.0 0.55 10.72 1.0
0.74 6.20 2.1 0.44 7.05 2.0
23 0.39 7.68 2.3 0.64 7.84 2.2
0.36 7.80 2.3 0.39 7.90 2.3
0.74 15.22 0.7 1.70 16.15 0.7
24 0.39 18.58 0.8 1.16 18.94 0.8
0.36 18.50 0.7 0.49 17.45 0.7
0.74 16.13 0.5 0.37 15.49 0.5
25 0.39 12.58 0.6 0.36 12.82 0.4
0.36 18.01 0.5 0.26 17.33 0.6
0.74 7.95 1.6 0.47 8.22 1.6
26 0.39 8.71 1.8 0.59 9.15 1.8
0.36 9.98 1.8 0.65 9.55 1.8
0.74 14.66 1.1 0.51 15.30 1.1
27 0.39 14.28 0.9 0.34 13.69 0.9
0.36 15.29 1.0 0.55 14.92 1.0
0.74 17.43 0.6 0.52 17.41 0.6
28 0.39 16.50 0.6 0.28 16.69 0.6
0.36 18.56 0.6 0.43 18.15 0.6
0.74 15.20 1.0 0.72 15.08 1.0
34 0.39 15.56 1.0 1.19 15.80 1.0
0.36 15.43 1.1 0.75 15.91 1.0
0.74 14.57 0.8 0.71 15.45 0.8
35 0.39 16.76 0.8 0.23 16.26 0.8
0.36 16.56 0.7 1.04 15.34 0.8
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Tab. 46: Kinetic data for compounds 21 – 31, 34 and 35.
Standard error











21 0.74 14.7 4.1 0.04 0.7 0.03
22 1.11 10.0 4.5 0.02 0.2 0.06
23 0.76 21.8 4.5 0.03 0.8 0.07
24 1.80 7.3 4.4 0.08 0.3 0.2
25 1.52 4.9 4.1 0.10 0.4 0.2
26 0.90 17.2 4.4 0.04 0.8 0.08
27 1.46 10.0 4.1 0.05 0.3 0.2
28 1.74 6.0 4.6 0.04 0.1 0.05
34 1.56 9.9 4.7 0.02 0.1 0.04
35 1.57 7.8 4.8 0.02 0.1 0.009
Protonation Dependence
















HEPES 21.1 -35.9 -41.9 -6.1 0.1 0.3 0.3
TRICIN 32.0 -35.7 -43.5 -7.9 0.4 0.8 1.0
TRIS 48.1 -35.7 -45.1 -9.3 0.2 0.2 0.4
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ΔH°ion / kJ mol-1
Fig. 68: Plot of ∆H° as a function of ∆Hion for the titration of hCAIIwith compound 4 in HEPES, TRIS and TRICIN from Tab. 47.
Determination of the Instrument Response Time
2 µL of an aqueous solution of ethanol (p.a., 1 %, v/v) were titrated into demineralized water at
an injection rate of 0.5 µL s−1. _e syringe plunger motor was primed with a preceding injection
of 0.3 µL. _e procedure was repeated three times. _e resulting heat signals were plotted with
QtiPlot 1.0.0-rc2. Equation (24) was ûtted to the right half of the injection signal, beginning
with the data point closest to half the amplitude as described by Dumas et al.115 _e constant C
was added as signals were not shied to PQ = 0 before ûtting.
Pm(t) = Pmax ⋅ e
−t












































0 20 40 60 80 100 120 140 160
A B C
Fig. 69: Plotted heat signalswith tted equation 24 in orange. Data points are connected for clarity.
Tab. 48: Parameters for the tting of equation (24) to heat signals in Fig. 69.
Measurement Pmax τITC C
A –6.61 ± 0.02 4.29 ± 0.06 4.76 ± 0.0008
B –6.58 ± 0.20 4.47 ± 0.06 4.76 ± 0.0008
C –6.44 ± 0.22 4.32 ± 0.08 4.76 ± 0.0008
Sulfoxide










0.84 -35.5 -50.1 14.6 1.67 599
37 0.17 -34.9 -53.2 18.2 1.32 756
0.14 -35.0 -52.8 17.8 1.35 740
0.13 -35.0 -52.3 17.3 1.34 748
37/43 0.30 -35.2 -54.9 19.7 1.45 689
0.21 -34.4 -54.0 19.6 1.07 936
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Tab. 50: Kinetic parameters for individual measurements of compound 37 and 37 in combination with 43 before (left) and after (right)
global adjustment.
Before global adjust-
ment Aer global adjustment







0.41 5.61 4.2 0.46 5.44 4.3
37 0.62 4.81 3.3 0.33 4.58 3.6
1.09 4.10 3.8 1.11 4.94 3.9
0.97 3.77 2.3 0.95 3.46 2.4
37/43 0.26 3.72 2.8 0.24 4.03 2.8





Raw and Processed Thermograms, Integrated Heat Values
and Equilibration Time Curves
Exemplary plots for the titration of every compound are provided. In addition to the raw data
analysis, the integrated heat values and ETCs aer application of the globally ûtted parameters
are shown. For compounds 9, 29, 30 and 31, raw and processed thermograms and the globally
ûtted integrated heat values are shown. _ermograms for reference compound 20 are only































Raw data and global t for direct titration
Raw data and global t for reference compound 20






















































































Raw data and global t for direct titration
Global t for reference compound 20
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Global t for reference compound 20




Raw data and global t for direct titration
Global t for reference compound 20
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